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Thesis abstract 
Factor XI (FXI) is a plasma glycoprotein that participates in the consolidation phase of blood 
coagulation and is important in the creation of a stable fibrin clot.  Deficiency of FXI leads to an 
injury-related bleeding diathesis, which is notable for the variability in the bleeding tendency 
and the lack of a clear relationship between bleeding and FXI coagulant activity (FXI:C).  A 
comprehensive understanding of the factors which influence the bleeding tendency in factor XI 
deficiency would enable a more structured evaluation of bleeding risk and would focus the 
treatment choices for individual patients.  The purpose of this work is to comprehensively 
analyse physiological and genetic factors which modify the clinical phenotype of FXI 
deficiency.  In this study, a comprehensive bleeding history was obtained from participating 
patients with known FXI deficiency (n=102) which was then independently scored.  This 
clinical bleeding score was utilised to compare the following laboratory parameters between 
patients with and without a clinical bleeding tendency: aPTT, FXI:C, FXI:Ag, Blood group, von 
Willebrand factor levels, inherited thrombophilic traits, Thrombin generation (by subsampling 
and continuous methods) and TAFI levels (as evaluated by TAFI antigen and a clot lysis assay).  
The underlying genetic mutation causing the FXI deficiency was evaluated in all patients and 
where an existing Jewish mutation was not found, novel mutations were sought. Molecular 
modelling of mutations in the FXI gene was undertaken which required development of 
molecular models of the apple domains and serine protease domain of the FXI protein.  In 
addition, genetic analysis of a polymorphism in a gene (ALG6) encoding a specific glucosyl 
transferase was undertaken due to the link between FXI deficiency and congenital disorders of 
glycosylation.  Finally, the first clinical trial of the use of recombinant FVIIa in FXI deficiency 
was conducted as part of this study. 
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Chapter 1 Introduction 
 
1.1 Introduction 
Factor XI (FXI) is a plasma glycoprotein that participates in the consolidation phase of 
blood coagulation and is important in the creation of a stable fibrin clot.(1)  Deficiency 
of FXI leads to an injury-related bleeding diathesis, which was first described in 1953 
and has been historically termed ‗Haemophilia C‘, ‗plasma thromboplastin antecedent 
deficiency‘ and ‗Rosenthal syndrome‘.(2-4) The bleeding disorder is now known as 
‗factor XI deficiency‘ and is notable for the variability in the bleeding tendency and the 
lack of a clear relationship between bleeding and FXI coagulant activity (FXI:C).(5-7)  
This creates clinical difficulty in planning therapy for elective invasive procedures or in 
treating patients for acute injuries, since the available therapeutic agents have potential 
side effects.  Currently, bleeding risk is predicted empirically by assessing the FXI:C 
level, past bleeding history and the nature of the injury or surgery.  However, some 
patients have had no or few prior surgical procedures and it is often difficult to obtain 
reliable information about remote events.  A comprehensive understanding of the 
factors which influence the bleeding tendency in factor XI deficiency would enable a 
more structured evaluation of bleeding risk and would focus the treatment choices for 
individual patients.  The purpose of this work is to comprehensively analyse 
physiological and genetic factors which modify the clinical phenotype of FXI 
deficiency. 
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1.2 FXI protein structure and function 
1.2.1 The F11 gene and FXI protein biochemistry 
The FXI gene is located at the distal end of the long arm of chromosome four.(8)  This 
23 kb gene consists of 15 exons and 14 introns, and encodes a 607 amino acid mature 
protein, which is the zymogen for a serine protease.(9)  The C-terminal light chain 
contains the serine protease domain which is similar to that of many other coagulation 
factors.  The N-terminal heavy chain is unusual in that it contains four tandem Apple 
domains, each of which has a specific role in binding co-factors, substrate, platelets or 
other FXI monomers.(10;11)  The only other coagulation factor to possess similar 
tandem Apple domains is Prekallikrein.(12;13) The substrate FIX is bound by apples 2 
and 3 whereas apple 3 is the main site for platelet binding.(14;15)  High molecular 
weight kininogen (HK) circulates in a non-covalent complex with FXI and facilitates 
binding of FXI to activated platelets.  All of the apple domains are involved in the 
complex formation with HK, with apple 2 playing the most important role.(16) 
 
FXI is unique amongst coagulation serine proteases in that it exists as a homodimer, 
with two identical 80 kD monomers joined by both covalent and non-covalent 
bonds.(17)  The apple 4 domains dimerise through covalent protein-protein interactions 
which are stabilised by the formation of a disulphide bond at Cys321, although the latter 
is not critical to dimerisation.(18;19)  Apples 2 and 3 make contributions to 
dimerisation but hydrophobic interactions between the two FXI monomer apple 4 
domains are critical, in particular residues Leu284, Ile290 and Tyr329.(20-23) 
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FXI may be activated by factor XIIa, thrombin or FXIa and the dimeric conformation is 
essential for activation, although the primary physiological activator remains 
controversial.(22;24)  Cleavage occurs at Arg369-Ile370 in each monomer and the 
activated FXI remains in dimeric form.(17)  However, an intermediate form of activated 
FXI has been identified in which only one of the FXI monomers has been activated 
(termed ½-FXIa).(25) 
 
FIX binds to FXIa but not to the zymogen FXI as a consequence of a conformational 
change in the FXIa protein which allows substrate binding to occur.(21;26)  FXIa 
cleaves FIX at two sites (Arg 145 and Arg 180) although a singly cleaved intermediate 
is not formed, unlike the situation during activation of FIX by FVIIa/TF.(27)  Both 
active sites of the FXIa dimer are not required for successful cleavage of FIX.(22;25)   
 
1.2.2 Role of FXI in coagulation 
There are a number of conundrums associated with the role of FXI in the coagulation 
cascade.  Firstly, the realisation that activated FVII (FVIIa)/tissue factor (TF) complex 
can activate FIX and promote coagulation via the intrinsic as well as the extrinsic 
systems has called into question the role of the contact factors.(28)  Deficiencies of the 
contact factors (FXII, HK and prekallikrein) do not lead to a clinical bleeding 
phenotype.  Despite the fact that HK and Zn
2+
 ions are important chaperones for FXI in 
the circulation, HK deficiencies are not detrimental to normal coagulation.  The 
clinically important coagulation serine proteases contain a GLA domain to interact with 
the platelet surface which is not present in FXI.(29)  Finally, the FXI protein uniquely 
exists as a homodimer. 
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Advances in the understanding of the biochemistry of FXI in recent years have 
explained some of these conundrums.(30)  The small amounts of thrombin, which are 
generated in the initiation phase of coagulation, are sufficient to activate FXI, which can 
then activate FIX and further increase the thrombin-generating potential of the 
consolidation phase of coagulation.(24)  Despite the fact that FXI is known as a contact 
factor, activated platelets, rather than negatively charged surfaces, provide a preferential 
surface for the activation of FIX by FXI.(31;32)  The binding of FXI to activated 
platelets occurs via the third apple domain of FXI and platelet glycoprotein 
Ib/IX/V.(33;34)  Prothrombin and Ca
2+
 ions can substitute for HK/ Zn
2+ 
, explaining 
why deficiencies of HK do not lead to bleeding.(35)  The dimeric structure of FXI is 
important for activation to FXIa and for the dual roles of platelet binding and substrate 
activation.(22;30) 
 
The current understanding of the role of FXI in the coagulation cascade may be 
hypothesised as follows.  Small amounts of thrombin, generated by the exposure of 
FVIIa/TF at the site of vessel injury during the initiation phase of coagulation, serve to 
activate platelets and FXI, possibly to the ½-FXIa intermediate.  Binding of the 
zymogen portion of ½-FXIa to activated platelets via apple 3 and GPIb localises FXI to 
the surface on which the consolidation phase of coagulation occurs.(29)  The apple 3 
domain of the activated monomer of the FXI molecule is then available for substrate 
binding and activation.  Although FVIIa/TF activate FIX, this pathway is rapidly 
inhibited by Tissue Factor Pathway Inhibitor (TFPI).  The activity of the primary 
inhibitor of FXI, protease nexin II, is confined to the fluid phase and therefore platelet-
bound FXI is able to freely activate FIX and thus provide a burst of thrombin localised 
to the site of vessel injury.  
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1.2.3 Platelet FXI 
The presence of FXI activity in platelets which is distinct from plasma FXI has been 
described.(36;37)  An alternatively spliced variant of FXI which lacked exon 5 was 
demonstrated in platelets and a megakaryocytic cell line and it was hypothesised that 
even patients with very low levels of plasma FXI could retain some haemostatic 
function via this alternative platelet FXI.(38;39)  However, another group were unable 
to replicate this finding and demonstrated that platelet FXI mRNA had the same 
sequence as liver mRNA.(40)  Subsequently, a highly sensitive real-time RT-PCR 
technique was used to evaluate FXI mRNA isolated from the platelets of FXI deficient 
individuals and again no alternatively spliced variant was detected.(41)  Normally 
spliced FXI mRNA was detected in monocytes and granulocytes as well as in platelets 
and levels were similarly low in all three cell types, possibly a result of ectopic 
transcription. 
 
Given current evidence, platelets do not appear to contain an alternatively spliced 
FXI.(42)  If platelet FXI activity is present, it is likely to be derived from the product of 
the full-length FXI mRNA, either synthesised in the megakaryocyte or internalised from 
plasma. 
 
Thrombin generation and platelet FXI 
Two studies of thrombin generation in FXI deficiency have evaluated the possibility 
that normal platelet derived FXI may compensate for the impairment in thrombin 
generation seen in severe FXI deficient plasma.(43;44)  In both studies normal washed 
platelets were added to PPP derived from the plasma of patients with a homozygous 
type II mutation but no correction of the impaired thrombin generation was seen.  This 
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appears to refute the hypothesis that platelet derived FXI (at least in the in-vitro 
thrombin generation assay) can substitute for a deficiency in plasma FXI. 
 
1.2.4 FXI molecular model and crystal structure 
Up to 2004 there was no available molecular model or crystal structure for the FXI 
protein.  The first crystal structure published was of a recombinant protein consisting of 
the catalytic domain of FXIa (rhFXI370-607).  This protein was crystallised in complex 
with a substitution mutant of ecotin, a pan-serine protease inhibitor.(45)  The isolated 
catalytic domain was subsequently crystallised but neither of these crystal structures 
gave any indication of the interactions of the four apple domains with each other and 
with the protease domain.(46) 
 
More recently, the FXI zymogen has been purified from human plasma and the crystal 
structure determined.(47)  The four apple domains have a unique ternary packing 
structure which is said to resemble a flat saucer and form a platform on which the 
protease domain sits.  When dimerised, these apple domain ―saucers‖ are inclined at an 
angle of 70º and form an inverted V shape with the protease domain active site clefts 
pointing away.  The crystal structure gives insight into the activation of the FXI protein.  
Thrombin binds to the Apple 1 domain via Glu66 (48) and platelet GP1b binds to the 
Apple 3 domain via Lys252 and Lys253.(32)  In the monomer saucer structure of the 
apple domains, Apple 1 and 3 are diametrically opposite one another and are sterically 
separated by the protease domain.  However, in the dimer conformation the Apple 1 
domain of one monomer is in close proximity to the Apple 3 domain of the other 
monomer and it is likely that the FXI dimer supports ternary binding and a trans-
activation mechanism. 
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1.3 FXI deficiency 
1.3.1 Incidence of FXI deficiency 
FXI deficiency is a rare bleeding disorder, first described in 1953 (2) and occurring at a 
frequency of one in a million in the general population.  However, the condition is 
known to be more common among a number of well-defined populations, including all 
Jewish communities, Iranians and French Basques.(49-51)  The Ashkenazi Jews have 
the highest incidence of FXI deficiency amongst the Jewish communities.  The gene 
frequency for FXI deficiency was calculated on the basis of FXI:C levels and family 
history in 36 Ashkenazi Jewish probands, 114 relatives of the probands and 428 healthy 
Ashkenazi Jewish people and the estimated frequencies for ―homozygotes‖ was 0.1-
0.3% and for ―heterozygotes‖ was 5.5-11%.(52)  Subsequently, 1040 patients were 
evaluated using molecular techniques and the estimated risk for heterozygous FXI 
deficiency was 9% (1:11) in Ashkenazi Jews and 3.3% (1:30) in Iraqi Jews.(49)  The 
risk for homozygous or compound heterozygous FXI deficiency was 1:450 and 1:3571 
in the two groups respectively.  The incidence in other communities is lower but can 
represent a significant minority in the population e.g. the 1% incidence of FXI 
deficiency in the Basque community.(51) 
 
1.3.2 FXI coagulant activity and antigen levels 
Normal levels of FXI range from 70 to 150 U/dL.(5)  The lower limit of normal for FXI 
is higher than that seen for other coagulation factors which have a lower limit of normal 
of approximately 50 U/dL.  The lower limit of normal for FXI of 70 U/dL was 
confirmed in 103 blood donors.(53) 
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Homozygotes or compound heterozygotes for mutations causing FXI deficiency have a 
severe deficiency of FXI and their FXI:C levels are less than 20 U/dL (5) although some 
groups quote levels of <15U/dL for severely deficient individuals.(54)  In a study of 24 
families, none of 16 severely deficient patients had a FXI:C level >11 U/dL (5) while in 
another study of 41 presumed homozygotes levels ranged from <1 to 12 U/dL.(55)  In 
46 severely deficient Ashkenazi Jews with disease severity confirmed by molecular 
analysis, FXI:C ranged from to <1 to 13.5 %.(56)  
Heterozygotes for a mutation in the FXI gene have a partial deficiency of FXI.  In 
earlier studies, partial deficiency was defined as a FXI:C of 15-49 U/dL (52), 20-61 
U/dL (57) and 28-60 U/dL.(56)  However this was revised to define partial deficiency 
as FXI levels between 20 and 70 U/dL.(5)  In 62 presumed heterozygotes, FXI:C ranged 
from 17-72 U/dL.(55)  It should be noted that some partially deficient patients can have 
FXI:C levels within the normal range.  Twenty (49%) of 41 ―obligatory carriers‖ had 
FXI:C levels above 50 U/dL and six had levels >100 U/dL.(52)  Heterozygotes for 
mutations causing FXI deficiency had FXI levels ranging from 28 to 126% of 
normal.(56)  Amongst 39 partially deficient patients, 29 (74%) had FXI:C levels of >50 
U/dL but 6/39 (15%) patients had levels >70 U/dL.(5)  In a study of 38 FXI deficient 
patients from Iran, patients were characterised as having severe/moderate (FXI:C < 6%) 
or mild FXI deficiency (FXI:C 6-30%), in a classification of FXI deficiency modelled 
on that used for Haemophilia A and B.(50)  However, this classification is not 
conventionally used in FXI deficiency.  Patients did not have FXI genotyping 
performed and it is probable that there were homozygotes or compound heterozygotes 
in both groups.  This causes considerable difficulty in interpreting the correlation 
between disease severity and bleeding symptoms. 
 
    24 
1.3.3 FXI gene mutations 
FXI deficiency in the Jewish community is caused by four well-defined 
mutations.(58;59)  It is important to note that the nomenclature commonly used to 
describe these Jewish mutations may be confused with the nomenclature used to 
describe the phenotypic expression of mutations in coagulation factor genes, where a 
type I mutation results in concordant reductions in protein expression and function 
(cross-reacting material negative, CRM-) and a type II mutation causes normal 
expression of a dysfunctional protein (cross-reacting material positive, CRM+).  The 
Jewish mutations are termed Types I–IV and are the equivalent of type I (CRM-) 
mutations of other coagulation factor genes, characterized by low FXI coagulant activity 
and antigen.  Type II and Type III are the two most common mutations and the mutated 
alleles occur with equal frequency in severely deficient patients (49% and 47% of 
mutant alleles respectively).(56)  The Type II mutation is a nonsense mutation 
(Glu117Stop) in the Apple 2 domain responsible for substrate binding, while Type III is 
a missense mutation (Phe283Leu) in Apple 4, the domain important for dimerisation.  
Type I and Type IV mutations (a G to A transition at the donor splice site in intron N 
and a 14 bp deletion at the exon 14 / intron N splice site, respectively) both affect 
splicing in the catalytic domain. 
 
People of Ashkenazi descent have a heterozygote frequency of 9% and a homozygote 
frequency of 0.22%.(49)  Analysis of the genotypes of 125 unrelated Ashkenazi Jews 
with severe FXI deficiency found the most common genotype to be compound 
heterozygosity for the Types II and III mutations (52% of patients).  Homozygosity for 
these two mutations was also equally prevalent (22.4% of patients for each mutation).  
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The frequencies of the Type I and Type IV mutant alleles were much lower at 1.2% and 
0.4%. 
 
The Type II mutation is believed to have arisen between 586 BC and 70 AD and is 
prevalent in all main Jewish communities, Iraqi, Sephardic and Ashkenazi Jews.(49)  In 
contrast, the Type III mutation occurs only in Ashkenazi Jews, suggesting that it arose 
more recently (15th–20th centuries).  The type III mutation is not found in Iraqi Jews 
who lived in relative isolation in Iraq until the 1950s.  Comparison of the frequency of 
FXI intragenic polymorphisms in FXI deficient Iraqi, Sephardic and Ashkenazi Jews 
with unaffected Jewish individuals has confirmed a founder effect for both the Type II 
and Type III mutations.(60) 
 
Genotype appears to be associated with the level of FXI clotting activity in severely 
deficient patients.(56)  Type II homozygotes have the lowest levels and Type III 
homozygotes the highest (mean percentage of normal values of 1.2% and 9.7%, 
respectively), with intermediate levels seen in compound heterozygotes (3.3%). 
 
1.3.4 Clinical phenotype 
Classification of bleeding symptoms in FXI deficiency has been variable.  One group 
defined patients as bleeders if they had two or more of the following symptoms: easy 
bruising, epistaxis, menorrhagia, postpartum bleeding, prolonged bleeding after 
superficial cuts or haemorrhage after surgery or dental extraction.(61)  A five point 
classification system has also been used and in these studies, experienced haemostasis 
physicians were asked to use their usual criteria to assign patients to one of five 
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categories of bleeding - definite bleeder (1), probable bleeder (2), indeterminate (3), 
probable non-bleeder (4) and definite non-bleeder (5).(5;7)  Concordance between two 
assessors was found to be 67% and receiver-operator (ROC) curves confirmed that the 
bleeding tendency, as assessed by the five point scale, was more sensitive than other 
parameters such as excessive menstrual bleeding and bleeding after tonsillectomy.  
Another study used pre-defined criteria for epistaxis, menorrhagia, internal bleeding, 
muscle haematoma, haemarthrosis and post-operative bleeding to identify significant 
bleeding although such criteria can be difficult to apply in a retrospective setting.(50) 
 
Surgical and traumatic bleeding 
Unlike the haemophilias, FXI deficiency is rarely manifested as spontaneous bleeding 
even in severely affected patients and bleeding is typically related to trauma, surgery, 
menstruation or childbirth.(6)  Surgical procedures on areas of high intrinsic fibrinolytic 
activity such as the oral and nasal cavities, prostate and uterus are associated with 
increased rates of post-operative haemorrhage.(7;55;56)  Collins et al evaluated 156 
procedures in 25 severely deficient and 30 partially deficient patients who were treated 
prior to the widespread availability of effective treatment.(55)  Patients did not receive 
FXI replacement or tranexamic acid.  Of these 156 procedures, dental surgery accounted 
for 55, tonsillectomy for 31 and 70 were a heterogeneous group of other procedures.  
Bleeding occurred after 51% of dental procedures, 71% of tonsillectomies and 31% of 
other procedures.  Bleeding rates were higher for severely deficient patients for dental 
surgery (60% versus 43%) and tonsillectomy (86% versus 59%) but were similar for 
―other‖ procedures (32% versus 31%).  However, as can be seen, bleeding rates in 
untreated partially deficient patients ranged from 31% to 59%.  In contrast in this study, 
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there was one episode of bleeding after 38 procedures covered with FFP and no 
bleeding after 45 procedures covered with FXI concentrate. 
 
In a cohort of Iranian patients with FXI:C < 30U/dL who underwent surgery without 
cover, bleeding occurred in 24 of 38 patients (63%) after general surgery and 21 of 38 
(55%) after dental procedures.(50)  In a recent analysis of 120 unrelated patients with 
severe FXI deficiency (FXI:C < 15 U/dL), bleeding rates were evaluated after surgery, 
without the use of either FXI replacement or antifibrinolytic agents.(62)  Bleeding rates 
were 49-66.7% when surgery was carried out in tissues with high fibrinolytic activity 
(e.g. oral cavity, nasal mucosa, prostate and urinary tract).  This contrasted with 
bleeding rates of 1.5-40% in other sites.  The highest rate of bleeding at non-fibrinolytic 
sites was for hysterectomy (40% bleeding rate in five patients) followed by 23% for 13 
patients undergoing herniorraphy and 20% in five patients undergoing cholecystectomy.  
Bleeding rates for appendicectomy was 4.5% and for circumcision was 1.5%.  No 
bleeding was recorded in six fracture surgeries, one knee replacement and two halux 
valgus repairs.  Thirty-six patients had surgeries in areas with and without high levels of 
fibrinolytic activity and 18 had similar bleeding symptoms (i.e. whether bleeder or non-
bleeder) in both surgery types.  Of the remaining 18 patients, the majority (15 patients) 
only bled in sites with high fibrinolysis.  These data were used to advocate against the 
use of elective FXI replacement, at least in procedures on tissues without high 
fibrinolytic activity. 
 
Although, the published literature from the Israeli group suggests that bleeding rates in 
non treated Israeli patients are not as high as that suggested by literature from other 
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countries, the figures for bleeding from the oral cavity in particular are broadly in line 
across the studies.(63) 
 
Bleeding and genotype 
Bleeding is more common in severely deficient patients than in partially deficient 
patients.(7)  However, evidence linking the Jewish F11 gene mutations with bleeding 
tendency is limited.  There is evidence to suggest that some Jewish patients with Type II 
mutations and very low FXI levels experience more bleeding with surgical procedures 
than Type III homozygotes.(56)  The relationship between genotype and bleeding 
tendency was assessed in 20 patients known to be heterozygous for the type II mutation 
and compared to 41 partially deficient patients with an unknown mutation.(7)  
Approximately half of the patients in each group were classified as bleeders: 45% of 
patients heterozygous for the type II mutation and 49% of patients with an unknown 
mutation.(7)  However, no differences in bleeding tendency were identified between the 
two groups of heterozygotes. 
 
More recently, the genotype of 120 severely deficient patients did not influence the 
bleeding rate regardless of the site of the procedure.(62) 
 
Bleeding related to severity of FXI deficiency 
In the earliest studies of FXI deficient patients, partially deficient patients were said to 
rarely experience bleeding with invasive procedures and urological procedures were 
successfully performed without plasma cover.(3;4;54;64)  Other authors have stated that 
―heterozygotes rarely bleed excessively following trauma‖.(6)  However, post-operative 
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or traumatic bleeding was reported in 22 of 48 deficient patients from 25 kindreds, of 
whom nine were classified as severely deficient and 13 were classified as partially 
deficient.(57)  The frequency of bleeding in 81 partially deficient patients was 48% 
(28/58 patients after exclusion of 23 patients with indeterminate bleeding histories) 
which is more pronounced than the other rare bleeding disorders.(7)  Bleeding 
symptoms were compared between patients with partial FXI deficiency and relatives 
with a normal FXI:C.  Partially deficient patients were more likely to bleed after dental 
extractions (51% versus 9%) and have menorrhagia (41% versus 18%).  Eighteen of 30 
kindreds in this study came to medical attention due to bleeding in partially deficient 
patients, including one case of fatal post-operative haemorrhage.  A study of 45 Israeli 
families with FXI deficiency showed that bleeding symptoms were reported by 58% of 
26 severely deficient individuals compared with 20% of 46 partially deficient patients 
and 9% of 47 unaffected family members.(65)  Predictors of bleeding were the FXI:C 
(i.e. severe deficiency was more likely to be associated with bleeding than partial 
deficiency) and surgery involving mucous membranes. 
 
The bleeding tendency in women may manifest as menorrhagia which was reported in 
41% of partially deficient patients in one study and another report found that 
menorrhagia was present in 59% of a cohort of 20 women with FXI deficiency, without 
any relationship to FXI levels.(7;66) 
 
Co-inherited bleeding or thrombotic disorders 
In view of the lack of correlation between bleeding and FXI levels, other haemostatic 
modifiers such as co-inherited bleeding or thrombotic disorders have been considered.  
Von Willebrand disease (VWD) was diagnosed in 13% of the patients with FXI 
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deficiency in a small study.(61)  Bolton-Maggs et al did not find an increased incidence 
of type I VWD but did find a correlation between von Willebrand factor antigen 
(VWF:Ag) levels and bleeding.(7)  There was an increase in bleeding in 62% of patients 
with VWF:Ag less that 70 U/dL, in addition to a partial deficiency of FXI.  However, 
the use of a VWF level of 70 U/dL to predict bleeding tendency would lead to a 25% 
false positive rate.  Patients with blood group O had slightly lower levels of VWF:Ag 
and a slightly increased risk of bleeding symptoms but these differences did not reach 
statistical significance.  FVIII:C was correlated with FXI:C in a study of 26 severely 
deficient and 46 partially deficient patients.(65)  However, levels of FVIII and VWF 
were not associated with bleeding.  Blood group O had a minor association with 
bleeding. 
 
Co-inherited thrombophilic traits have been reported to alleviate bleeding symptoms in 
patients with haemophilia.  Heterozygosity for the FV Leiden mutation reduced 
concentrate usage and the number of bleeding episodes in patients with severe 
haemophilia A.(67)  The influence of these traits on the clinical phenotype of FXI 
deficient patients requires further study. 
 
FXI deficiency in pregnancy 
Unlike FVIII and von Willebrand factor, factor XI levels do not change significantly in 
FXI deficient women in pregnancy although some conflicting evidence of changes in 
FXI levels has been reported in normal women.(68-70)  This may be due to differences 
in FXI assay reliability and technique over the time period between studies. 
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Obstetrical outcomes have been evaluated in 28 pregnancies in 11 women with FXI 
deficiency (four severely and seven partially deficient).(70)  One patient had a 
spontaneous miscarriage.  Bleeding complications were documented in 15 of 28 
pregnancies (one post abortal bleed, four antepartum haemorrhages, four primary post-
partum haemorrhages (PPH), six secondary postpartum haemorrhages).  Postpartum 
haemorrhage was seen in 24% of pregnancies and included women with partial as well 
as severe deficiency.  Transfusion of red cells was required in two cases and transfusion 
of plasma was needed in three cases.  Elective FXI replacement was used to cover 
labour and delivery in five cases and no bleeding complications were reported (FXI 
concentrate for two caesarean sections and one vaginal delivery and plasma for two 
other vaginal deliveries). 
 
In a study of 164 pregnancies in 62 severely deficient women, 19 deliveries were 
covered with fresh frozen plasma while the remainder received no elective FXI 
replacement.(71)  Postpartum haemorrhage occurred in 36 cases, with transfusion of red 
cells required in 12 cases.  Rates of PPH were higher following vaginal delivery in 
which FXI replacement with plasma was not given versus those in which plasma was 
administered (24% versus 14%).  There were 18 Caesarean deliveries, of which six 
were covered with plasma.  PPH was recorded in two caesarean deliveries in which 
elective FXI replacement was not given.  Neither the presence of a thrombophilic trait 
(Factor V Leiden or the Prothrombin gene mutation) nor the occurrence of bleeding 
with a prior procedure influenced the likelihood of obstetrical bleeding.  
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FXI deficiency in the neonatal period: Circumcision 
Religious circumcision is carried out on male Jewish infants at day eight of life unless 
there is a clear medical contra-indication e.g. jaundice.  There is little prospective 
evidence in the literature regarding outcomes post circumcision in FXI deficient 
families.  Many reports in the literature are anecdotal or rely on hearsay evidence from 
an adult patient regarding events in the neonatal period.  Bolton-Maggs et al reported 
that four of 16 infants with levels <10 U/dL bled post circumcision, one requiring ITU 
admission and blood transfusion.(5)  In the same study, retrospective reporting of 
symptoms by adults revealed that one individual with a FXI:C of 34 U/dL bled after 
circumcision but other patients who had no bleeding after circumcision had post-
operative bleeding later in life.  Reporting from the same centre, another author reported 
that three of 16 (19%) patients bled post circumcision, two with FXI:C <2 U/dL and one 
with FXI:C of 34 U/dL, the latter probably the same patient reported by Bolton-
Maggs.(55)  A later report detailed seven circumcisions without bleeding (7) while a 
study of obstetrical outcomes reported that a neonate of a FXI deficient woman bled 
after circumcision requiring blood transfusion.  In a recent study of 120 severely 
deficient adult patients, 65 patients reported having had a circumcision but only one 
patient reported bleeding.(62) 
 
1.3.5 Treatment of FXI deficiency 
Tranexamic acid and topical fibrin glue 
Bleeding in FXI deficiency is especially likely in areas of high fibrinolytic activity and, 
therefore, antifibrinolytic agents have been used extensively in this condition.(56;72;73)  
Tranexamic acid is the most frequently used agent and has the advantage that it can be 
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given orally as a tablet or a 5% mouthwash, as well as intravenously.  Dental extraction 
in 19 severely deficient patients undergoing 41 dental procedures (mainly extractions) 
were managed successfully with tranexamic acid alone (1g QDS starting at 12 hours pre 
surgery and continuing for 1 week).(74)  All patients had a documented bleeding 
tendency (14 bled with prior dental procedures, five bled following other surgery or 
trauma).  Topical fibrin glue has also been used for dental procedures.(74;75) 
 
Desmopression (DDAVP) 
A number of case reports have suggested that small but significant increases in FXI 
levels occur after treatment with Desmopressin (DDAVP).(76;77)  Intravenous infusion 
of DDAVP (0.3μg/kg) resulted in a mean increase in FXI:C of 19 U/dL (range 12-25 
U/dL) in two normal individuals and patients with VWD and FXI deficiency (two 
patients each).(76)  A mean increase of 12 U/dL (range 9-14 U/dL) was recorded in six 
patients with partial FXI deficiency given DDAVP at a dose of 0.3μg/kg 
subcutaneously.(77)  However, in a study of 33 individuals with von Willebrand disease 
or Mild Haemophilia A, who underwent a DDAVP trial, increases in FXI:C and FXI:Ag 
were clinically insignificant.(78)  The mean ± SD FXI:C pre DDAVP was 90.7 U/dL 
(±22.9) and was 92.1 U/dL (±20.9) one hour post DDAVP.  Similarly FXI:Ag was 92.2 
U/dL (±20.1) and 89.9 U/dL (±21.3) one hour post DDAVP.  No difference was seen 
whether the DDAVP was administered intravenously (n = 16) or subcutaneously (n = 
17).  One patient in this study had a combined FVIII and FXI deficiency and the FXI:C 
did not increase with DDAVP.  The lack of evidence of a specific increase in FXI:C 
with DDAVP does not preclude a more general pro-haemostatic effect.(79) 
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FXI replacement 
In circumstances where the bleeding phenotype of the patient and/or the nature of an 
impending surgical procedure suggest that there is likely to be an increased risk of 
bleeding, the accepted method of prevention of bleeding is the replacement of 
FXI.(6;72;80)  FXI replacement is achieved by the use of fresh frozen plasma (FFP) or 
FXI concentrate.  Solvent-detergent treated FFP is preferred due to improved viral 
safety.(81)  FXI concentrate has limited availability and in many countries world-wide, 
plasma is the only available treatment.(72;82) 
 
Plasma 
The use of plasma to replace deficient FXI and prevent bleeding during a hernia repair 
was described in 1955.(83)  More recently, 38 procedures (including 18 dental 
extractions) in which FFP was used to prevent bleeding were reported.(7)  Bleeding was 
reported after only one procedure, a uterine D&C.  No further details were presented on 
pre and post FXI:C levels but a modest increase in FXI:C to < 30 U/dL in patients with 
severe FXI deficiency was subsequently referred to in a later paper by the same 
author.(72)  Similarly, an earlier case report suggested that the average rise in FXI was 
37% for each litre of plasma infused.(84) 
 
Solvent-detergent treated plasma (SD-FP) is now recommended on the basis of 
improved viral safety.(81)  This product was evaluated in eight patients with 
coagulation factor deficiencies including FXI deficiency and had a similar half-life to 
FFP (45 hours).(85)  One commentator has expressed concern about possible variability 
in FXI content in SD plasma.(53)  Treatment with SD-FP may lead to volume overload 
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and allergic reactions.(86)  In a study of severely deficient coagulopathic patients, 
standard doses of SD plasma did not normalise FXI:C activity.(87) 
 
FXI concentrate 
FXI concentrate is manufactured in the United Kingdom by BioProducts Laboratory 
(BPL) and in France by Laboratoire Francais du Fractionnement et des Biotechnologies 
(LFB).(88;89)  It is an unlicensed product, available on a named patient basis and is not 
freely available in many countries including the United States.(82) 
 
The BPL product is derived from pooled donor plasma and viral inactivation consists of 
dry heating at 80ºC for 72 hours in the final container.(88)  The initial formulation 
included antithrombin to inhibit FXIa (mean 102 U/mL).  Haemostatic efficacy was 
confirmed in 30 patients in whom 31 invasive procedures were carried out.  Normal 
levels of FXI activity were recorded in all patients and bleeding occurred in one case (a 
patient undergoing coronary artery bypass grafting with evidence of thoracic bleeding 
but no bleeding from the vein graft site).  The LFB product is also manufactured from 
pooled donor plasma.(89)  Viral inactivation consists of solvent-detergent (SD) 
treatment and nanofiltration and the product contains heparin (3-5 U/mL) and 
antithrombin (2-3 U/mL).  The original paper did not include evidence of clinical 
efficacy but in-vitro and in-vivo animal studies of thrombogenicity did not reveal any 
concerns regarding toxicity. 
 
However, a number of reports of thrombo-embolic side effects emerged after these 
concentrates were introduced.  Of three patients who received a SD treated FXI 
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concentrate which is not currently in use, one patient died after occlusion of all coronary 
artery grafts while another developed severe anaphylaxis.(90)  Subsequently, two 
patients receiving the LFB product showed evidence of activation of the coagulation 
system by in-vitro testing but no clinical thrombosis.(91)  Four elderly patients with 
pre-existing cardiovascular disease were reported to have had thrombotic complications 
using the BPL product.(92)  Mild activation of coagulation was described in two of 
three patients receiving 30 U/kg of the LFB FXI concentrate in a pharmacokinetic study 
prior to surgery but one of the patients developed disseminated intravascular 
coagulation (DIC) after a 60 U/kg dose subsequently administered for surgery.(93)   
 
Modification of the BPL product occurred in 1993 with the addition of heparin 10 
U/mL and the use of in-vitro batch testing for thrombogenicity.(82)  A review of a 
decade of experience with the BPL FXI concentrate showed that in 129 patients 
receiving treatment for 179 treatment episodes, there were 10 possible thrombotic 
events and the majority of cases occurred in patients with pre-existing vascular disease 
and aged > 60 years.(94)  In 1998 these data were updated and 12 probable or definite 
thrombotic episodes were reported for 229 treatment episodes in 161 patients.(72) 
 
Data on the use of the LFB FXI concentrate in 56 FXI deficient patients undergoing 85 
procedures were collected using a questionnaire.(82)  Three cases of thrombosis were 
reported: two DIC with thrombosis and one pulmonary embolus.  All three cases were 
aged more than 60 years and the first infusion was more than 40 U/kg.  
Recommendations on the administration of FXI concentrate now advise treating 
physicians to avoid doses of more than 30 U/kg, to avoid peak FXI:C levels of more 
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than 70 U/dL and to consider the risk-benefit ratio carefully in patients with pre-existing 
risk-factors for thrombosis.(80)  Avoidance of the use of concomitant anti-fibrinolytic 
agents and monitoring of laboratory markers of thrombosis are also suggested. 
 
With-holding upfront FXI replacement 
The Israeli group have recently suggested that replacement therapy is not required for 
severely deficient patients undergoing certain surgical procedures including 
circumcision, appendicectomy and orthopaedic surgery, based on a retrospective review 
of clinical history and medical notes.(62)  It is suggested that treatment could be 
reserved for patients who develop bleeding post-operatively.  No data on the validity of 
the latter course are presented with regard to outcomes associated with such a policy 
(e.g. requirement for cellular blood products, wound complication rates, duration of 
hospitalisation).  It should also be noted that the number of orthopaedic procedures 
reported is low (nine) and that no information about the prior bleeding history of the 
patients in the study was presented.  A similar policy has been suggested for labour and 
vaginal delivery.(71) 
 
1.3.6 FXI inhibitors 
Inhibitors to coagulation factors, acquired after treatment with exogenous clotting factor 
concentrates, pose a major difficulty in treatment.(95)  FXI inhibitors were first reported 
soon after the original description of FXI deficiency and by 2000, there were reports of 
15 individual patients in the literature.(96-104)  All reported patients had hereditary FXI 
deficiency and most had received plasma derived FXI replacement.  The FXI inhibitors 
were characterised as polyclonal IgG antibodies which bound primarily to the FXI 
domains involved in surface binding to FXII, HK and thrombin and neutralised FXI and 
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purified FXIa.(98;101;105)  The largest study of inhibitors in FXI deficiency evaluated 
118 severely deficient Israeli patients of whom seven had developed a FXI inhibitor and 
an additional three patients from the UK and the US.(106)  All FXI inhibitors were 
detected in patients with a II/II genotype who had previously been exposed to plasma.  
FXI inhibitors were not detected in patients with a II/III or a III/III genotype.  In this 
cohort, seven of 21 (33%) patients who were homozygous for the type II mutation and 
had received plasma, developed an inhibitor versus none of the 13 patients with the 
same genotype who had not received plasma.  It seems likely that the incidence of FXI 
inhibitors in the literature is an under-representation and that more comprehensive 
screening of at risk patients would identify additional patients.  Evaluation of the 
biochemical effects of six FXI inhibitors isolated from patient samples in this study 
confirmed earlier reports that FXI inhibitors impede activation of FXI by thrombin and 
FXIIa and impair activation of FIX but do not impair amidolytic cleavage of small 
substrates by FXIa. 
 
FXI inhibitors tend not to present as spontaneous bleeding but may be detected 
clinically in the peri-operative period as breakthrough bleeding and /or a worsening 
response to FXI replacement.  Pre-operative screening should detect clinically relevant 
inhibitors and is recommended in patients with the II/II genotype who have previously 
received FXI replacement (either plasma or FXI concentrate).  Inhibitor screening 
should also be performed in any patient who shows an unexpectedly poor response to 
treatment or a worsening clinical phenotype.  Current evidence suggests that 
development of FXI inhibitors is unlikely with other Jewish genotypes but information 
is lacking for non-Jewish genotypes. 
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1.3.7 Recombinant factor VIIa 
The recognition of the presence of FXI inhibitors and the development of a new 
coagulation factor for use in Haemophilia A and B with inhibitors, led to the early use 
of recombinant factor VIIa (rFVIIa) in a patient with an inhibitor to FXI.(102)  
Subsequently a number of case reports have appeared in abstract or journal article 
format which support the efficacy of peri-operative rFVIIa in patients with FXI 
deficiency with inhibitors.(107-111)  The dose of rFVIIa used initially varied from 60 to 
90 μg/kg but more recently lower bolus doses have been suggested (12 to 20 
μg/kg).(110;111)  Continuous infusion has been used in some cases.(107;111) 
 
In a fluorogenic thrombin generation assay using PPP from five patients with inhibitors 
to FXI, rFVIIa corrected the ETP to 50% of normal at a concentration of 1 μg/mL 
(equivalent to a clinical dose of 45 μg/kg).(106) 
 
1.4 Thrombin generation and FXI 
1.4.1 The history of thrombin generation assays 
Two versions of the thrombin generation assay were described in the 1950s but since 
these methods were time-consuming and cumbersome for routine use, the assay was not 
adopted widely.(112-114)  A method of continuously measuring thrombin generation 
was developed which was less labour intensive, less prone to manual error and 
amenable to semi-automation.(115;116)  With the advent of a range of suitable 
substrates and technology which allows rapid analysis, thrombin generation began to be 
applied to the clinical settings of hypo- and hyper-coagulability.(117-119)  The 
endogenous thrombin potential (ETP) was used to describe the total amount of thrombin 
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generated in the test but other parameters such as lag-time and peak thrombin generated 
can also be measured.  The continuous method was suitable for evaluation of platelet 
poor plasma (PPP) but the chromogenic substrates used and the defibrination process 
ruled out using platelet rich plasma (PRP) in a continuous method.  Nonetheless, the 
procoagulant surface of platelets was felt to be important and thrombin generation was 
shown to be defective in PRP from patients with Bernard-Soulier syndrome using a 
subsampling method and a chromogenic substrate.(120)  The development of 
fluorogenic substrates and a method for calculating thrombin concentrations (which is 
more complex than for chromogenic substrates) enabled the development of a 
continuous fluorogenic thrombin generation test (TGT) which was suitable for both PPP 
and PRP.(121;122) The presence of the substrate itself throughout the reaction does 
influence the amount of thrombin generated in the continuous method but choice of the 
correct substrate and use of appropriate calculations allow accurate assessment of 
thrombin generation.(123;124)  Since the rediscovery of the thrombin generation assay 
and the development of automated technology, thrombin generation has been evaluated 
in Haemophilia A and B, rare bleeding disorders, and thrombophilia (reviewed in 
(122)). 
 
1.4.2 Standardisation of TGT 
With the emergence of the TGT as a coagulation test with widespread clinical utility, 
standardisation of the assay became imperative.  The published data up to 2003 had 
used a range of TF concentrations, PL sources and concentrations, substrates, reaction 
volumes and reagents.  In an attempt to quantify the variation and eliminate it with the 
use of standard protocols, a study was undertaken in four separate laboratories of 
samples from normal individuals (ten), two lyophilised reference normal plasmas and 
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four lyophilised samples from individuals receiving anticoagulants.(125)  Plasma 
samples from these patients were double centrifuged.  There was a considerable 
variability between four different centres when analysing the various samples using a 
TGT customised in each laboratory (CVs varied from 2% to 114%, mean 60%).  
Imprecision studies varied from 1.15% to 19.72%.  Using a standardised protocol on the 
same samples, the intercentre CV was 18.1% and the imprecision study CVs varied 
from 2% to 14.5%.  Of note, these studies used a low dilution of TF (Recombiplastin 
diluted 1 in 2 in buffer) and so may not be applicable to TGT using lower 
concentrations of TF. 
 
Influence of phospholipid source 
The phospholipid (PL) surface is now appreciated as the critical platform on which the 
initiation and propagation phases of coagulation take place.  Activation of FIX by 
surface bound FXIa is accelerated by the presence of phospholipids.(126)  The source of 
phospholipids varies in in-vitro coagulation testing, from synthetic phospholipid 
mixtures to synthetic phospholipid vesicles to PRP or the addition of exogenous washed 
platelets to PPP.  In addition, residual platelets and platelet microparticles may be found 
in PPP prepared by standard methods.(127) 
 
In studies of thrombin generation in FXI deficient plasma, there has been no direct 
comparison of PPP and PRP.  Studies of PPP have variously used synthetic mixtures of 
PL (106;128) and PL vesicles.(43;119)  One study of thrombin generation in FXI 
deficiency used PRP or exogenous normal washed platelets added to PPP in a 
fluorogenic assay.(44) 
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The concentration of PL has also varied but concentrations between 1-10μM have 
generally been used.  In a fluorogenic assay of rFVIIa induced thrombin generation, the 
effect of varying the phospholipid concentration varied from 0 to 64μM was 
evaluated.(128)  In FXI deficient plasma, an increase in the amount of thrombin 
generated occurred with increasing PL concentrations up to a concentration of 32μM, 
above which no further increase was seen.  The addition of 0.2pM TF to a TGT 
containing PL and rFVIIa, markedly augmented the amount of thrombin generated.  In 
the absence of PL, regardless of the addition of rFVIIa or rFVIIa/TF, no thrombin was 
generated. 
 
The conclusion which may be drawn from these studies is that the addition of PL to PPP 
is critical.  Synthetic PL mixtures and PL vesicles have been used without clear 
evidence of superiority of one over another.  Similarly, there is insufficient evidence for 
the use of PRP in preference to PPP but the use of PRP is likely to most closely 
resemble the conditions which pertain to in-vivo coagulation. 
 
Influence of plasma preparation on TGT 
After routine centrifugation, residual platelets may remain in plasma and there is a 
concern that freezing and thawing of PPP may cause disruption of residual platelets and 
provide an additional phospholipid surface on which thrombin may form, altering the 
ETP.  This effect in most clearly seen in TGT which do not contain added PL and the 
effect may be abolished by filtration through cellulose filters or ultracentrifugation. 
(127;129)  The effects of pre- or post-thaw filtration of PPP was further investigated in 
a TGT using 1pM concentrations of rTF and varying concentrations of PL (0, 0.5 and 1 
μmol/L).(130)  In this experiment on the standardization of ETP measurements, 
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filtration of plasma which had been centrifuged once was necessary either before or 
after freezing to eliminate the effects of disrupted residual platelets which increased the 
ETP when plasmas were thawed.  This effect was most evident in experimental 
conditions which did not contain added PL.  Of note, the authors did not study the effect 
of double centrifugation prior to freezing.  Platelet microparticles are present in the 
circulation and can provide a phospholipid source even after routine centrifugation.  
Ultracentrifugation removes all platelet microparticles.(131)  In a study of thrombin 
generation associated with viable internal mammary artery sections, a chromogenic 
subsampling TGT, using PPP and 0.6 pM TF and no additional PL, was evaluated.(132)  
No difference in thrombin generation in this assay was seen between standard 
centrifugation and ultracentrifugation.  A study which was designed to evaluate the 
relative effects of TF and PL in FVIII, FIX and FXI deficient plasmas also used 
ultracentrifugation (presumably to outrule any confounding effects of residual 
platelets).(128) 
 
Influence of contact activation 
Contact activation of FXII with subsequent activation of FXI has been postulated to be 
a possible confounding factor in ETP studies.(133)  Studies of the individual factors in a 
synthetic model of coagulation included the addition of corn trypsin inhibitor (CTI) to 
ensure that contact activation was fully inhibited.(134;135)  However, contact activation 
did not appear to occur to any significant degree in a dilute thromboplastin assay 
evaluating the contribution of FXI to coagulation using low concentrations of TF as the 
initiator.(136)  No differences were seen in a chromogenic TGT in FXI deficient plasma 
in the presence and absence of a monoclonal antibody to FXII.(43)  Inhibition of FXII 
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was not used in two other studies of thrombin generation in FXI deficient plasmas using 
chromogenic substrates.(106;119)     
 
In a fluorogenic TGT in PRP, recalcification resulted in the onset of thrombin 
generation after a lag phase of 20 minutes, which was fully inhibited by CTI.(44)  
Subsequently, the use of CTI in a fluorogenic thrombin generation assay has been 
shown to abolish contact activation at concentrations of TF <15pM in PPP and 
PRP.(133;137)  However, in a fluorogenic assay of FXI deficient plasma no contact 
inhibition was used and no thrombin was generated over 60 minutes in FXI deficient 
plasma which was recalcified.(128)   
 
Thus, the evaluation of the effects of contact inhibition has been conflicting.  In a 
chromogenic assay, inhibition of FXII has not influenced the thrombin generation curve 
in FXI deficient plasma.(43)  In the fluorogenic assay, there is evidence in some (but 
not all) studies of contact activation requiring the use of CTI.(44;128;133) 
 
1.4.3 The role of FXI as determined by thrombin generation assays 
In in-vitro and synthetic models of coagulation, deficiencies of FXI are not associated 
with a reduction in thrombin generation when high concentrations of TF are used 
(>10pM).(43;134;136;138)  However, at low TF concentrations (< 5 pM ≈ 175 pg/mL) 
there is impairment of thrombin generation in FXI deficient plasma.(43;134)  The role 
of FXI in the coagulation cascade appears to be especially relevant in circumstances 
where the initiation phase of coagulation is prolonged.  This may be due to the fact that 
FXI activation by thrombin occurs late in the coagulation cascade.(138)  In situations 
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where the initiation phase is rapid (e.g. when using higher concentrations of TF) the 
contribution of FXI may be relatively less important. 
 
In a further study of a synthetic coagulation system FXI was found to reverse the 
inhibitory effect of elevated levels of Vitamin K dependent clotting factors.(139)  FIX 
inhibits the activation of FX by the FVIIa/TF complex due to competition by the two 
zymogens for the same complex enzyme and results in a prolongation of the initiation 
phase.  Elevated prothrombin appears to be particularly relevant in the presence of a 
limited phospholipid concentration (2 μM) and when using phospholipids rather than 
platelets.  This inhibitory effect of elevated FIX or prothrombin is abolished by 
physiological levels of FXI and by the use of platelets as the phospholipid surface.  The 
effectiveness of FXI in reversing the inhibitory effect of elevated vitamin K dependent 
clotting factors may be due to the slower generation of FXa and the prolongation of the 
initiation phase of coagulation in this setting. 
 
Wielders et al examined the role of thrombin in the feedback activation of FXI in a 
thrombin generation assay using PRP.(44)  Washed platelets were obtained from normal 
donors and FXI deficient PRP was prepared by suspending the normal washed platelets 
in FXI deficient plasma (the patient from whom the plasma was obtained was a 
homozygote for the type II mutation and had a FXI:C < 1%).  A continuous thrombin 
generation assay was performed using a fluorogenic substrate and coagulation was 
initiated with varying concentrations of thrombin (0 to 5 nM).  Of note, in this assay 
contact activation of coagulation (with a lag time of 20 minutes) was noted when the 
PRP was recalcified and all assays were performed in the presence of CTI. 
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The hypothesis to be tested was that thrombin could promote further thrombin 
production in PRP in a FXI dependent manner.  In this study thrombin dose-
dependently increased thrombin generation in the presence but not in the absence of 
platelets.  There was a marked reduction in the lagtime and the peak thrombin generated 
in FXI deficient plasma but thrombin generation was restored by adding 10% normal 
plasma.   
 
The authors also evaluated the effect of collagen which was found to enhance thrombin 
generation, possibly due to the procoagulant effect that collagen induces via platelet 
glycoprotein VI and exposure of anionic phospholipids.   
 
Activation of PRP by the addition of 2 nM or 20 nM rFVIIa was also enhanced by pre-
incubation with collagen. The addition of 20 nM rFVIIa and 5 μg/mL collagen also 
partially restored thrombin generation in PRP containing FXI deficient plasma. 
 
In conclusion, this study suggests that thrombin can initiate and maintain further 
thrombin generation in PRP but only in the presence of FXI.  Furthermore, platelet 
derived FXI and TF are not involved in this generation of thrombin but activated 
platelets are crucial.  Collagen enhances thrombin generation. 
 
1.4.4 Tissue factor as initiator 
Factor XI is activated by FXII in the presence of high molecular weight kininogen and a 
negatively charged surface.(17)  However, characterisation of FXI as part of the contact 
activation system, whose other members are not known to be associated with a bleeding 
diathesis, was problematic, since patients with both severe and partial FXI deficiency 
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are known to have bleeding symptoms (section 1.3.4).  The Josso loop was evidence for 
the importance of feedback activation by thrombin of FIX and explained the critical 
bleeding diathesis of severe FVIII and FIX deficiency.(140)  The confirmation that FXI 
too could be activated by small amounts of thrombin provided an explanation of the role 
of FXI in coagulation.(141;142)  The importance of FXI in the maintenance of a stable 
clot was shown by the demonstration that FXI is necessary for the generation of TAFI at 
low concentrations of TF.(143)  Cawthern et al showed that at low concentrations of 
TF, FXI deficient plasma did show evidence of thrombin generation but at a slower rate 
than in normal plasma.  Subsequently the importance of the phospholipid surface was 
well described.  FXI is activated on the surface of activated platelets and platelet GP1b 
is the critical receptor.(144) 
 
Concentration of TF used for initiation 
Butenas et al chose a recombinant tissue factor (rTF) concentration of 5 pmol/L 
(approx. 175 pg/mL) when conducting studies of thrombin generation in the context of 
varying concentrations of essential coagulation proteins and their inhibitors.(135;145)  
This rTF concentration was chosen to enable generation of thrombin even when 
procoagulant proteins were reduced to 50% of mean plasma levels. 
 
Wielders et al state that in normal plasma prothrombin is maximally converted at a TF 
concentration of approximately 2.5 pM.(118)  In this paper, the authors demonstrate that 
the ETP is dependent on the concentration of TF up to a concentration of approximately 
3 pM. Above this level ETP and prothrombin consumption are independent of the TF 
concentration and type of thromboplastin.  Other authors have quoted TF concentrations 
of >5 pM as the level above which the concentration of TF ceases to influence 
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prothrombin consumption.(145)  By using a 5pM concentration of rTF, Wielders et al 
sought to create a test of ETP which was independent of changes in the activity of the 
thromboplastin but yet would be close to the physiological situation. 
 
Lawrie et al conducted a multicentre assessment of ETP and in their standardized assay 
protocol used 100 μL of Recombiplastin diluted 1 in 2 with HEPES buffered saline to 
initiate coagulation in 80 μL of plasma.(125)  Although the concentrations of rTF are 
not given, such a low dilution of rTF will equate to a high concentration of rTF for 
initiation. Of note, this protocol was used to evaluate intra- and inter-laboratory CVs for 
normal plasma pools and anticoagulated plasma samples. 
 
In PRP, rTF concentrations of 1pM were used.(121)  Concentrations of 1pM and 0.6 
pM have also been used in more recent studies.(130;132) 
 
In FXI deficient plasma, Keularts showed that a difference in ETP was seen when a 
concentration of 7.5 pg/mL (approximately 0.21 pM) whereas no change in thrombin 
generating ability was seen when a TF concentration of 37.5 pg/mL(=1pM) was 
used.(43)  Subsequently, Al Dieri evaluated seven individual FXI deficient plasmas and 
found a normal ETP but rTF at a concentration of 15 pM (525 pg/mL) was used.(119) 
 
1.4.5 Thrombin generation studies in patients with FXI deficiency 
Following from these initial studies which indicated that FXI was important in the 
generation of thrombin, particularly at low TF concentrations, the recently re-discovered 
thrombin generation assay has been used to quantitate thrombin generation in FXI 
deficient plasma.  Keularts et al conducted a series of experiments on plasma from 
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normal volunteers and nine patients with severe FXI deficiency.(43)  No information on 
patient bleeding symptoms was presented. 
 
Both PRP and PPP were evaluated in a chromogenic subsampling thrombin generation 
assay using a 10μM concentration of phospholipid and varying concentrations of TF.  In 
these experiments, FXI deficiency was found to influence thrombin generation only 
when TF concentrations were 7-10 pg/mL (the concentration found in the 
thromboplastin time is 10 ng/mL).  At concentrations of TF higher than 10 pg/mL, 
thrombin generation was normal even in patients with a type II mutation and severe FXI 
deficiency.  At a concentration of TF of 7.5 pg/mL, there was a relationship between the 
FXI concentration and the ETP.  At 10% FXI levels, the ETP in PPP was 50% of 
normal.  In PRP from patients with a type II mutation, there was a marked impairment 
of ETP at low TF concentrations which was corrected by addition of 1% PPP.  Plasma 
from patients with a type III mutation who had a FXI:C of approximately 9% had 
normal thrombin generation in PRP.  Of note, in these studies there was no evidence of 
influence of contact activation since the addition of monoclonal antibodies to FXII did 
not alter the results found.  Additionally, plasma with severe FXII deficiency was 
evaluated in a similar TGT.  Without TF there was little thrombin generated but with 
7.5 pg/mL of TF, thrombin generation was normal.  Finally, in this study washed 
normal platelets were added to FXI deficient PPP but no effect of platelet derived FXI 
was evident in the amount of thrombin generated. 
 
A subsequent study of thrombin generation was undertaken in a variety of factor 
deficiencies including FXI deficiency.(119)  In this study, plasma was derived from 
patients and importantly bleeding symptoms were documented with a specific 
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questionnaire.  The thrombin generation assay used was a subsampling method with 
4μM phospholipids and activation by 15 pM TF.  The ETP was evaluated in seven 
patients with FXI deficiency whose baseline FXI:C ranged from <1% to 54%. In this 
study, the ETP was reduced by approximately 50% in patients with FXI:C <1% and was 
normal in patients with higher FXI:C.  Patient with FXI:C <1% were also stated to have 
a ―mild‖ bleeding symptoms and patients with levels >1% had no bleeding.  However, 
the total number of patients is small and it is unclear from the paper how many of the 
seven patients had FXI:C <1%.  The earlier Keularts study had stated that the use of TF 
at concentrations > 10 pg/mL(≈ 0.2pM) was not sensitive to alterations in thrombin 
generation in FXI deficient patients and more recently, in a synthetic model of 
coagulation, it has been confirmed that at a TF concentration of 10pM thrombin 
generation is normal when FXI is deficient.  Therefore, the usefulness of this study is 
limited due to the use of a high concentration of TF for initiation of coagulation. 
 
Plasma from five patients with severe FXI deficiency and inhibitors was evaluated in a 
fluorogenic thrombin generation assay using PPP and added phospholipids 
(concentration not stated).(106)  No thrombin was generated on recalcification. 
 
Thrombin generation was evaluated in 14 patients with severe FXI deficiency in a 
fluorogenic thrombin generation assay.(128)  No information was given regarding the 
exact FXI:C for each patient or the presence or absence of bleeding symptoms.  
Phospholipids at a concentration of 4μM were used and coagulation was initiated by 
recalcification.  No TF was used initially since the subsequent experiments were 
designed to evaluate the effect of rFVIIa, TF and phospholipid concentration.  No 
thrombin generation was evident in recalcified severely FXI deficient PPP.  
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It is apparent from these studies, that there is an impairment of thrombin generation in 
patients with severe FXI deficiency at low TF concentrations or when TF is not 
available.  If the TF concentration is >1pM, the thrombin generation is likely to be 
normal.  None of the studies published to date have evaluated partial deficiency of FXI 
and no correlation between thrombin generation and bleeding symptoms has been 
published. 
 
1.4.6 The effect of rFVIIa in thrombin generation studies of FXI deficiency 
Thrombin generation was evaluated in five patients with severe FXI deficiency with 
inhibitors (all were homozygous for the type II mutation).(106)  A fluorogenic substrate 
was used with synthetic phospholipids.  Thrombin generation was initiated by 
recalcification and increasing concentrations of rFVIIa (0-7 μg/mL) were added.  In the 
absence of rFVIIa, the thrombin generation curve was flat and was similar to that of 
patients with severe FXI deficiency without inhibitors.  Increasing amounts of rFVIIa 
resulted in increasing amounts of thrombin generation.  In all five patient samples, 
correction of the ETP to 50% of normal was obtained with a mean rFVIIa concentration 
of 1 μg/mL, equivalent to a clinical dose of 45 μg/kg. 
 
As part of a larger study on the effect of rFVIIa on thrombin generation in patients with 
haemophilia, 14 patients with severe FXI deficiency were included.(128)  The thrombin 
generation assay in this study was a fluorogenic assay in which PPP was recalcified to 
initiate coagulation (CTI was not used) and no exogenous source of TF was added.  
There was no thrombin generation over 60 minutes in FXI deficient plasmas in the 
presence of phospholipids alone but the addition of rFVIIa at a concentration of 1.75 
μg/mL (35 nM, equivalent to a clinical dose of 80 μg/kg) restored thrombin generation.  
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The latter effect was reduced if either FVIII or FIX were inhibited.  Increasing 
concentrations of phospholipid increased the amount of thrombin generated in FXI 
deficient plasma treated with 1.75 μg/mL rFVIIa up to a concentration of 32 μM.  
Adding 0.2 pM (≈10 pg/mL) TF and rFVIIa at a concentration of 0.875 μg/mL 
(17.5nM) to FXI deficient plasma resulted in an additive increase in the amount of 
thrombin generated which was more marked if the concentration of phospholipids was 
also increased to 32 μM from 4 μM. 
 
1.5 Thrombin activatable fibrinolysis inhibitor (TAFI) 
1.5.1 Introduction 
TAFI and the fibrinolytic system 
The fibrinolytic system is a critical element of haemostasis since it is pivotal to the 
dissolution of clot and the maintenance of a patent vascular tree.  The fibrinolytic 
system is comprised of the inactive proenzyme Plasminogen, two Plasminogen 
activators (tissue plasminogen activator, tPA and urokinase-type plasminogen activator, 
uPA), one inhibitor of Plasminogen activation (Plasminogen activator inhibitor 1, PAI 
1) and two inactivators of plasmin, α2-antiplasmin and Thrombin activatable 
fibrinolysis inhibitor (TAFI).(146) 
 
The TAFI protein was identified in the mid 1990s when it was also termed 
Carboxypeptidase U or Carboxypeptidase R.(147-149)  The term TAFI is now the 
recognised nomenclature and a crystal structure has recently been published for human 
TAFI.(150) 
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TAFI is a 60 kDa procarboxypeptidase glycoprotein which consists of 423 amino acid 
residues which, following activation, has a molecular weight of 53 kDa and consists of 
401 amino acids.(147;148)  The TAFI gene is located at chromosome 13q14.11 and has 
11 exons spanning 48kb.(151)  Thrombin is the main activator of TAFI, a reaction 
which is increased by a factor of 1250 by thrombomodulin (152), although it may also 
be activated by plasmin and trypsin.(153)  Activation occurs by cleavage of the Arg92-
Ala93 peptide bond with release of a 92 amino acid activation peptide and an active 
molecule TAFIa.  There is a biphasic pattern of TAFIa generation during in vitro clot 
lysis, the first wave is mediated by thrombin and the second by plasmin.(154)  The 
active enzyme is inactivated by a conformational change which is temperature 
dependent.  Release of the activation peptide results in the conformational change in 
TAFIa which disrupts the catalytic site.(150;155)  TAFIa exhibits thermal instability 
and has a half-life of 8 minutes at 37ºC, which increases to two hours at 25ºC.(156;157)  
 
TAFI inactivates fibrinolysis in an indirect manner by cleaving C-terminal lysine and 
arginine residues from partially degraded fibrin.  The removal of these residues reduces 
the number of binding sites for plasminogen and tPA on fibrin, and consequently the 
degradation of fibrin is slowed.  In addition, TAFIa eliminates the conversion of Glu-
Plasminogen to Lys-Plasminogen and reduces protection of plasmin from α2-
antiplasmin.(158) 
 
There are two naturally occurring variants of TAFI with either a Threonine or an 
Isoleucine residue at position 325.(159)  These variants have different properties after 
activation with respect to thermal instability (differing by a factor of 2, the isoleucine 
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isoform being more stable) and antifibrinolytic activity (differing by 60%, the 
isoleucine isoform being more active).  
The Km for the activation of TAFI by thrombin is far below the plasma TAFI 
concentration.(152)  For this reason, it may be hypothesised that an increase in TAFI 
concentration will result in increased formation of TAFIa, with a consequent decrease in 
fibrinolysis and promotion of thrombosis.  Experimentally, addition of increasing 
amounts of purified TAFI to normal plasma results in a linear dose-dependent increase 
in the clot lysis time (CLT).(160)  Alternatively, changes in TAFI activity or rates of 
inactivation could be wholly or partially responsible for the influence of TAFI on 
fibrinolysis. It should be noted though that the effect of TAFIa on fibrinolysis shows 
saturation with regards to TAFIa levels.  The extent of prolongation of fibrinolysis is 
approximately 3-4 fold at saturation TAFIa levels.  Under certain conditions, TAFIa can 
be stabilized by competitive inhibitors and the antifibrinolytic effect can be enhanced to 
a 20-fold prolongation of fibrinolysis.(161)  Therefore, alterations in TAFIa may 
attenuate but do not eliminate fibrinolysis. 
 
A threshold effect has been demonstrated for TAFIa which is defined as the minimal 
TAFI activity necessary to prevent acceleration of fibrinolysis and is dependent on tPA 
concentration.  The TAFIa threshold has been calculated at 8 U/L at a tPA concentration 
of 40ng/mL which is a limited percentage of the total amount of TAFI available for 
activation (963 U/L).(162;163)  
 
More recently, it has been suggested that the pro-enzyme TAFI may have intrinsic 
enzymatic activity (164) and that this continuous and stable activity may have a role in 
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protecting clot from fibrinolysis after the initial burst of TAFIa which is rapidly 
inactivated at 37ºC.  
 
Role of FXI in Fibrinolysis 
FXI contributes to the generation of thrombin and to the inhibition of fibrinolysis. In a 
turbidometric assay, fibrin generation was initiated with decreasing concentrations of 
recombinant TF (Innovin) in plasma deficient in FXI and FXII and in the same plasma 
reconstituted with FXI (final concentration 0.5 U/mL).(143)  While at higher rTF 
concentrations  there was no difference in the amount of fibrin generated, less fibrin was 
generated in FXI deficient plasmas at rTF dilutions ranging from 3 X 10
4 
to 3 X 10
5 
.  
This effect was abolished with pre-incubation of the FXI used to reconstitute the 
deficient plasma with a specific antibody.  The effect of FXI on clot lysis was then 
studied by adding t-PA (final concentration 30 U/mL, chosen to produce clot lysis in 60 
to 90 minutes).  At the highest rTF concentration (10
3
 dilution), no effect of FXI on clot 
lysis is seen when deficient plasma is compared with plasma reconstituted with FXI.  
However, at lower rTF concentrations (10
4 
and 10
5
 dilutions) the rate of clot lysis is 
increased in FXI deficient plasma.  It is notable that the effect of FXI in clot lysis is 
seen at rTF concentrations at which no alteration in fibrin formation was noted.  The 
possibility that the newly described TAFI protein was responsible for the effects 
described was mentioned in a note added in proof. 
 
Once the TAFI molecule had been identified it was then confirmed that FXI dependent 
inhibition of fibrinolysis was TAFI dependent. (165)  In this study, inhibition of 
fibrinolysis in FXI deficient plasma is restored by the addition of FXIa but this effect is 
completely abolished by pre-incubation with an antibody to TAFI.  Fibrinolysis is 
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enhanced in TAFI deficient plasma which is restored by the addition of purified TAFI 
but this restorative effect is again abolished by pre-incubation with an antibody to FXI. 
 
1.5.2 TAFI Antigen 
Measurement of TAFI:Ag 
There are a number of commercially available kits for the detection of TAFI antigen.  It 
has been suggested that there is an association between TAFI:Ag levels and genotype 
for certain TAFI polymorphisms which is more marked with certain assays.  This is 
postulated to result from variable antibody reactivity to TAFI isoforms, in particular the 
The325Ile (1040C/T) variant.  In 92 healthy individuals, the TAFI genotype was as 
follows: Ile/Ile 9%, Thr/Ile 42% and Thr/Thr 49% and the corresponding TAFI levels as 
measured by Elisa were 0.45, 0.6 and 0.83 U/mL.(166) 
 
TAFI:Ag levels in normal individuals 
TAFI antigen levels show considerable variability but are normally distributed in the 
human population.  In an early evaluation of TAFI:Ag using an Elisa technique and 
murine monoclonal anti-TAFI antibodies, the mean level was 111.4%±25.2 (compared 
to a normal pool) in 20 individuals with a range of 72-154%.(160)  Chetaille et al 
evaluated 249 healthy Caucasian men and non-pregnant women, 118 black African men 
and 12 pregnant women using a sheep anti-TAFI IgG in a commercial kit (Milan 
Analytica).(167)  In this study, there was no gender variation between men and women 
but TAFI:Ag levels were lower in African males than Caucasian males.  TAFI:Ag 
increased with age in women but there was no alteration in pregnancy.  There was no 
evidence of an influence by circadian rhythm or of inter-individual variation over time.  
In a study of 948 patients with venous thromboembolism and controls, TAFI:Ag was 
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measured by electroimmunoassay using rabbit anti-TAFI IgG and the lack of a gender 
difference in TAFI:Ag was confirmed as was an increase in TAFI:Ag with age in 
women.(168)  In addition, in this study, women on the combined oral contraceptive pill 
showed increased levels of TAFI:Ag.  In these early studies, results were expressed as a 
% of a pool of normal individuals, varying from 30 to 64 individuals.  TAFI:Ag levels 
(using the Affinity Biologicals kit) in a series of 96 unrelated patients with severe FXI 
deficiency were determined to be 121.2±30.7% in patients with acute myocardial 
infarction and  134.3±47.2% in patients without myocardial infarction.(169) 
 
A number of polymorphisms have been described in the promoter region of the TAFI 
gene and in the 3'UTR which have been associated with variations in TAFI antigen 
levels.(170)   
 
TAFI levels and disease associations 
In cardiovascular disease, it was unexpectedly found that cases had lower TAFI levels 
and a higher incidence of ―lowering‖ TAFI polymorphisms than controls.(171)  
 
Increased levels of TAFI:Ag have been postulated to be associated with thrombosis and 
in the Leiden thrombophilia (LETS) study, TAFI:Ag levels above the 90
th
 centile, as 
seen in 9% of controls and 14% of patients, were associated with a two fold increase in 
the risk of thrombosis.(168)  In addition, individuals in the LETS study with a CLT > 
the 90
th
 percentile had a two-fold increased risk of thrombosis.(172)  Increases in the 
CLT were not strongly correlated with any particular coagulation factor or TAFI and are 
presumed to reflect the balance of procoagulant and fibrinolytic factors. 
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1.5.3 TAFI activity 
Measurement of TAFIa: Clot Lysis and enzymatic methods 
TAFI activity can be evaluated either by performing a specific enzymatic assay or by a 
clot lysis assay. 
 
The clot lysis assay is a global assay encompassing the entire fibrinolytic system.  It is a 
plasma based assay which utilises an activator of thrombosis, usually thrombin or 
recombinant tissue factor and the reaction mix will generally contain a phospholipid 
source, calcium, tPA and buffer.  Potato tuber carboxypeptidase inhibitor (PTCI) is a 
specific inhibitor of TAFI and may be added to the reaction mix to define the 
contribution of TAFI to the CLT.(154;173;174)  In this way, the CLT is a surrogate 
measurement of TAFIa activity in a given plasma sample.  Other coagulation factors 
and inhibitors may also be added such as recombinant factor VIIa or antibodies to FXI 
for example to evaluate their specific effect on fibrinolysis.(173) 
 
The clot lysis assay requires a prolonged incubation from 80 to 220 minutes at 
37ºC.(143;154;160;173;174)  The clot lysis time (CLT) is measured in minutes and has 
been defined in two ways: as the time from the midpoint of the clear-to-maximum 
turbid transition to the midpoint of the maximum turbid-to-clear transition and also as 
the time to achieve a 50% reduction in the maximum turbidity.(143;173)  
 
Two groups have described enzymatic assays for TAFIa.(175;176)  Both use 
thrombin/thrombomodulin as the activator of TAFI and detect the TAFIa formed by 
detecting cleavage of hippuryl-Arg, either by a colorimetric reaction (175) or by 
HPLC.(176)  Assays are run with and without PTCI to determine the contribution 
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attributable to TAFI versus other plasma carboxypetidases e.g. Carboxypeptidase N.  A 
commercially available kit has been developed which is based on the enzymatic assay 
(Actichrome® TAFI activity assay; American Diagnostica, CT, USA). 
 
TAFIa in normal individuals and in Haemophilia 
TAFI was confirmed to play a role in the modulation of clot lysis in healthy individuals 
in the presence of a normal intrinsic pathway.(160)  There is a linear relationship 
between TAFI antigen and clot lysis time when purified TAFI is added to TAFI 
depleted plasma. In 20 healthy volunteers, the mean clot lysis time was found to be 62 ± 
11.5 minutes but there was considerable inter-individual variation (41 – 82 mins).  
When the clot lysis assay was repeated in the presence of a FXI antibody the clot lysis 
time was reduced to 38.7 ± 8.6 minutes.  A significant correlation was seen between the 
TAFI antigen and both clot lysis time and TAFI activity levels in these individuals.  The 
correlation between TAFI antigen and clot lysis is lost when a FXI inhibiting antibody 
is used.  TAFI activity was also measured enzymatically after activation by 
thrombin/thrombomodulin and this was correlated with clot lysis indicating that the clot 
lysis assay is an accurate surrogate for the functional activity of TAFIa in plasma. 
 
In pooled severe Haemophilia A plasma, clot lysis times were normal at high TF 
concentrations but were severely decreased at moderate to low concentrations of 
TF.(177)  Addition of FVIII, TAFI or thrombomodulin restored clot lysis times in the 
presence of low concentrations of TF.  Fifty-six individuals with severe Haemophilia A 
were studied and again, clot lysis times at baseline were decreased.  CLT in the 
presence of PTCI were similar to the baseline CLT, showing that minimal activation of 
TAFI occurs in Haemophilia A plasma.  Addition of physiological concentrations of 
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FVIII, TAFI or TM increases the CLT significantly.  Notably, some individuals with 
Haemophilia A had normal CLT at baseline, illustrating the inter-individual variability 
seen.  No correlation between TAFI levels and bleeding was reported. 
 
1.5.4 The influence of rFVIIa on fibrinolysis 
In haemophilic plasma, the addition of recombinant factor VIIa (rFVIIa) at 
concentrations above 31.3 U/mL significantly prolonged the CLT and this effect was 
abolished by the addition of a specific inhibitor to TAFI (PTCI).(173)  It was noted that 
there was considerable variability in the concentration of rFVIIa required for half 
maximal prolongation of the CLT (median 73 U/mL, range 10.7-250 U/mL) and that the 
corresponding concentration of rFVIIa required to shorten the clotting time was much 
less (median 8.4 U/mL, range 1.7-22.5 U/mL).  The effects of rFVIIa on clotting time 
and CLT were not correlated with each other.  It is notable that the concentrations of 
rFVIIa required for clotting in this study are similar to those needed to promote 
haemostasis while the higher concentrations needed to inhibit lysis are similar to those 
required to maintain haemostasis.(178) 
 
In a study of fibrin aggregation curves, initiated by thrombin and performed in a 
microplate, commercially purchased FXI deficient plasma had a CLT of 22.5±0.7 
minutes compared to 24±2.2 minutes for pooled normal plasma.(179)  The addition of 
rFVIIa at concentrations from 2.4, 4.8 and 9.6 μg/mL normalised the CLT.  It could be 
argued that the use of thrombin as the initiator results in significant activation of TAFI 
which is non-physiological compared to the amount of thrombin that might be 
generated in a severely FXI deficient patient in-vivo. 
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1.6 Conclusion 
Considerable progress has been made in the understanding of the genetics, structure and 
function of the FXI protein in recent years.  In particular, the interaction between the 
FXI apple domains and its activators, co-factors and substrates has been clarified.  
Identification of mutations in the F11 gene causing clinical FXI deficiency is also 
adding to the understanding of the function and importance of specific residues and 
regions. 
 
However, the increase in knowledge has not yet translated into a better understanding of 
the bleeding diathesis in deficient patients.  The variable and unpredictable bleeding 
tendency in this condition continues to present great difficulties to clinicians counselling 
and treating patients.  Although a considerable amount of clinical data have been 
published on FXI deficiency, much of the clinical research was done at a time when 
detailed genetic analysis was not readily available, newer proteins such as TAFI were 
unknown and re-emergent techniques such as thrombin generation had not yet become 
widely utilised.  Indeed there remains some controversy about the prevalence and 
importance of clinical bleeding symptoms in FXI deficient individuals, especially those 
with partial deficiency.  The optimum treatment for patients requiring invasive 
procedures is uncertain and new products with increased viral safety are needed.  The 
rarity of this bleeding disorder means that it can be difficult to accumulate data on large 
numbers of patients and clinical recommendations may be based on case reports and 
small case series. 
 
In this context, a project to study the clinical and laboratory features which determine 
the bleeding tendency in FXI deficiency was designed.  The aims of this project were to 
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clearly define the genotype and phenotype of a large cohort of FXI deficient patients 
and to try to identify modifying factors which influence the bleeding tendency using the 
following methods:  
 Allocation of a bleeding score to all participating patients, having determined 
the bleeding history by the use of a standard questionnaire 
 Evaluation of routine laboratory coagulation parameters including FXI:C, 
FXI:Ag, von Willebrand screen, blood group and thrombophilia screen 
 Evaluation of the influence of TAFI by means of estimation of TAFI:Ag, 
TAFI:Ac and clot lysis time   
 Development of a thrombin generation assay with appropriate modification for 
use in FXI deficient plasma   
 Screening of the F11 gene for causative mutations  
 Development of a molecular model of the FXI protein to evaluate the effect of 
mutations on protein structure and function, since a crystal structure for the FXI 
protein did not exist at the time of the study   
 Evaluation of the use of recombinant factor VIIa for the prevention of bleeding 
associated with surgery in FXI deficient patients in a pilot clinical trial. 
 
The assessment of bleeding tendency in this study was fundamental and was utilised 
through the different aspects of the work to define the relationship between possible 
modifiers of bleeding and clinical bleeding phenotype.  
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Chapter 2 Standard Materials and Methods 
2.1 Patient recruitment 
All patients studied were aged >18 years and were registered as having FXI deficiency 
at the Katharine Dormandy Haemophilia Centre and Haemostasis Unit, Royal Free and 
University College Medical School, London, United Kingdom.  The local Ethics 
Committee approved the study.  Informed patient consent was obtained in all cases.  
Patient consent, bleeding history and blood samples were taken at a dedicated clinic 
held weekly over a six month period in 2001/2002.  The patient information leaflet, 
consent form and data collection form along with a statement of ethical approval and 
clearance from the Royal Free Hampstead NHS Trust Clinical Governance Support 
centre are shown in Appendix 10.1. 
 
2.2 Specimen collection 
Whole blood samples were collected by venepuncture from participating patients, using 
minimal venous stasis.  For coagulation analysis, 40 mLs of blood was drawn into 
citrate (0.106mol/L trisodium citrate solution, Sarstedt Monovette, Nümbrecht, 
Germany).  The citrate samples were spun for 12 minutes at a speed of 3000rpm and a 
temperature of 4
0
C. The supernatant plasma was separated and spun again for a further 
12 minutes before being aliquoted into 1 mL Eppendorf tubes and frozen at –700C.(180)  
Prior to analysis, the plasma was defrosted at 37
0
C for 5 minutes.  Thawed plasmas 
were stored at 2-8 
0
C until assay and were assayed within 2 hours of thawing. 
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For genetic analysis, 10 mLs of whole blood was drawn into EDTA (K
3+
EDTA, 1.6 
mg/mL, Sarstedt Monovette, Nümbrecht, Germany).  The EDTA sample was spun for 
10 minutes.  The buffy coat was aspirated with a Pasteur pipette, placed in a clean 
Eppendorf and frozen at –700C. 
 
2.3 Bleeding history and Bleeding Score 
2.3.1 Bleeding history 
A detailed bleeding history was taken by a single clinician (NOC) at a dedicated clinic, 
using a standard data collection form (appendix 10.1).  Patients were assigned a unique 
study number.  The following details were recorded: 
 Demographics (name, DOB, ethnic origin, religion, registered baseline 
FXI:C, blood group) 
 Diagnosis of FXI deficiency (circumstances of diagnosis) 
 Bleeding history (dental extraction, epistaxis, trauma, major surgery, minor 
surgery, circumcision) 
 Medications (in particular aspirin, NSAIDs, anticoagulation) 
 Family history (number of first degree relatives, description of bleeding 
symptoms) 
 Menorrhagia, pregnancy history, post partum haemorrhage 
 Treatment episodes (number and type of treatments) 
 Vaccination status   
In the case of bleeding episodes, the type of treatment given including 
transfusion, re-operation and factor replacement was recorded. 
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2.3.2 Bleeding score 
The bleeding histories were subsequently scored independently by three clinicians with 
experience in haemostasis, one of whom was the clinician who had taken the original 
history.  Patients were identified by study number only.  The clinicians scoring the 
bleeding histories were blinded to the patients FXI:C and other laboratory results.  
Scores were compared to assess concordance between the three reviewers. 
 
A five point bleeding score was used to designate bleeding tendency.(5;7)  A definite 
bleeder was allocated a score of one and a probable bleeder was given a score of two 
(Table 2.1). Conversely, a definite non-bleeder was given a score of five and probable 
non-bleeders had a score of four.  A score of three (indeterminate) was applied if the 
reviewer felt that the patient had not undergone sufficient haemostatic challenges on 
which to base a judgement or if there was conflicting evidence.  In two cases, a bleeding 
score of three was applied where there was disagreement amongst the reviewers about 
the bleeding score. 
 
Table 2.1:  Bleeding score related to bleeding phenotype (5;7). 
Bleeding Score Bleeding Phenotype 
1 Definite bleeder 
2 Probable bleeder 
3 Indeterminate 
4 Probable non-bleeder 
5 Definite non-bleeder 
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2.3.3 Patient database 
All patient information gathered in the bleeding history (fig 2.1) and patient bleeding 
scores (fig. 2.2) were recorded in a specifically designed, password-protected patient 
database (Microsoft Access® 2002).  Individual data items were assigned numerical 
codes to aid data retrieval.   
 
Figure 2.1:  Patient demographics displayed in FXI patient database. 
 
 
Subsequently, patient data derived during the laboratory analysis was added to the 
patient database (fig. 2.3), thus ensuring a robust, secure and easily searchable patient 
database. 
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Figure 2.2:  Bleeding scores from each of three observers and consensus bleeding score 
displayed in FXI patient database. 
 
 
Figure 2.3:  Laboratory Investigations screen, FXI patient database. 
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Queries regarding individual parameters were easy to run.  In the example given in 
figure 2.4, the database is queried regarding patients undergoing combined 
tonsillectomy and adenoidectomy (code 27).  Seven patients are identified with study 
number and FXI:C.  None of the patients received pre-operative treatment (all code 0 in 
the ―PreOp treatment‖ column). One patient suffered post-operative bleeding (code 1 in 
the ―bleeding‖ column) and required a blood transfusion (code 8).  Database queries 
were easily customised to include or exclude additional data. 
 
Figure 2.4:  A database query on patients undergoing combined tonsillectomy and 
adenoidectomy. 
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2.4 Coagulation analysis 
FXI:C was measured using a one-stage activated partial thromboplastin time in three 
dilutions (1:10, 1:20 and 1:40) on an ACL-3000 (Instrumentation laboratories, Cheshire, 
UK).  FXI:C was assayed against a normal pool which had been assigned a value of 100 
U/dL.  The activator used in the factor assay was a lyophilized silica APTT reagent 
(Instrumentation laboratories, Cheshire, UK) and the activation time was five minutes.  
A FXI deficient plasma with a FXI:C <1 U/dL was used for all dilutions, either 
commercially obtained (Technoclone UK Ltd, Surrey, UK) or obtained from a patient 
known to be homozygous for the Jewish type II F11 gene mutation.  The reference 
interval was obtained from analysis of the FXI:C levels of 34 individuals without a 
known coagulation disorder and was calculated as the range encompassing the mean ± 
2SD (70-140 U/dL).  The inter-assay co-efficient of variation (CV) was 6.3% for 
normal plasma and 4.2% for abnormal plasma. 
 
FXI:Ag was measured using an enzyme-linked immunosorbent assay which utilised a 
polyclonal goat anti-human FXI IgG as the capture antibody and a peroxidase goat anti-
FXI as the detection antibody (Kordia Life Sciences, Leiden, The Netherlands). 
 
Assays for PT, aPTT, FVII:C, FVIII:C, VWF:Ag, VWF:CBA, antithrombin, protein C, 
protein S, APCR, lupus anticoagulant and blood group were performed according to the 
standard laboratory protocols in use at the time in the Katharine Dormandy 
Haemophilia centre Coagulation Laboratory. 
 
Thromboelastography (TEG) was performed using a computerized thromboelastograph 
(Haemoscope Corp., Illinois, USA).  Within 60 minutes of venepuncture, citrated whole 
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blood (340 μL) was added to a warmed TEG cup containing 20 μL of 0.2 mol/L calcium 
chloride and the pin was raised and lowered into the cup three times.  The TEG analyser 
recorded the following parameters: the reaction time (r time), the clot formation time (k 
time), the alpha angle and the maximum amplitude and these parameters were presented 
in graphical and numerical form. 
 
2.5 Thrombin Generation Tests 
2.5.1 Materials 
Common materials for all TGT 
Tris buffered saline (TBS): 3.03 g Trizma base, 4.4 g NaCl in 500 mLs sterile water, pH 
7.4 
Bovine serum albumin (BSA): 20% solution (Sigma-Aldrich, Dorset, United Kingdom). 
TBS/BSA: 1 mL of 20% BSA was added to 19 mLs TBS, (concentration 50mM Tris 
base, 150mM NaCl, 1% BSA, pH 7.4) 
Recombinant tissue factor (rTF): RecombiPlastin, (HemosIL, Instrumentation 
Laboratory, Cheshire, U.K.).  The Recombiplastin was reconstituted in 20 mLs of sterile 
water rather than the supplied diluent which contains calcium.  A 10 ng/mL solution of 
Recombiplastin was made by further dilutions in sterile water and stored at 4 
0
C (total 
dilution 1 in 2620). 
Phospholipid: Bell and Alton platelet subsitute (Diagen, Diagnostic reagents, Thame, 
Oxon.) 
1. Subsampling method: Reconstituted with 1 mL TBS (concentration 233 
μg/mL(181)) giving final concentration 4.66 μg/mL (13 μM) in the reaction mix. 
2. Continuous method: Reconstituted with 4 mLs TBS giving final concentration 
6.5 μM in the reaction mix. 
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Reptilase: (Pentapharm, Basel, Switzerland) reconstituted with 1 mL sterile water. 
0.1 M calcium chloride: (Baxter, Berkshire, U.K.)  
Sterile water: (Baxter, Berkshire, U.K.) 
Flat bottomed microtitre plate: Nunc Maxisorp (Thermo Fisher Scientific, Roskilde, 
Denmark) 
Water bath at 37
0
C 
Ice 
Wooden sticks 
 
Specific materials and working solutions for subsampling method 
Chromogenic substrate: H-D-Phenylalanyl-L-pipecolyl-L-arginine-p-nitroaniline 
dihydrochloride - S2238 (Chromogenix, Milan, Italy).  16.55mLs sterile water was 
added to a 25mg vial of substrate and a working solution was made by diluting this 
50:50 in TBS/BSA. 
EDTA buffer: 3.03 g Trizma base, 5.1135 g NaCl, 1.395 g EDTA in 500 mLs sterile 
water, pH 8.4 
EDTA/BSA buffer: 5 mLs 20% BSA added to 95 mLs EDTA buffer (concentration 
7.5mM EDTA, 50mM Tris base, 175mM NaCl, 1% BSA, pH 8.4) 
rTF/CaCl2: A working solution of rTF/ CaCl2, to give a final concentration of 10 pg/mL 
in the reaction mix, was made on the day of each experiment by diluting the 10 ng/mL 
rTF stock solution in 0.1M CaCl2 (1 in 216 dilution, total dilution approximately 1 in 
565920). 
50% acetic acid: glacial acetic acid mixed 50:50 with sterile water 
Bovine thrombin: (Sigma-Aldrich, Dorset, United Kingdom) 1000 U/mL for standard 
curve 
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Plate reader: Dynex MRX (Dynex technologies, West Sussex, U.K.) to read at 405nm. 
Polystyrene LP4 test tubes: (Western Laboratory Service Ltd, Hampshire, U.K.) 
 
Specific materials and working solutions for continuous method 
Chromogenic substrate: Methylmalonyl-L-α-methylalanyl-arginyl-paranitroanilide - 
CBS 00.68 (Diagnostica Stago, Reading, U.K.).  The vial was reconsitituted with 1.25 
mLs sterile water to give a concentration of 6 mmol/L.  A working solution was made 
by diluting this solution 50:50 in 0.1M CaCl2. 
Normal plasma control: Cryocheck (Precision Biologic, Hampshire, U.K.) 
rTF/TBS/BSA: A working solution of rTF in TBS/BSA, to give a final concentration of 
10 pg/mL in the reaction mix, was made on the day of each experiment by diluting 5.5 
μl of the 10 ng/mL stock solution in 1994.5 μl TBS/BSA. 
Kinetic plate reader: Versamax tuneable microplate reader (Molecular Devices (UK) 
Ltd, Berkshire, U.K.) 
 
2.5.2 Subsampling method 
Thawed plasma was defibrinated by adding 20 μl of reptilase to 1mL of plasma.  The 
plasma sample was vortexed briefly and incubated in a waterbath at 37
0
C for 15 
minutes.  The sample was then placed on ice for 10 minutes before the clot was 
removed by winding onto a wooden stick.  The plasma was centrifuged at 13,000 rpm 
for three minutes and any residual clot removed.  The defibrinated plasma sample was 
kept on ice until assayed.  Plasmas were tested in triplicate. 
 
To assay thrombin generation by the sub-sampling method, 300 μl of plasma was 
incubated with 20 μl phospholipid (final concentration 13 μM) and 40 μl TBS/BSA 
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buffer at 37
0C for 5 minutes.  Clotting was initiated by adding 100 μl recombinant tissue 
factor diluted in 0.1M calcium chloride (rTF/CaCl2, final concentration 10 pg/mL) 
which had been warmed in the waterbath for two to three minutes.  Exactly 30 seconds 
after addition of the rTF/CaCl2, the first 10 μl sample was removed and added to a well 
of a microtitre plate containing 140 μl of an EDTA/BSA buffer to stop the reaction.  
Sequential 10 μl samples were removed and added to individual wells of the microtitre 
plate every 30 seconds for 30 minutes in the case of partially deficient or rFVIIa treated 
plasmas or every 60 seconds for 60 minutes in the case of severely deficient plasmas.  
When the plate was full or the end time had been reached, 50 μl of chromogenic 
substrate S2238 was added to each well and exactly 3 minutes later, 80 μl of 50% acetic 
acid was added to stop colour formation.  The plate was then read at 405nm.  The 
absorbance from the first well of a series of wells for an individual sample was 
subtracted as a blank from all raw absorbances to control for the baseline colour of the 
plasma.  The contributions of thrombin and the thrombin-α2-macroglobulin were 
calculated using a macro supplied by the National Institute for Biological Standards and 
Controls (NIBSC, Potters Bar, U.K.) and based on the method described by 
Hemker.(116)  The thrombin generated for each triplicate plasma was calculated and 
averaged.  The thrombin curve was graphed and the area under the curve (AUC) and 
peak thrombin calculated using a standard curve generated by assaying serial dilutions 
of bovine thrombin. 
 
2.5.3 Continuous method 
Plasma was defibrinated as outlined above and was kept on ice until assayed.  Plasma 
samples were tested in duplicate and two normal plasma controls were tested in 
duplicate in the first and last wells of each microtitre plate. 
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To assay thrombin generation by the continuous method, 20 μl of Phospholipid (final 
concentration 6.5 μM) was added to each well of a flat bottomed plate. 80 μl of 
prewarmed rTF suspended in a TBS/BSA solution (final concentration of  rTF 10 
pg/mL) and 80 μl of test plasma were then added to the well. The plate was mixed on 
the plate reader and incubated at 37
0
C for 2 minutes. Coagulation was initiated by 
adding 40 μl  of substrate/CaCl2 solution.  The plate was mixed and the plate reader was 
set to commence reading at 405 nm every 30 seconds continuously for 30 minutes. The 
results were downloaded to an Excel spread sheet (Microsoft® Excel 2002). The 
contributions of thrombin and thrombin- α2-macroglobulin complex to the absorbances 
recorded by the plate reader were calculated using a macro (see below). The 
endogenous thrombin potential was calculated as the sum of the absorbances 
attributable to thrombin expressed as a percentage of normal plasma control. 
 
2.5.4 Mathematical calculation of Endogenous Thrombin Potential in the 
Continuous Thrombin Generation Test 
In the course of the thrombin generation test, thrombin is generated which converts 
substrate which is detected by measuring optical density  However, as the experiment 
proceeds a portion of the thrombin generated complexes with α2-macroglobulin and this 
complex also converts substrate.  If the contribution of the α2-macroglobulin - thrombin 
complex to the total optical density is not subtracted, an overestimation of thrombin 
generation will result.  The mathematical formula to perform this calculation has been 
described by Hemker, both for the subsampling and the continuous methods for 
measuring thrombin generation.(116)  The formula for the continuous method was 
entered onto an Excel (Microsoft® Excel 2002) spreadsheet in the form of a macro 
which could be applied rapidly and accurately to the raw data obtained from the 
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microtitre plate reader.  The macro was validated against a manual calculation for 
conversion of the raw data to ensure accuracy of the computer generated results before 
it was applied to patient data. 
2.6 TAFI  
2.6.1 TAFI Antigen 
Materials 
Imulyse® TAFI Antigen kit (Biopool International, Sweden), subsequently 
marketed as VisuLize® TAFI Antigen kit (Affinity Biologicals Inc., Ontario, 
Canada) containing: 
 6 strips of 16 wells pre coated with a polyclonal sheep 
antibody to human TAFI 
 Standard reference plasma 
 Control plasma A 
 Control plasma B 
 TAFI deficient plasma 
 10x wash buffer concentrate 
 Sample diluent 
 Peroxidase labelled detecting antibody 
 Tetramethylbenzidine (TMB) substrate 
 0.2M H2SO4 (Stop solution) 
 Adhesive plate sealer 
Also required were: 
 Reagent grade water 
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 1 channel pipettes 
 8 channel pipettes 
 Laboratory timer 
 Microplate reader: Dynex MRX (Dynex technologies, West 
Sussex, U.K.) to read at 450 nm  
Method 
A six point standard curve (1/100 to 1/3200 dilutions) was derived by diluting the 
standard reference plasma in TAFI deficient plasma.  Control and test plasmas were 
diluted 1 in 2 in TAFI deficient plasma and then 1 in 100 in sample diluent, to give a 
final dilution of 1/200. 
 
The pre-coated wells were prepared by washing three times with wash buffer (300 μL 
per well).  Standards and samples were loaded into the wells in duplicate (100 μL per 
sample) and incubated at room temperature for one hour.  100 μL of sample diluent is 
loaded in duplicate as a ―blank‖.  The wells were emptied by inverting onto absorbent 
blotting paper and were washed three times.  100 μL of detecting antibody was applied 
to the wells and incubated at room temperature for 30 minutes.  Again the wells were 
emptied and washed three times as before.  100 μL of TMB substrate was added to each 
well and the colour was developed for exactly 10 minutes at room temperature.  100 μL 
of 0.2M H2SO4  stop solution was added to the wells in the same order as the TMB 
substrate and the plate was read at 450nm. 
 
A standard curve was constructed by plotting the TAFI concentration (as given on the 
vial of standard reference plasma) on the x axis and the mean absorbance value for each 
of the dilutions on the y axis of log-log graph paper.  The mean absorbance values of 
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the control and test plasmas was read off the standard curve and multiplied by the 
appropriate dilution factor (2 for 1/200 dilution).  The TAFI concentration obtained for 
the control plasmas must be within the range stated on the vial labels.  The intra-assay 
C.V. was 5.8% and the inter-assay C.V. was 8%, as quoted by the kit manufacturer. 
2.6.2 TAFI Activity 
Materials 
Actichrome® TAFI Activity kit (Product no. 874, American Diagnostica, 
Greenwich, CT, USA) containing: 
 TAFIa standard 
 Assay buffer 
 TAFI developer 
 TAFI activation reagent 
 Activation stop reagent 
 Activation enhancer reagent 
96 well microtitre roundbottomed plate 
Deionized filtered water 
8 channel pipette (50-200 μl) 
1 channel pipette (10-200 μl) 
1.5 mL Microfuge tubes 
Micro-titre plate shaker 
Micro-titre plate reader: Dynex MRX (Dynex technologies, West Sussex, U.K.) to 
read at 490 nm  
2M H2SO4 (sulphuric acid) 
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Method 
Each test plasma was assayed in duplicate in the unactivated form and after activation 
by a thrombin/thrombomodulin complex.  The difference in absorbance between the 
activated and the unactivated plasma represents the amount of activatable TAFI in the 
sample. 
 
Each test plasma (20 μL) was first diluted in assay buffer (480 μL) in a microfuge tube 
and vortexed.  For each unactivated plasma sample, 115 μL of assay buffer and 25 μL 
of diluted plasma was added to the well.  For the activated plasma samples, 90 μL of 
assay buffer, 25 μL of diluted plasma, 10 μL of TAFI activation enhancer and 15 μL of 
TAFI activation reagent were added to the well.  The plate was incubated at room 
temperature on an orbital plate shaker for 20 minutes. 
 
During the 20 minute incubation, the TAFIa standards were prepared.  Microfuge tubes 
were labelled A1/A2 to E1/E2.  250 μL of assay buffer and 50 μL of TAFIa standard are 
added to tubes A1 and A2.  150 μL of assay buffer was added to the remaining 
microfuge tubes.  150 μL of TAFIa standard was transferred from tube A1 to B1 and 
from A2 to B2.  This was repeated from B1/B2 to C1/C2 and so on to E1/E2.  The 150 
μL removed from E1/E2 was discarded.  When incubation of the plate was complete, 
the TAFIa standards were transferred from the microfuge tubes to the appropriate wells 
on the plate.  150 μL of assay buffer in wells F1/F2 was the ―blank‖.  The resulting 
concentrations of TAFIa standard dilutions were 2, 1, 0.5, 0.25 and 0.125 μg/mL in 
wells A1/A2 to E1/E2 respectively. 
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After incubation, 10 μL of activation stop reagent was added to the test but not the 
standard or blank wells.  50 μL of TAFI developer was then added to each well and the 
plate was incubated at 37
0C on a plate shaker for 30 minutes.  50 μL of 2M H2SO4 stop 
solution was added to each well and the absorbance was read at 490nm. 
 
A standard curve was constructed on linear graph paper.  The mean absorbance of the 
unactivated plasma was subtracted from the activated sample.  The resulting absorbance 
represents the TAFI carboxypeptidase activity and the TAFI concentration was read off 
the standard curve and multiplied by 25 to account for the original dilution. 
 
2.6.3 Clot Lysis Assay 
Materials 
1x10
5
 dilution of recombinant TF: Innovin (Dade Behring, Milton Keynes, U.K.) 
1M Calcium Chloride (CaCl2) 
Phospholipid source: Phospholipid vesicles, 1μM solution diluted 1:500 in Hepes buffer 
Tissue plasminogen activator (tPA): (Sigma-Aldrich, Dorset, United Kingdom) 
Potato tuber carboxypeptidase inhibitor (PTCI): (Sigma-Aldrich, Dorset, United 
Kingdom) 
Recombinant factor VIIa: NovoSeven® (NovoNordisk, Bagsvaerd, Denmark) 
HEPES buffer: 
25mM HEPES = 2.98 g/500 mLs 
137mM NaCl = 4 g/500 mLs 
3.5mM KCl = 0.13 g/500 mLs 
3mM CaCl2 = 1.5 mLs 1M CaCl2 in 500 mLs 
20% bovine serum albumin: (Sigma-Aldrich, Dorset, United Kingdom) 
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Kinetic plate reader: Versamax tuneable microplate reader (Molecular Devices (UK) 
Ltd, Berkshire, U.K.) 
Flat bottomed microtitre plate: Nunc Maxisorp (Thermo Fisher Scientific, Roskilde, 
Denmark) 
 
Working solutions & reagents 
12.75mLs of 1M calcium chloride was added to 87.25 mLs of distilled, sterile water, 
giving a concentration of 127.5mM.  20 µL of this solution was added to the final 
reaction volume of 150 µL to give a final concentration of 17mM. 
 
The tPA vial was reconstituted by adding 5.95 mLs of distilled, sterile water to the vial 
containing 10 µg tPA, creating a 1680 ng/mL solution. A final concentration of 56 
ng/mL was obtained when 5 µL of this solution was added to the final volume of 150 
µL. 
 
The vial of PTCI was reconstituted by adding 6.7 mLs of distilled, sterile water to the 
vial containing 5mg of PTCI, creating a 750 µg/mL solution.  When 5 µL of this 
solution was added to the final volume of 150 µL, a final concentration of PTCI of 25 
µg/mL was obtained. 
 
rFVIIa was reconstituted by adding 20 mLs of distilled, sterile water to a vial of rFVIIa 
containing 1.2 mg of the active agent (eptacog alpha).  The addition of 5 µL of this 
solution to the final reaction volume of 150 µL created a final concentration of 40nM. 
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The HEPES Buffer was made up by dissolving 2.98 g of HEPES, 4 g of NaCl, and 0.13 
g of KCl in 400 mL of distilled, sterile water and by adding 1.5 mLs of 1M calcium 
chloride.  The pH was checked and adjusted to 7.4 as necessary.  The volume was made 
up to 500 mL with water in a volumetric flask.  The buffer was stored at 4
0
C.  
Immediately prior to use, 0.5 mL of 20% BSA was added to 100 mL of HEPES buffer.  
Buffer with added BSA was used within 24 hours. 
 
Method 
Test and normal plasma (a pool of 20 normal individuals) were thawed at 37
0
C for five 
minutes, then kept on ice until assayed.  All assays were performed within two hours of 
thawing.  Note, lipaemic plasma samples were unsuitable for analysis. 
 
To perform the clot lysis assay, 75 μL of plasma was added to 30 μL of buffer, 10 μL of 
phospholipid, 5 μL of tPA, 5 μL of rTF and 5 μL of PTCI or rFVIIa.  If neither of the 
latter two reagents were to be added, an extra 5μL of buffer was added to make a total 
of 35μL of buffer.  Samples were analysed in duplicate.  The plate was mixed and 
incubated at 37
0C for two minutes.  Finally, 20μL of CaCl2 was added and the plate was 
mixed.  The plate was read at 405nm every 2.5 minutes for 120 minutes.  The plate 
reader was maintained at a temperature of 37
0
C throughout.  A lid was placed on the 
plate to prevent evaporation. 
 
When the assay was complete, the Optical Density curve was reviewed and the raw data 
was exported to the Excel program (Microsoft®Excel 2002).  The start OD and 
maximum OD were identified and entered onto a separate Excel worksheet.  The 
midpoint of the clear-to-maximum turbid transition was calculated and the time that this 
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point was reached was obtained from the raw OD curve.  Similarly, the time to the 
midpoint of the turbid-to-clear transition was calculated.  The clot lysis time was 
calculated as the time interval in minutes between these midpoints (termed CLT1).  The 
CLT obtained was the mean of two experiments.  Clot lysis curves were obtained in the 
presence (CLT -PTCI) and absence of PTCI (CLT-buffer)and the contribution 
attributable to TAFI was calculated as the difference between these two results (i.e. 
CLT-buffer minus CLT-PTCI). 
 
An alternative method of calculation of the clot lysis time was also used (the time from 
the occurrence of the maximum OD to the midpoint of the turbid-to-clear transition) and 
was termed CLT2. 
 
2.7 Genetic analysis 
2.7.1 Specimen collection and DNA extraction 
DNA extraction was performed on thawed buffy coat samples using a kit according to 
the manufacturer‘s instructions (QIAamp DNA Blood Mini kit, Qiagen GmBH, Hilden, 
Germany).  DNA was quantitated by running the patient samples on a 2% gel at 100v 
for 40 minutes or by using a spectrophotometric method. 
2.7.2 Materials for PCR and sequencing 
Primers: MWG-Biotech UK Ltd Milton Keynes, U.K. 
PCR nucleotide mix (dNTPs): Promega, Southampton, U.K. 
TAQ polymerase: Bioline, London, U.K. 
Restriction endonucleases: Roche Diagnostics, East Sussex, U.K. 
Sequencing PCR purification kit: QiaQuick PCR Purification kit, Qiagen Ltd, West 
Sussex, U.K. 
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Big dye terminator v1.1 Cycle sequencing kit: Applied Biosystems, Warrington, U.K. 
Sterile water: Baxter, Berkshire, U.K. 
NH4 buffer: Bioline, London, U.K. 
Magnesium 
SeaKem LE Agarose: Cambrex BioScience, Berkshire, U.K. 
NuSieve GTG agarose: Cambrex BioScience, Berkshire, U.K. 
TBE buffer: Promega, Southampton, U.K 
Ethidium bromide 
6Xsucrose loading buffer 
DNA molecular Marker V (fragment sizes  8-587bp): Roche Applied Science, East 
Sussex, U.K. 
Techne PHC-3 thermal cycler: www.techne.com, Bibby Scientific, Staffordshire, U.K. 
3100 Avant Sequencer: Applied Biosystems, Warrington, U.K. 
Electrophoresis tank 
Eppendorf tubes 
Strip tubes (for PCR) 
Microtitre plates and covers (for overnight restriction) 
Pipettes: Gilson 
Disposable pipette tips: CLP Ltd, Northampton, U.K. 
 
2.7.3 General method for PCR 
A PCR worksheet was completed for each PCR experiment.  A bulk mix was made up 
in a clean PCR area consisting of the following: Sterile water 711 μL, NH4 buffer 100 
μL, 1.25mM dNTPs 100 μL, Mg2+ 24 μL, forward and reverse primers 20 μL.  This 
mix was sufficient to assay 20 samples and each sample contained Sterile water 35.5 
    84 
μL, NH4 buffer 5 μL, 1.25mM dNTPs 5 μL, Mg2+ 1.2 μL, forward and reverse primers 
1 μL. The bulk mix was exposed to UV light for 10 minutes on a transilluminator.  Taq 
polymerase (5 μL) was then added to the bulk mix, ensuring each sample contained 0.25 
μL.  An aliquot of 48 μL of bulk mix was added to a plastic strip tube for each sample 
and control.  Sample and control DNA (2 μL) was added to the relevant tubes and no 
DNA was added to the blank control.  The strip tubes were placed in a Techne PHC-3 
thermal cycler at the appropriate settings (see below). The PCR products were stored at 
4
0
C until further analysed. 
 
To assess the PCR products after amplification, a 1.5% agarose gel was poured.  An 
aliquot (5 μL) from each sample was added to 6Xsucrose loading buffer (2 μL) in an 
eppendorf tube.  The sample/buffer mix was then loaded on to the gel and 
electrophoresed at 100v for 20 minutes.  Marker V (5 μL) was placed in lanes 1 and 13 
to indicate the size of the PCR products.  The gel was then visualised using the UV 
transilluminator to confirm that a PCR product of the correct size had been amplified, 
that the blank control did not contain PCR product and that there were no additional 
PCR products.   
 
2.7.4 Genetic analysis for thrombophilia 
The factor V (FV) Leiden and prothrombin gene mutations were analysed using a 
multiplex PCR, according to the standard operating procedure in use in the laboratory at 
the time.  Each sample contained sterile water 36 μL, NH4 buffer 5 μL, 1.25mM dNTPs 
5 μL, Mg2+ 1.5 μL, forward and reverse primers for FVLeiden and the Prothrombin 
gene mutation 2 μL, Taq polymerase 0.25 μL and DNA 1 μL. 
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The PCR conditions for the multiplex PCR were as follows: 
   40 Cycles   
 94
o
C | 94
o
C     | 
             4:00 | 0:30     | 
  |    72
o
C | 72
o
C 
  |    56
o
C  0:30 | 10:00 
  |    0:30   | 
  |     |          4
o
C 
  |     |          END 
 
 
The PCR products were checked as described above, then underwent restriction enzyme 
digestion overnight with HindIII at 37
0
C.  The samples were then run on a 2% gel 
consisting of 1% agarose and 1% NuSieve GTG agarose, at 120v for two hours.  A 
blank and two controls (FVLeiden and Prothrombin gene mutation heterozygous and 
FVLeiden homozygous and Prothrombin gene heterozygous) were run with each set of 
patient samples. The gel was examined under UV light and photographed. 
 
Normal (wild type samples) had bands of 241bp for the FVLeiden mutation and 345bp 
for the Prothrombin gene mutation. Heterozygotes had bands of 241/209bp and 
345/322bp respectively and the FVLeiden Homozygote control had a band of 209bp 
after restriction. 
 
2.7.5 Genetic analysis for Jewish mutations in F11 gene 
The four Jewish mutations in the F11 gene were analysed by restriction analysis.  Exons 
5 and 9 were amplified by PCR, using primers as set out in table 2.2, to identify type II 
and III mutations respectively. A third set of primers, which amplify the junction of 
exon 14-intron N, were used to identify patients with type I and IV mutations (table 
2.2).   
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Table 2.2:  Primer sequences for restriction enzyme analysis of the Jewish type I – IV 
mutations. 
FXI Region Primer Sequences Product size (bp) 
Exon 5 Forward 5‘-gcc cct aga atc tgg aag gta-3‘ 
Reverse 5‘-cgc ttt tga aat tag cca agt at-3‘ 
458 
Exon 9 Forward 5‘-gcc ccg agg agg ctg ata-3‘ 
Reverse 5‘-cct cct ctc ccg tga agt att tt-3‘ 
380 
Exon14/ 
Intron N 
Forward 5‘-tta gtg acc aac gaa gag tgc cag-3‘ 
Reverse 5‘-ccc caa cgc att aag cat tcc aat-3‘ 
162 
 
 
The PCR conditions for amplification of exon 5 were as follows: 
   40 Cycles   
 94
o
C | 94
o
C     | 
             5:00 | 0:30     | 
  |    72
o
C | 72
o
C 
  |    53
o
C  0:30 | 10:00 
  |    0:30   | 
  |     |          4
o
C 
  |     |          END 
 
 
The PCR conditions for amplification of exon 9 were as follows: 
   40 Cycles   
 94
o
C | 94
o
C     | 
             5:00 | 0:30     | 
  |    72
o
C | 72
o
C 
  |    57
o
C  0:30 | 10:00 
  |    0:30   | 
  |     |          4
o
C 
  |     |          END 
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The PCR conditions for amplification of exon 14/Intron N were as follows: 
   40 Cycles   
 94
o
C | 94
o
C     | 
             4:00 | 0:30     | 
  |    72
o
C | 72
o
C 
  |    55
o
C  0:30 | 10:00 
  |    0:30   | 
  |     |          4
o
C 
  |     |          END 
 
The PCR products were digested overnight with BsmI, Sau3A and MaeIII for the type 
II, III and I/IV mutations respectively (table 2.3).  The type I mutation abolishes a 
MaeIII restriction site, the type II mutation abolishes a BsmI restriction site while the 
type III mutation creates a Sau3A restriction site and the type IV 14bp deletion 
abolishes the donor splice site and an MaeIII restriction site in intron N creating two 
aberrant PCR products.(58;59)  The samples were then run on a 2% gel at 120v for two 
hours for the type II and III mutations and on a 4% gel at 120v for two hours for the 
type I and IV mutations.  The gel was examined under UV light and photographed.  A 
blank and normal, heterozygous and homozygous controls (where available) were run 
with each sample.  Examples of each restriction enzyme analysis are shown in figures 
2.5 to 2.7.
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Table 2.3:  Restriction enzyme analysis for the Jewish type I-IV mutations including restriction conditions and products. 
Mutation 
Type 
Restriction 
enzyme(vol) 
Vol. of 
PCR 
product 
(μl) 
Conditions Restriction products (bp) 
 Normal HeZ* HoZ** 
I MaeIII (1 μl) 19 55oC overnight 99/60/3 159/99/60/3 159/3 
II Bsm1 (1 μl) 19 65oC overnight 333/125 458/333/125 458 
III Sau3A (1 μl) 19 37oC overnight 380 380/280/100 280/100 
IV MaeIII(1 μl) 19 55oC overnight 99/60/3 99/60/3 & 2 
aberrant 
bands~160bp 
2 aberrant 
bands~160bp 
*HeZ: Heterozygous for the mutation 
**HoZ: Homozygous for the mutation 
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Figure 2.5:  Restriction enzyme analysis F11 Exon 5.  
Lane 1: Heterozygote patient, Lanes 2&3: Normal patients, Lane 4: Blank,  
Lane 5: Heterozygote control, Lane 6: Homozygote control, Lane 7: Normal control. 
 
 
 
 
Figure 2.6:  Restriction enzyme analysis F11 Exon 9.  
Lane 1: Homozygote patient, Lanes 2-5: Normal patients, Lane 6: Blank, Lane 7: 
Normal control, Lane 8: Heterozygote control. 
 
 
 
 
 
Lanes:  1    2     3    4     5     6    7     8  
Lanes: 1       2       3        4        5        6        7 
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Figure 2.7:  Restriction enzyme analysis F11 Exon 14/Intron N. 
Lane 1: DNA ladder, Lanes 2-11 and 13-18: Normal patients, Lane 12: Heterozygote 
patient, Lane 19: Blank, Lane 20: Normal control. 
 
 
 
 
2.7.6 Sequencing of F11 gene  
Primer Design and PCR 
Primers were designed using a combination of previously described primers and newly 
designed primers (see table 2.4).  Annealing conditions for the PCR reactions and 
product size are also given in table 2.4.  Primers that enabled the amplification of the 
exons and  preceding and proceeding regions of intronic DNA were chosen. All 
sequence information was gathered from the NCBI database.  
 
The PCR reactions were carried out according to the general method for PCR reactions 
given above.  All samples were purified using the Qiagen QiaQuick PCR Purification 
kit to remove unused PCR reagents. 
 
Lanes:1-20 from left to right 
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Table 2.4:  Primer sequences, annealing temperatures, product sizes and references for 
sequencing PCR of the 15 exons of the F11 gene. 
F11 
region 
Primer Sequences Tm 
(
0
C) 
Product 
size (bp) 
Ref 
Exon 1 
 
Forward 5‘- att cag tgt att gag aaa gca ag-
3‘ 
Reverse 5‘- gct tga gag gaa tgt taa ata gt-3‘ 
55 291 (182) 
Exon 2 
 
Forward 5‘- ccc tat ttc ttg taa gtc-3‘ 
Reverse 5‘- aat ggt gtg gga ttc tcc-3‘ 
47 227 New 
Exon 3 
 
Forward 5‘- atg tat gcc cag taa aat cc-3‘ 
Reverse 5‘- atg tta gat gga aat gtg tt-3‘ 
50 293 New 
Exon 4 
 
Forward 5‘- gct ttc tgt gtg ctg act tt-3‘ 
Reverse 5‘- cag ctg gta ttt gtt gat tc-3‘ 
57 226 (183) 
Exon 5 
 
Forward 5‘- ccc cta gat ct gga agg ta-3‘ 
Reverse 5‘- cga ttc tgt ttt tca tcg ac-3‘ 
53 253 (183) 
Exon 6 
 
Forward 5‘- gca gtt gga aga ata aga cac-3‘ 
Reverse 5‘- gaa tta cat cat caa gaa gtc g-3‘ 
46 185 (182) 
Exon 7 
 
Forward 5‘- tcc tga tag ctg gtg aat tg-3‘ 
Reverse 5‘- gaa gat aac aaa tta tcc tta ctt g-
3‘ 
57 247 (183) 
Exon 8 Forward 5‘- gat ata ttt cta ctt ccc ttt tg -3‘ 
Reverse 5‘- ctc agc cag aat gca gaa ct-3‘ 
46 173 (182) 
Exon 9 Forward 5‘- aca tgc tga ggg agg gtc t-3‘ 
Reverse 5‘- gac aag ggt gtc tgc ata ac-3‘ 
52 245 (182) 
Exon 10 Forward 5‘- gca tta tgt tta tac cgt ttt g-3‘ 
Reverse 5‘- cag cta tat ttt ttc aag tga c-3‘ 
52 175 (182) 
Exon 11 
 
Forward 5‘- aag ctg ctc atc aca atg ct-3‘ 
Reverse 5‘- ttt cct aac atg cta gta at-3‘ 
51 274 New 
Exon 12 
 
Forward 5‘- gcc aca cac ttc aca atg tc-3‘ 
Reverse 5‘- ggt cag gcc gta agt cta gt-3‘ 
57 332 (183) 
Exon 13 
 
Forward 5‘- tac agt gga aga aga gtc tc -3‘ 
Reverse 5‘- tga cag ggc aga aaa ggt tc-3‘ 
53 242 new 
Exon 14 
 
Forward 5‘- tat ggt tat tct aca aac gaa c-3‘ 
Reverse 5‘- caa ttt gca tat att cca ttg g-3‘ 
46 220 (182) 
Exon 15 
 
Forward 5‘- tct gag ttg atc tgt gca cc-3‘ 
Reverse 5‘- tac aac gat cat aga acg gg-3‘ 
57 398 (183) 
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Sequencing: 
Sequencing of the PCR products was carried out on an Applied Biosystems 3100 Avant 
Sequencer. Each sequencing reaction was carried out using 1.5 μl of ready reaction mix 
(as supplied in the Big Dye Terminator v1.1 Cycle sequencing kit), 1 μl of template 
DNA, 3.2pmol of sequencing primer and 16.5 μl of dH2O for a final reaction volume of 
20 μl. This was then placed in a thermal cycler on the following program: 
 
  |  25 Cycles  | 
  | 96
o
C     | 
 | 0:10     | 
  |    60
o
C |  
  |    50
o
C  4:00 |  
  |    0:05   | 
  |     |        4
o
C 
  |     |       END 
 
Following amplification the products were purified using the following protocol. EDTA 
(2 μL), sodium acetate(2 μL) and 50 μl of 95% ethanol were added to each sample, 
mixed and left to incubate at room temperature for 15 minutes. The microcentrifuge 
tubes were then spun for 20 minutes.  The supernatant was then removed carefully.  The 
pellet was rinsed with 250 μL of 70% ethanol and the sample was centrifuged for five 
minutes and the supernatant was discarded.  The samples were dried at 95
0
C for one 
minute in the thermal cycler. The samples were resuspended in 20 μL Template 
suppression reagent as supplied and were transferred to sequencing tubes. The samples 
were rendered single stranded by placing the samples at 95
0
C  for two minutes.  The 
samples were then placed on ice and loaded on to the sequencer for automated capillary 
sequencing. 
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2.7.7 ALG6 Polymorphism 
The PCR and sequencing reactions for exon 10 were carried out according to the 
general methods given above.  PCR conditions are given below. The primers are given 
in table 2.5. 
    35 cycles 
   
95
o
C | 94
o
C     | 
             3:00 | 0:20     | 
  |    70
o
C | 70
o
C 
  |    56
o
C  0:45 | 07:00 
  |    0:30   | 
  |     |          4
o
C 
  |     |          END 
 
 
Table 2.5:  Primer sequences for PCR and sequencing of exon 10 ALG6 gene. 
ALG6 Primer Sequences 
 
Reference 
Forward 5‘-aaa ctt aag ttg ata aat aat atg atc-3‘ (184) 
Reverse 5‘- gtc taa cac aga agc taa gta tgg g -3‘ 
 
(184) 
 
2.8 Molecular Modelling 
2.8.1 Identification of F11 gene mutations 
Mutations in the F11 gene causing FXI deficiency were identified by searching the 
Human Gene Mutation database (http://archive.uwcm.ac.uk/uwcm/mg/hgmd0.htmL).  
Additional mutations were identified by a Medline search using the following search 
expressions: factor XI, FXI, F11 deficiency, plasma thromboplastin antecedent (PTA), 
PTA deficiency, Rosenthal‘s syndrome.  Other mutations were identified by searches of 
abstracts from recent international haematology and haemostasis meetings.  For the 
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mutations that had been published in sufficient detail, phenotypic data was included, 
namely FXI:C in most cases, and FXI:Ag and/or bleeding phenotype in some cases.  
Mutations published in abstract format were grouped according to the presence or 
absence of phenotypic data. 
 
2.8.2 Construction of FXI homology models 
Homology models of the Apple (Ap) 1 to Ap4 and serine protease (SP) domains were 
constructed using INSIGHT II 98.0 modelling software with HOMOLOGY, 
DISCOVER and BIOPOLYMER modules (Accelrys, San Diego, CA) and the structural 
refinement program O (185) on Silicon Graphics workstations.  Alignments of the five 
FXI domain sequences with their template structures resulted in the identification of the 
structurally conserved regions (SCRs) within these sequences, and these SCRs were 
built using a rigid body fragment assembly method implemented by the HOMOLOGY 
module.  The loop regions between the SCRs were then either modelled from a database 
of protein fragments using the Brookhaven loop database of INSIGHT II or generated 
using a constrained minimization algorithm implemented by HOMOLOGY.  Energy 
refinements using the DISCOVER module were then carried out on these initial models 
in order to refine the connectivity of the loop splice junctions, the loop regions and the 
N- and C-termini.  The structure verification program PROCHECK (186) and O were 
used alongside the energy minimisation program of the DISCOVER module and the 
structure idealisation program REFMAC5 of CCP4i (187) in order to improve the 
connectivity, check bond angles and lengths and reduce the number of bad contacts 
within the five domain models.  
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Suitable template protein structures for modelling the FXI Ap domains (members of the 
PAN-module superfamily) were obtained from PSI-BLAST (188) searches of the 
Protein Data Bank (PDB) (189) using the PredictProtein server 
(http://cubic.bioc.columbia.edu/predictprotein/submit_def.htmL).  The PAN-module 
superfamily contains the following protein domains: the N-terminal N domains of 
members of the plasminogen/hepatocyte growth factor family, the apple domains of the 
plasma prekallikrein/coagulation factor XI family and domains of various nematode 
proteins.(190)  The HOMOLOGY module produced a structural alignment of the 
sequences of these known structures by constructing a Cα distance matrix for each 
structure and calculating the root mean square distances for elements within the matrix.  
CLUSTALW (191) alignments of other sequences belonging to the PAN-module 
superfamily (190) of the InterPro database (192) were also added to the Ap domain 
alignment.  The Ap sequences obtained were the E. Tenella adhesin protein (PDB code: 
1HKY) and the anti-platelet toxin from H. officinalis (PDB code: 1I8N_A).  The N-
terminal domains of human (PDB code: 2HGF), rat (HGF_RAT), mouse 
(HGF_MOUSE) and Xenopus (HGF_XENOPUS) hepatocyte growth factor, and the N-
terminal domains of mouse (PLMN_MOUSE), bovine (PLMN_BOVIN), macaque 
(PLMN_MACMU) and human (PLMN_HUMAN) plasminogen were also used.  The 
four closely-related Ap domains of mouse (KAL_MOUSE1-4), rat (KAL_RAT1-4) and 
human (KAL_HUMAN1-4) prekallikrein were directly compared with the four Ap 
domains of FXI (FXI_AP1-4).  For completeness, two hypothetical nematode proteins 
with the same conserved pattern of cysteine residues were also included 
(YMP9_CAEEL, YSM5_CAEEL.1), as well as other PAN modules such as Microneme 
Antigen precursor (MIA_SARMU) and a rat macrophage stimulating protein precursor 
(MSP_RAT).  Secondary structure assignments were included in order to correctly 
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assign sequence gaps to the loop regions, and to conserve the location of the cysteine 
residues.  The secondary structure of Ap1 was predicted from the sequence alignment of 
the sequences specified above using the consensus result of five methods, namely the 
GOR III (193), PHD (194), JPred  (195), PSI-PRED (196) and SAMT-99 algorithms 
(197-199). 
 
Suitable templates for the SP domain were identified using BLAST (188) to search the 
Protein Data Bank.  From this, the top 500 matches were analysed with CLUSTALW to 
identify five close homologues from a total of 84 unique structures using a guide tree.  
These were human -thrombin (PDB code 1H8I), human protein C (PDB code 1AUT), 
human complement C1r (PDB code 1GPZ), boar sperm -acrosin (PDB code 1FIZ) and 
human mast cell -tryptase (PDB code 1AOL).  The HOMOLOGY module was used to 
structurally align these five templates.  The FXI SP domain was then added to this 
alignment using a consensus of the pairwise sequence alignments with the five 
templates.  
 
The DSSP program (200) was used to assign secondary structures in both the crystal 
and NMR structures and the final modelled structures.  Secondary structures are 
assigned as follows: H and G, -helix and 310 helix; E and B, -strand; T, turn; C and S, 
coil and loop. Side chain solvent accessibilities in the structures and models were 
calculated using NACCESS (201), this being based on an implementation of the Lee 
and Richards algorithm using a probe radius of 1.4 Å to represent the water molecule.  
The results are on a scale of 0 to 9 for each residue, where 0 corresponds to 0% to 9% 
accessibility, 1 corresponds to 10% to 19% accessibility, and so on.  Buried residues 
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have accessibilities of 0 or 1.  Figures of the protein structures were generated using 
MOLSCRIPT (202) and RASTER3D (203). 
 
2.9 Statistical Analysis 
Statistical analysis for laboratory parameters was performed using SAS (SSPS, NC) or 
the statistics package on Excel (Microsoft® Excel 2002).  For evaluation of correlation, 
the Pearson correlation coefficient (coefficient of variance) was calculated using Excel.  
The Wilcoxon two-sample test (SAS) was used for analysis of numerical data between 
two groups for the thrombin generation test i.e AUC and peak thrombin versus severe or 
partial FXI deficiency and AUC, peak thrombin and ETP versus bleeding history 
(bleeder or non-bleeder).  The Kruskal-Wallis test (SAS) was used for analysis of 
numerical data for more than two groups (i.e. evaluation of bleeding tendency versus 
tertiles of FXI:C, VWF:AG, VWF:CBA and TAFI:Ag and versus multiple genotypes).  
The ANOVA analysis of variance (Excel) was used to calculate the significance of 
TAFI activity as measured by the CLT versus severe or partial deficiency.  The Chi-
squared test (SAS) was used to evaluate proportions of patients with different blood 
groups in bleeder and non-bleeder categories.   
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Chapter 3 Clinical and laboratory features of FXI deficiency 
3.1 Introduction 
A key feature of FXI deficiency is the variable nature of the bleeding phenotype.(6;7)  It 
is the unpredictable nature of the bleeding tendency coupled with the known side effects 
of haemostatic therapy in this condition which make clinical determination of the need 
for treatment so difficult.(72)   
 
Since the condition was established in the 1950s, a considerable published literature has 
documented the range of bleeding symptoms in FXI deficient patients (see Introduction 
Chapter 1 for a detailed analysis).(3;5-7;50;54-57)  More recently, a number of 
publications have appeared which have focused on clinical manifestations of bleeding in 
severely deficient patients.(62;71)  However, questions still remain regarding the cause 
of the variable bleeding tendency, the existence of a clinically relevant bleeding 
disorder in heterozygotes and the optimal treatment for FXI deficient patients.(50;204) 
 
The aim of this study is to rigorously evaluate modifiers of the bleeding tendency in 
FXI deficiency, in order to define the nature of the variable bleeding tendency and to 
evaluate possible causes for the variability.  A critical element of this study is the 
careful documentation of the prior bleeding history and allocation of a bleeding 
score.(5;7)  The pattern of prior bleeding history is compared to previous studies, in 
particular in the light of more recent evidence suggesting that haemostatic cover is not 
always required.(62;71)  The bleeding score can then be correlated with laboratory 
assessments of coagulation and genetic studies.  In this study, the basic diagnostic tools 
for FXI deficiency (aPTT, FXI:C, FXI:Ag and genetic analysis) are evaluated for 
diagnostic sensitivity and correlated with bleeding score. 
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VWF:Ag and VWF:Ac, blood group and thrombophilic traits, which have been 
previously suggested to modify the bleeding tendency in FXI deficiency and 
Haemophilia, are re-evaluated in this cohort of patients, with particular reference to the 
bleeding score.  The state of glycosylation of the FXI protein may influence activity and 
a preliminary analysis of a potential genetic modifier (ALG6) is undertaken. 
 
3.2 Methods 
3.2.1 Bleeding scores 
As outlined in the Methods (Chapter 2) a detailed bleeding history was taken by a single 
clinician using a standard template.  A five point bleeding score was used to designate 
bleeding tendency (Table 3.1).(5;7)  The bleeding histories were scored independently 
by three clinicians with experience in haemostasis and inter-observer concordance was 
assessed. 
 
A score of three (indeterminate) was applied if the reviewer felt that the patient had not 
undergone sufficient haemostatic challenges to make a decision or if there was 
conflicting evidence.  In two cases, a bleeding score of three was applied where there 
was disagreement amongst the reviewers about the bleeding score. 
Table 3.1:  Bleeding score related to bleeding phenotype.(5;7) 
Bleeding Score Bleeding Phenotype 
1 Definite bleeder 
2 Probable bleeder 
3 Indeterminate 
4 Probable non-bleeder 
5 Definite non-bleeder 
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Bleeding score consensus 
In 73 cases (72%), there was either total consensus between all three reviewers (27 
cases) or two reviewers were agreed and one was within one point on the scoring 
system (46 cases).  In the latter case, the score applied was that of the two reviewers 
who were in agreement.  In ten cases, two reviewers agreed on the score but one applied 
a score that was more than one point different. In this case, the outlier score was 
disregarded.  In 19 cases (19%), all three reviewers disagreed in the score to be applied. 
The scores were then further reviewed by two reviewers together and a consensus score 
was applied in 17 cases. There were two cases where a consensus could not be agreed 
even after review and in these cases a score of three (indeterminate) was applied. 
 
3.2.2 Laboratory investigations 
The methods used for the evaluation of the aPTT, FXI:C, FXI:Ag, FVIII:C, VWF:Ag, 
VWF:CBA and thrombophilia screening are outlined in Chapter 2 Methods. 
Primers, PCR conditions and the methodology employed for sequencing exon 10 of the 
ALG6 gene are outlined in Chapter 2 Methods. 
 
3.3 Results 
3.3.1 Participants & patient demographics 
In 2001, the Katharine Dormandy Haemophilia Centre and Haemostasis Unit had 263 
patients, aged 18 years or over, who had been diagnosed and registered with FXI 
deficiency over a time period from 1978 to 2001.  All of these 263 patients were invited 
to participate in the study.  It was not known which of the participating patients had also 
participated in earlier studies but it is likely that there is some overlap in patient data 
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between this study and earlier work.(5;55)  103 individuals attended the study clinic and 
102 (39% of registered patients) agreed to participate in the study.  There were 
individuals from 80 families and in 65 of these, single family members were tested.  
More than one family member participated in the study in the remaining 15 families; 10 
families had two participants, three families had three participants and two families had 
four participants in the study.  Parental consanguinity was present in two severely 
deficient Jewish patients and one partially deficient Portuguese patient (first cousins in 
two cases and a more distant relationship in one case). 
 
Patient demographics are shown in Table 3.2.  The largest ethnic group was Ashkenazi 
Jewish reflecting the demographics of the catchment area of the haemophilia centre.  
The second largest group had English heritage (16%).  The remaining eight patients 
came from Ireland, Portugal, Turkey, Cyprus, Ghana, Bangladesh, South-east Asia and 
the Caribbean. 
 
Table 3.2:  Patient demographics 
Patient characteristics  
Age Years 
Median 46.5 
Range 18-84 
Gender Number of patients 
Male 42 
Female 60 
Ethnic origin  
Jewish 78 
English 16 
Other 8 
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3.3.2 Bleeding phenotype 
In all, 636 episodes with potential for bleeding were recorded and comprised major and 
minor surgery, dental procedures, trauma, bruising and epistaxis.   
 
124 dental procedures were reported. Treatment prior to the dental procedure was given 
to cover 22 episodes (9 FXI concentrate, 7 plasma, 3 rFVIIa, 3 tranexamic acid) and 14 
of these procedures were carried out on 11 severely deficient patients.  One patient 
suffered bleeding post dental extraction despite prior treatment with plasma.  In 
contrast, there were 41 reports of bleeding where prior treatment was not given and 14 
of the patients involved had a severe deficiency.  This gives a crude bleeding rate of 
40% for dental extractions without prior treatment. 
 
A total of 330 invasive procedures involving major or minor surgery were reported.  In 
55 of these episodes, pre-operative treatment was given and in two of these procedures 
bleeding occurred despite treatment (one severely deficient patient who received 
tranexamic acid cover for minor breast surgery and one partially deficient patient who 
bled post rhinoplasty and septoplasty despite FXI concentrate).  In the surgical 
procedures where pre-operative treatment was not administered, bleeding was reported 
by patients in 85 cases (crude bleeding rate 26%).  However, certain procedures like 
tonsillectomy are associated with bleeding in 60% of patients while untreated patients 
with severe FXI deficiency have a definite bleeding risk with procedures such as hernia 
repair and CABG.  Selected procedures with pre-operative treatment rates and bleeding 
outcomes are given in table 3.3. 
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In the overall patient group the following therapies were given in the management of 
unexpected post-operative bleeding: cellular blood transfusion (23 episodes), FXI 
concentrate (18 episodes), plasma (17 episodes), FXI replacement unspecified (2 
episodes) and re-operation (12 episodes). 
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Table 3.3:  Bleeding outcomes in selected invasive procedures (all patients) 
 
 
 
 
 
 
 
 
 
Procedure No. of 
procedures 
No. of pts No. of severely 
deficient pts 
Prior treatment Bleeding in 
untreated pts 
(%) 
Bleeding in 
severely 
deficient pts (%) 
Tonsillectomy 33 33 16 0 20 (60.1) 14 (87.5) 
Appendicectomy 22 22 5 0 3 (13.6) 1 (20) 
Hernia repair 7 6 3 2 3 (60) 2 (67) 
CABG 3 3 2 1 2 (100) 1 (50) 
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Male patients 
Amongst 42 male patients, 23 confirmed that they had had a circumcision in the 
neonatal period, of whom 11 patients had severe FXI deficiency (table 3.4).  Bleeding 
was reported after circumcision in two cases (one severe and one partial deficiency).  
Later in life, six patients had prostate biopsy or thermal treatment, of whom two 
severely deficient patients had prior treatment with FXI concentrate and plasma and did 
not have bleeding and four partially deficient patients had no prior treatment and one 
had bleeding.  Additionally, two partially deficient male patients reported prostatectomy 
or TURP without pre-operative treatment.  One patient had two such procedures and 
bled on both occasions while the other patient did not report bleeding. 
 
Table 3.4:  Selected invasive procedures in male patients with FXI deficiency 
Procedure No. of 
procedures 
No. of 
patients 
No. of 
severely 
deficient 
patients 
Prior 
treatment 
Bleeding 
Circumcision 23 23 11 0 2 
Prostate bx/ 
thermal Rx 
6 6 2 2 1 
Prostatectomy/TURP 3 2 0 0 2 
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Female patients 
In 60 women with FXI deficiency, the invasive procedures most likely to result in 
bleeding were gynaecological procedures (n=28).  Bleeding after gynaecological 
procedures was associated as might be expected with major procedures such as 
hysterectomy (42%) and caesarean section (29% of procedures performed without 
cover) but was also seen after minor procedures such as laparoscopy and resection of 
cysts and polyps (table 3.5).  Bleeding was also reported associated with a wide variety 
of other invasive procedures ranging from minor procedures such as breast surgery and 
varicose vein surgery to major procedures such as nephrectomy and oesophagectomy. 
 
Table 3.5:  Gynaecological procedures associated with bleeding. 
Gynaecological procedures No. of procedures No. of episodes 
associated with bleeding 
Dilatation and curettage 23 6 
Hysterectomy 12 5 
Laparoscopy 17 4 
Caesarean section 8 2 
Cone biopsy 2 2 
Resection cervical polyp 2 2 
Resection vaginal cyst 2 2 
D&C/hysteroscopy/laparoscopy 2 1 
Oopherectomy 2 2 
Hysterectomy and oopherectomy 1 1 
Vaginal repair 1 1 
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Pre-operative treatment was given in only five cases and no bleeding was reported (FXI 
concentrate was given to four severely deficient patients and plasma was given to one 
partially deficient patient).  Conversely, post-operative treatment was required in 47 
episodes of bleeding, including a cellular transfusion rate of 32% of these bleeding 
episodes (table 3.6). 
 
Table 3.6:  Post-operative treatment required in female patients reporting bleeding 
after any invasive procedure (47 episodes, 4 episodes counted twice due to dual 
therapies, see below). 
Post-operative treatment Number of bleeding episodes treated 
FXI replacement 7 
Tranexamic acid 5 
Transfusion* 15 
Re-operation
†
 8 
Other (suturing, packing etc) 16 
*
Two patients also received FXI replacement, one patient also underwent a re-
operation 
†
One patient also received a transfusion as above. 
 
Of the sixty women who participated in the study, 31 (52%) subjectively reported heavy 
menses (fig. 3.1).  Of the women who reported heavy menses, 11 were in the severely 
deficient category and the proportion was similar to the overall proportion of severely 
deficient patients in the study.  Two thirds of FXI deficient women with heavy menses 
(20 of 31 patients) had a partial deficiency of FXI.  Of the 31 women who self-reported 
heavy menses, 25 reported clots, 22 required double protection and 20 stated that their 
menses had always been heavy.  Seventeen women sought medical attention for heavy 
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menses and of these, 13 received one or more specific treatments, most commonly the 
combined oral contraceptive pill (8 cases) and hysterectomy (4 cases). 
 
Figure 3.1:  Patient subjective description of menses (n=60). Numbers of patients: 
heavy 31, normal-heavy 7, normal 19, normal-light 1, light 2. 
Light
Light-normal
Normal
Normal-heavy
Heavy
 
 
Pregnancy 
Of the sixty women participating in the study, 47 had had at least one pregnancy.  Of 
these 47 women, 14 were severely deficient and 33 were partially deficient in FXI.  134 
pregnancies were recorded and comprised 98 full term deliveries, 1 premature delivery, 
21 spontaneous miscarriages and 14 terminations.  Only six deliveries were covered 
with FXI replacement prior to delivery (five full term deliveries including one caesarean 
section and one termination).  The full term deliveries occurred in five women of whom 
one was severely deficient.  FXI concentrate was used in three cases, plasma in two 
cases and FXI replacement was unspecified in one case.  The severely deficient patient 
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had a baseline FXI:C of 8 U/mL and had two deliveries covered by plasma; one was 
associated with bleeding despite plasma and one was uneventful. 
 
The mode of delivery was known in 87 full-term deliveries.  Vaginal delivery was 
recorded for 79 pregnancies in total and bleeding was reported in 20 of these (25%).  
Caesarean section was recorded for eight pregnancies of which one patient received pre-
operative FXI replacement (baseline FXI:C 52 U/mL) and no bleeding was reported.  
Seven caesarean sections were not covered with FXI replacement and bleeding occurred 
in two cases (28.6%), one of which required a blood transfusion.In total, bleeding 
occurred in 36 pregnancies (27% of pregnancies involving 26 women).  Nine of these 
bleeding events occurred in seven severely deficient patients.  The majority of bleeding 
episodes (23 of 36, 64%) were related to full term deliveries (fig. 3.2).  The bleeding 
episodes were treated with blood transfusion in 7 cases, dilatation and curettage alone in 
6 cases, D&C with FXI replacement in 3 cases, oral iron in one case and treatment was 
unknown or no treatment was reported as given in 19 cases. 
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Figure 3.2:  Bleeding associated with pregnancy (n=36 episodes in 26 women). 
Numbers of patients: fullterm pregnancy 23, miscarriage 7, termination of pregnancy 5 
and premature delivery 1. 
Fullterm 
Premature
Miscarriage
TOP
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3.3.3 Laboratory investigations 
Activated partial thromboplastin time 
The activated partial thromboplastin time (aPTT) was performed in all patients (fig.3.3).  
The aPTT was within the normal range (28-38 seconds) in 37 patients (36%), of whom 
the FXI:C was below the normal range in 23 (23%). 
 
Figure 3.3: The relationship between FXI:C and aPTT (102 patients). 
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FXI:C and FXI:Ag levels 
Patients were registered with FXI:C levels ranging from <1-70 U/dL.  On re-testing the 
FXI:C levels ranged from <1 to 113 U/dL (figure 3.4 and table 3.7).  No overlap in 
FXI:C levels is seen between severely deficient and partially deficient patients. 
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Figure 3.4:  Individual FXI:C levels for 102 patients registered with FXI deficiency 
(each dot represents one patient FXI:C measurement).  Note the clear demarcation 
(arrow) between severely deficient patients (maximum FXI:C 15 U/dL) and partially 
deficient patients (minimum FXI:C 30 U/dL). 
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Table 3.7:  FXI:C levels in 102 individuals with Factor XI deficiency. 
FXI levels (U/dL) Number of patients 
Severe deficiency (FXI < 20) 32 
<2 10 
2-5 10 
6-20 12 
Partial deficiency (FXI 20-70) 70 
20-50 17 
51-59 23 
60-69 13 
>70 17 
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Only 17 of 70 (24%) partially deficient patients had FXI:C <50 U/dL (the previously 
accepted lower limit of normal for FXI:C, now considered obsolete).  A further 51% of 
partially deficient patients had FXI:C between 51 and 69 U/dL.   
 
Normal FXI:C levels were found in 17 patients.  The registered levels in these patients 
ranged from 42-68 U/dL.  Of these 17 patients with FXI:C > 70 U/dL, six had a FXI:Ag 
< 70 U/dL and Jewish mutations were present in five. Of the 11 patients with normal 
FXI:C and FXI:Ag, Jewish mutations were present in five patients and four of the five 
patients had positive family histories.  In these five cases reliance on coagulation assays 
alone for diagnosis would have resulted in incorrect genetic counselling being given. 
 
The FXI:Ag was correlated well with the FXI:C in the majority of cases (Fig 3.5, 
r=0.95).  One patient had a severely deficient FXI:C <1 U/dL, a normal FXI:Ag 105 
U/dL and evidence of a lupus-type FXI inhibitor.   
 
Figure 3.5:  Correlation between FXI:C and FXI:Ag in 101 patients with FXI deficiency 
(excluding one patient with an acquired inhibitor to FXI and a FXI:C <1 U/dL and 
FXI:Ag 105 U/dL). 
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r=0.95 
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There were nine partially deficient patients with discordant results where either the 
FXI:C or FXI:Ag was in the deficient range but the other parameter was normal (table 
3.8).  In one case the normal FXI:Ag was indicative of a mutation causing secretion of a 
functionally defective protein (Ser576Arg) but in two other cases the normal FXI:Ag 
occurred in patients with confirmed Jewish mutations.  In the cases of six patients with 
a normal FXI:C but a low FXI:Ag, Jewish mutations were present in five of them and 
the deficiency state would have been missed if FXI:C alone was used as the screening 
test. 
 
 
Table 3.8:  Patients with partial FXI deficiency and discordant FXI:C and FXI:Ag.  
Patients heterozygous for the Jewish type II mutation are indicated by II/WT and those 
heterozygous for the type III mutation are indicated by III/WT. 
Patient study 
number 
FXI:C FXI:Ag Genotype 
Patients with low FXI:C and normal FXI:Ag 
005 46 71 Ser576Arg 
076 60 80 III/WT 
027 66 83 II/WT 
Patients with normal FXI:C and low FXI:Ag 
083 72 60 II/WT 
014 77 67 III/WT 
009 81 53 II/WT 
071 84 61 Unknown 
081 86 58 III/WT 
003 95 68 II/WT 
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There was some variation noted between the registered FXI:C and the level measured in 
the current study.  Overall of 70 partially deficient patients, 29 had a current FXI:C 
which was within 15% of their registered level, two patients had levels which were 
more than 15% lower that the registered level and 39 patients had levels which were 
more than 15% above their registered FXI levels.  The mean increase over baseline 
registered FXI:C was 49% in patients whose current FXI:C was >70 U/dL (range 17-
90%). 
 
Of 32 severely deficient patients, 13 had a current FXI:C which was within 15% of their 
registered level but all remained within the severely deficient FXI:C range.  One patient 
with a registered level of 10 U/dL was found to have a current FXI:C of 62 U/dL and a 
FXI:Ag of 56 U/dL which was confirmed on repeat testing, indicating an error in the 
original sample.   
 
Correlation between bleeding score and FXI:C 
The bleeding scores in relation to phenotypic severity and FXI:C level are given in 
Table 3.9.  A positive bleeding history (scores 1 or 2) was seen in 81% of severely 
deficient patients.  However, five patients (16%) with FXI:C levels of <20U/dL were 
scored as probable non-bleeders (score 4).  No severely affected patient was scored as a 
definite non-bleeder (score 5).   
 
In contrast, the partially deficient patients were equally likely to be bleeders (47%) as 
non-bleeders (46%).  The percentage of definite bleeders was higher in severely 
affected patients than in the patients with partial deficiency (50% versus 14%).  There 
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was no difference in the FXI:C levels in either group between the bleeders versus the 
non-bleeders.   
 
One severely affected patient and five partially deficient patients were allocated an 
indeterminate bleeding score, in the majority of cases because the patient had 
insufficient haemostatic challenges on which to determine a bleeding tendency but in 
two cases because of disagreement amongst reviewers.  
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Table 3.9:  Bleeding scores versus severity of FXI deficiency and FXI:C. 
Severe deficiency* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Severe deficiency: Patients registered with FXI:C < 20 U/dL. n=32 
†
Partial deficiency:
 
Patients registered with FXI:C  20-70 U/dL. n=70 
 
Bleeding Score 1 2 3 4 5 
No. of patients
 
16 10 1 5 0 
% of patients 50 31 3 16 0 
FXI:C U/dL  
Median 
 
3 
 
6.5 
 
5 
 
3.6 
 
n/a 
Range <1-12 <1-15 n/a <1-6 n/a 
Partial deficiency
†
 
Bleeding Score 1 2 3 4 5 
No. of patients
 
10 23 5 17 15 
% of patients 14 33 7 24 22 
FXI:C U/dL  
Median 
 
51.5 
 
52 
 
66 
 
64 
 
56 
Range 46-113 30-79 45-69 40-110 40-84 
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The bleeding tendency is significantly associated with FXI:C but only in the lowest 
third of the patient group.  Patients in the lowest tertile of FXI:C levels having a 
significantly higher incidence of bleeding scores 1 and 2 compared to patients in the 
middle and highest tertiles of FXI:C (fig.3.6).  All but two of the patients in the lowest 
tertile (32 of 34 patients) had a severe deficiency of FXI (FXI:C <1-15 U/dL) and 
82.3% of these patients were classified as bleeders.  However, there were also five 
patients in this group who were classified as probable non-bleeders, indicating that 
FXI:C alone is not predictive of bleeding.  There was no significant difference in 
bleeding scores between the middle and highest tertiles. 
 
A similar relationship existed for FXI:Ag with a significant increase in patients with 
bleeding scores 1 and 2 in the lowest tertile: 84.8% versus 48.5% and 39.4% in the 
middle and highest tertiles respectively (p<0.0001, Kruskal-Wallis test).   
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Figure 3.6:  The relationship between bleeding tendency and FXI:C.   
Patients (n=102) were divided into three groups (tertiles) according to the FXI:C level 
and the proportion of patients classified as bleeders, indeterminate or non-bleeders was 
calculated for each tertile.  Patients in the lowest tertile had FXI:C levels of <1-38 U/dL, 
patients in the middle tertile had FXI:C levels of 38-58 U/dL and patients in the highest 
tertile had FXI:C levels of 58-113 U/dL.  
 
* p<0.0001 for the comparison between lowest and middle tertiles (Kruskal-Wallis test) 
** p<0.0001 for the comparison between lowest and highest tertiles (Kruskal-Wallis 
test) 
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Von Willebrand factor and blood group 
Mild type 1 von Willebrand disease was previously diagnosed in one patient entered in 
the study and a further patient had FVIII:C, VWF:Ag and VWF:CBA levels consistent 
with the disease.  Both of these patients were classified as probable non-bleeders.  One 
further patient who is a probable bleeder had borderline FVIII:C and VWF:CBA. 
 
The relationship between VWF:Ag and VWF:CBA levels and bleeding tendency were 
statistically analysed in tertiles.  The likelihood of having a positive bleeding history 
was not statistically different between the highest, intermediate and lowest tertiles of 
VWF:ag or VWF:CBA (p=0.28 and p=0.48 respectively, Kruskal-Wallis test).  No 
significant difference in levels of VWF antigen or activity was seen when bleeders 
(score 1 or 2) were compared to non-bleeders (score 4 or 5)(p=0.5, Kruskal-Wallis test). 
 
Partially deficient patients were further studied to assess the ability of VWF and FVIII 
levels to predict bleeding, as had been previously suggested.(7)  Table 3.10 
 shows the mean, median and range in partially deficient patients.   
 
Table 3.10:  VWF and FVIII levels in 70 partially deficient patients 
 FVIII:C VWF:Ag VWF:CBA 
Mean 97 100 101 
Median 92.8 99.5 102.3 
Range 34-198 49-284 46-257 
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The use of VWF and FVIII cut-off points of 70 IU/dL would not accurately predict 
bleeders in this patient group (table 3.11).(7)  In only four patients were all three 
parameters (FVIII:C, VWF:Ag and VWF:CBA) < 70 IU/dL.  Three of these were 
classified as probable or definite bleeders and one was classified as a probable non-
bleeder. 
 
Table 3.11:  Lack of correlation of bleeding score with specific VWF and FVIII levels 
 VWF:Ag <70 VWF:CBA <70 FVIII:C <70 
N 12 11 9 
Bleeder* 5 6 5 
Indeterminate 2 0 0 
Non-bleeder
†
 5 5 4 
*
Bleeder includes patients with a bleeding score of 1 or 2.
 
†
Non-bleeder includes patients with a bleeding score of 4 or 5. 
 
 
Blood group data was available in 89 of 102 patients (27 severely and 62 partially 
deficient patients).  Blood group O was present in 44 of 89 patients (49%) and the 
proportion of patients classified as probable or definite bleeders was 64%.  In contrast 
groups A and B accounted for 30% and 13% of patients respectively and the proportion 
of probable or definite bleeders was 48% in group A and 50% in group B.  Six patients 
were group AB with equal numbers of bleeders and non-bleeders.  The proportions of 
bleeders in patients with blood groups O and A was not significantly different (Chi-
squared test). 
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Thrombophilic traits 
Twelve patients had a reduced level of one or more of the natural anticoagulants 
(antithrombin, protein C and protein S) and two patients had a lupus anticoagulant, one 
of whom also had a low protein C (figure 3.7).  Combined deficiencies of the natural 
anticoagulants were seen in three patients, which was due to liver disease in one case.  
Five of these 14 patients (36%) were classified as probable or definite non-bleeders, 
including both patients positive for a lupus anticoagulant.  Five patients with low levels 
of natural anticoagulants were classified as definite bleeders (36%) and an additional 
four were probable bleeders (28%). 
 
Two patients were found to be heterozygous for the factor V Leiden mutation.  One was 
severely affected with a FXI:C of 7.4 U/dL and the second was partially deficient with a 
FXI:C of 50 U/dL.  Both patients were scored as probable bleeders but with low 
numbers it is impossible to determine whether the FVLeiden is preventing a more 
severe bleeding phenotype. 
 
The frequency of the prothrombin (PT) gene mutation was 6%, which is in keeping with 
published incidence rates in Jewish populations for this mutation.(169)  Of the six 
patients, two had bleeding scores of 1 (definite bleeders) and FXI:C levels of 3 U/dL 
and 50 U/dL, the latter patient also had a low protein S.  One patient (FXI:C 52 U/dL) 
was a probable bleeder.  Two patients were probable non-bleeders with levels of 8 U/dL 
and 40 U/dL while the last patient had an indeterminate bleeding history (FXI:C 68 
U/dL).  Again, with small numbers of affected patients, it is not possible to identify a 
modulatory effect of the PT gene mutation. 
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Of a total of 21 patients with an identifiable thrombophilic trait, 14 (66.7%) of patients 
are classified as probable or definite bleeders.  It is unlikely that these traits are 
modifying the bleeding phenotype to a large extent. 
 
Figure 3.7:  Thrombophilic traits in patients with FXI deficiency 
Patients (n=21) with deficiencies of the natural anticoagulants: antithrombin (AT), 
protein C (PC), protein S (PS) or with a lupus anticoagulant (LA) or with a genetic 
thrombophilia: factor V Leiden (FVL) or the prothrombin gene 3’UTR mutation 
(PTGM).   
PTGM, 5
PTGM & low  PS, 1
Low  PS, 4
Low  PC, 3
Low  AT, 1
Combined 
deficiencies   , 3
LA & low  PC, 1
LA , 1
FVL, 2
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FXI Glycosylation 
A further potential modulator of the bleeding tendency in FXI deficiency is the state of 
glycosylation of the FXI Protein.  The FXI protein has five potential N-linked 
glyscosylation sites as does Prekallikrein.(10;12)  However, not all of these are 
glycosylated in FXI since the carbohydrate content is 5% whereas in Prekallikrein the 
carbohydrate content is 15%.(205)  There is clearly potential for differences in the 
glycosylation pattern of the FXI protein which may be influenced by the presence of the 
polymorphisms in the glycosylation pathway. 
 
Investigation of the congenital disorders of glycosylation (CDG) have revealed that a 
polymorphism in the ALG6 gene (T911C leading to an amino acid change F304S), 
which encodes a critical enzyme in glycosylation, is associated with a more severe 
clinical phenotype and may act as a genetic modifier.(184)  In a Caucasian control 
group, the allelic frequency of the T911C polymorphism was 0.28.  In a group of 
patients with congenital disorders of glycosylation, the overall allelic frequency was 
similar (0.31) but when patients were subgrouped according to disease severity, patients 
with a severe disease phenotype were significantly more likely to carry a mutant allele 
(allelic frequency 0.41 versus 0.21 for the mild/moderate disease phenotype).  Thus, the 
presence of a mutant allele (whether in heterozygous or homozygous form) was 
associated with a worse clinical phenotype. 
 
Of the 102 FXI deficient patients in the study, 80 DNA samples were available for 
analysis.  Exon 10 of the ALG6 gene was sequenced and sequence alterations consistent 
with the F304S polymorphism were identified.  The results for analysis of the F304S 
polymorphism are shown in table 3.12.  The allelic frequency(q) was 0.24 (38 mutant 
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alleles of a total of 160 alleles) which is slightly less than the baseline Caucasian 
population.  The overall distribution of the ALG6 genotypes are similar to 
mild/moderate phenotypes in CDG (approximately 40% with a mutant allele) rather 
than severely affected CDG patients, of whom 70% had at least one mutant allele.  
There is therefore no evidence that the polymorphism in ALG6 is over-represented in an 
unselected cohort of FXI deficient patients. 
 
Table 3.12:  Frequency of the F304S polymorphism in the ALG6 gene in 80 patients 
with FXI deficiency. 
 Homozygous WT 
(Phenylalanine at 
aa position 304) 
Heterozygous 
Homozygous Mut 
(Serine at aa 
position 304) 
Number of patients 
with FXI 
deficiency 
47 28 5 
% of patients with 
FXI deficiency 
59 35 6 
% of patients with 
Mild/Moderate 
CDG 
61 36 3 
% of patients with 
Severe CDG 
30 60 10 
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3.4 Discussion 
The strength of this study is the comprehensive re-evaluation of a large cohort of 
patients with severe and partial FXI deficiency and the ability to correlate all variables 
to the bleeding score.  The bleeding tendency, as measured by a structured 
questionnaire, has been described previously in FXI deficiency.(5;7)  Concordance in 
that study between individual assessors of the bleeding history questionnaires was 67% 
which compares well with the current study (72%).   
 
A low proportion of indeterminate bleeding scores were assigned in the current study 
(6%) compared to 28% (43 of 152 individuals) in the earlier study.  In the latter, 
significant proportions of patients in the indeterminate category were < 15 years of age 
(44%) or had never had a haemostatic challenge (35%).  Allocation of a greater 
proportion of patients to specific bleeder or non-bleeder categories is likely to improve 
correlations with other laboratory and genetic parameters in this study.   
 
Bleeding rates following invasive procedures have been reported in a number of 
previous studies although the exact methodologies have been variable in regards to 
inclusion of severe and partial deficiency and description of procedures with and 
without pre-operative treatment.(5;7;50;55;62)  In relation to dental extraction, rates of 
bleeding have been recorded in two studies as 60% and 49% in severely deficient 
patients without prior treatment.(55;62) The rate of bleeding after dental extraction 
without prior treatment in the current study is 48.5% in severely deficient patients and 
40% for the whole patient group.  Similarly, rates of bleeding after tonsillectomy in 
untreated severely deficient patients in these two studies (86%,60.6%) compare to rates 
described in the current study (87.5% in untreated severely deficient patients).  Partially 
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deficient patients have been reported to have rates of bleeding (without prior treatment) 
after tonsillectomy of 28% and 59% in the literature compared to 35% in the current 
study.(7;55)  Therefore, bleeding rates in the current study, in relation to invasive 
procedures on areas of high fibrinolytic activity, are broadly in line with previously 
published rates in the literature.  
 
Bleeding after invasive procedures in the oral cavity is likely to result in the need for 
emergency treatment including transfusion.  In the current study, in untreated severely 
deficient patients, five required transfusion or FXI replacement after dental extraction 
while eight patients required transfusion and/or re-operation after tonsillectomy.  The 
balance of risk would appear to favour pre-operative treatment in such procedures.(62)  
In addition, there is evidence that prior treatment with FXI replacement prevents 
bleeding (no bleeding in 45 procedures covered with FXI concentrate in (55). 
 
In areas without high intrinsic fibrinolytic activity, the overall rate of bleeding is also 
broadly similar for procedures (31% in (55), 1-40% in (62), 26% in the current study).  
However, some variation in bleeding rates associated with individual procedures is 
evident.  For example, the Israeli group has published rates of bleeding in untreated 
severely deficient patients after circumcision (1.5%), appendicectomy (4.5%) and hernia 
repair (23%) which are less than those found in the current study (8.7%, 20%, 
60%).(62)  While numbers may be small for individual procedures, patients who 
develop bleeding frequently require transfusion of cellular blood products or re-
operation.  In the current study, there were 23 episodes of cellular blood transfusion, 17 
episodes of plasma transfusion and 12 re-operations required for management of post-
operative bleeding. 
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The Israeli group have used the data collected from their patient group to argue for 
with-holding upfront treatment for surgery on areas without high intrinsic levels of 
fibrinolytic activity.  However, the consequences of bleeding require evaluation also.  
These may include exposure to less virally safe cellular blood products in an emergency 
situation as opposed to treated FXI concentrate or plasma in an elective manner as well 
as risks of wound infection and an inferior wound outcome due to bleeding.  
 
Rates of bleeding after delivery in women with severe FXI deficiency have been 
described.(71)  For women who have not received prior treatment with plasma, bleeding 
rates of 24% for vaginal delivery and 16.7% for caesarean section were recorded.  In 
women who received plasma prior to delivery, bleeding was recorded in two of 14 
vaginal deliveries and none of six caesarean sections.  In the current study, data were 
recorded on deliveries in 47 women with severe (n=14) and partial deficiencies of FXI 
and interestingly, the rates of bleeding in untreated patients was similar to those for 
severely deficient patients in Israel for vaginal delivery (25%) but higher for caesarean 
section (28.6%).  Transfusion of plasma or red cells was required in 12 patients (35.5% 
of patients bleeding after vaginal delivery) in the Israeli study for the management of 
post-partum haemorrhage.  In this study, transfusion was recorded in one of two patients 
bleeding after caesarean section and in six of twenty episodes of bleeding after vaginal 
delivery.  In addition, FXI replacement was given in three episodes of bleeding. 
Therefore, the overall rate of emergency transfusion was 10 of 23 cases of bleeding 
(43%) which included patients with both severe and partial deficiency.  Again, the 
Israeli group have pointed to the figure that 70% of severely deficient women do not 
require any form of transfusion for management of labour.  However, risk balance 
analysis for upfront FXI replacement requires a review both of the rates of bleeding and 
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transfusion and the relative risks of adverse events for transfusion of untreated cellular 
blood products versus elective administration of a virally safe product. 
 
The data presented from this study confirm that a normal aPTT is not sufficient to 
outrule heterozygous FXI deficiency, since approximately a third of such patients will 
have a normal aPTT.  This finding that the prolongation of the aPTT is not found in all 
patients with FXI deficiency is in agreement with previous studies.(206-208)  The 
activator and phospholipid source and concentration used in different aPTT assay 
reagents have a significant effect on the sensitivity of the aPTT assay for the detection 
of mild FXI deficiency.(209)  The limit of sensitivity for prolongation of the aPTT in 
FXI deficient plasma with a silica aPTT activator was 57.5 U/dL in the latter study. 
 
All patients had a re-evaluation of FXI:C which resulted in the identification of one 
individual incorrectly registered as severely deficient, when both the FXI:C and FXI:Ag 
were in the partially deficient range.   
 
There were a relatively large number of patients whose FXI:C was higher than the 
registered FXI:C, even into the normal range.  Some of the registered FXI:C levels are 
likely to have been done many years previously.  The increase in FXI:C may be due to 
subtle changes in reagents or instrumentation in the aPTT-based FXI:C assay.  
Alternatively, FXI:C in these patients may have increased with age.  In the Leiden 
thrombophilia study the mean FXI:Ag was 91.8% in 77 control individuals <30 years 
versus 99% in 173 control individuals aged >50 years and the average increase in 
FXI:Ag was 0.19% per year of age suggesting that part of the increase may be age 
related.(210)  
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Ten Jewish individuals in this study had normal FXI:C levels but on genetic testing, a 
F11 mutation was confirmed.  Five of these also had normal FXI:Ag levels.  All of 
these patients had previously been registered with a lower FXI:C (< 70 U/dL), again 
raising the question that some current aPTT-based FXI assays may be less sensitive to 
heterozygous FXI deficiency. 
 
The addition of FXI:Ag to the diagnostic test repertoire for FXI deficiency enabled 
identification of six individuals with normal FXI:C but low FXI:Ag (of whom five had 
Jewish mutations confirmed), in whom FXI deficiency might have been outruled if only 
FXI:C had been performed.  In addition, evaluation of FXI:Ag resulted in the correct 
characterisation of a F11 gene mutation as a functional defect (see Chapter 6 for further 
details of this mutation – Ser576Arg). 
 
In populations with a high incidence of FXI deficiency and in patients with a confirmed 
family history of FXI deficiency, screening for FXI deficiency should include both the 
FXI:C and the FXI:Ag assays.  Since coagulation assays are not be sufficient to 
diagnose an underlying F11 gene mutation, genetic testing is recommended. 
 
Although the FXI:C is not completely determinant for the bleeding tendency, the 
likelihood of bleeding in the lowest tertile of FXI:C (corresponding to severe FXI 
deficiency) is significantly higher than for patients with partial deficiency and amounts 
to a positive bleeding history in 82% of patients.  In partially deficient patients, 40-50% 
of patients had a bleeding tendency but this is unrelated to whether the FXI:C falls in 
the middle or the highest tertile.  Clearly, the presence of severe FXI deficiency is a 
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significant but not an absolute predictor of the bleeding tendency.  In partial FXI 
deficiency, the absolute level of FXI:C does not appear to determine bleeding. 
 
A very small proportion of patients had a diagnosis of von Willebrand disease in this 
study, in  contrast to the 13% of patients diagnosed in an earlier study.(61)  Earlier 
reports had indicated that levels of FVIII or VWF could influence the bleeding tendency 
and were predictive of bleeding.(7;65)  In one study, a VWF:Ag less than 70 U/dL and 
a partial deficiency of FXI led to an increased incidence of bleeding (62% of 
patients).(7)  In another study, FVIII:C was correlated with FXI:C in a study of 26 
severely deficient and 46 partially deficient patients.(65)  However, the use of a VWF 
level of 70 U/dL in this study did not identify a group of patients at higher risk of 
bleeding.  Patients with blood group O in both studies had a slightly increased risk of 
bleeding symptoms.  In the current study, there was no statistical difference in 
proportions of bleeders in blood group O versus blood group A although the percentage 
of bleeders was higher in blood group O (64% versus 48% with blood group A). 
 
There have been a number of conflicting reports of modulation of the clinical phenotype 
of haemophilia by co-inherited thrombophilic traits.(67;211-214).  In a reconstituted 
model of coagulation, the presence of the FVLeiden gene mutation in haemophilic 
plasma led to an increase in thrombin generation.(215)  However, in this cohort of 
patients, despite the fact that 21% of patients had a thrombophilic trait, two thirds of 
these patients were still classified as bleeders.  It is therefore not likely that 
thrombophilic traits are modifying the bleeding phenotype in FXI deficiency. 
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There is evidence for alterations in clinical phenotype in von Willebrand disease 
associated with polymorphisms in genes encoding glycosylation enzymes.(216;217)  In 
the evaluation of children with congenital disorders of glycosylation (CDG), FXI levels 
are used as one of the laboratory parameters of disease severity.(218;219)  In this study, 
evaluation of one potential genetic modifier of glycosylation did not reveal an over-
representation of a polymorphism in the ALG6 gene associated with a more severe 
phenotype in CDG.  However, the possibility that variation in glycosylation is a 
modifier of phenotype in FXI deficiency remains and further evaluation in this area is 
warranted. 
 
In conclusion, at present the most robust predictor of bleeding in FXI deficiency is the 
presence of a severely reduced FXI:C (<20 U/dL).  However, within this group of 
patients a small number will not experience severe bleeding.  In patients with a partial 
deficiency, approximately half of the patients will have bleeding symptoms and lower 
levels of FXI:C, FVIII:C or VWF:Ag do not accurately predict bleeders.  In addition, 
blood group O and the presence of a thrombophilic trait do not influence bleeding 
tendency to any great extent.  The influence of FXI glycosylation remains to be further 
elucidated. 
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Chapter 4 Thrombin generation in Factor XI deficiency 
4.1 Introduction 
The detection of fibrin formed as a direct result of thrombin generation is the basis of 
the screening tests of coagulation: the prothrombin time(PT) and the activated partial 
thromboplastin time(aPTT) and others.  However, these tests are limited in their ability 
to detect subtle defects in thrombin generation since excessive amounts of initiators are 
used and consequently fibrin formation occurs very early in the time course of thrombin 
generation.(220)  At the end-point of the PT or APTT reaction, 5 to 10% of the total 
thrombin has been formed and the vast majority of the thrombin generated is formed 
after this point.(221)  The conventional screening tests for coagulation effectively 
measure the lag-time of thrombin generation rather than the total amount of thrombin 
generated by a given plasma.  The limitations of these tests are illustrated by the fact 
that the PT and aPTT are variably sensitive to hypocoagulable states and insensitive to 
hypercoagulable states.  For example, in the patient group under investigation in this 
work, 23% of patients had a normal aPTT despite a low FXI:C. 
 
Although two versions of the thrombin generation assay were described in the 1950s, 
the manual method was time-consuming and cumbersome for routine use.(112-114)  A 
method of continuously measuring thrombin generation was developed which was less 
labour intensive, less prone to manual error and amenable to semi-automation.(115)  
With the advent of a range of suitable substrates and technology which enables rapid 
analysis, interest in the thrombin generation assay as an assay of global coagulation 
function has increased.(117-119) 
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Factor XI deficiency leads to a defect in the generation of thrombin in the consolidation 
phase of coagulation since FXI is activated by thrombin late in the course of thrombin 
generation.(142)  FXIa further amplifies the generation of thrombin which serves to 
stabilise the clot through the activation of TAFI (thrombin activatable fibrinolysis 
inhibitor).(143) 
 
The variable bleeding tendency in FXI deficient patients is as yet unexplained.  The 
variability is not reflected in the FXI coagulant activity as measured by standard assays.  
A study of thrombin generation in plasma from nine severely deficient patients 
suggested that thrombin generation was dependent on FXI at low concentrations of 
tissue factor.(43)  However, other studies using higher concentrations of TF had 
suggested that significant thrombin generation could be seen in plasma with very low 
levels of FXI:C (1%).(119)  This study aimed to evaluate whether significant 
differences in thrombin generation could be seen in severe and partial FXI deficiency at 
low concentrations of TF and to define the relationship between thrombin generation 
and FXI:C levels, bleeding tendency and concomitant bleeding disorders or 
thrombophilic traits. 
4.2 Subsampling Thrombin Generation Test 
4.2.1 Method 
In brief, defibrinated platelet-poor plasma was incubated with phospholipid 
(concentration 13 μM) and buffer. Coagulation was initiated with rTF (concentration 10 
pg/mL[0.3pM]) and calcium chloride.  Timed subsampling from the reaction mix into a 
stop solution (comprising an EDTA/BSA buffer – 7.5mM EDTA, 50mM Tris base, 
175mM NaCl, 1% BSA, pH 8.4) was commenced 30 seconds after the initiation of 
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coagulation and continued every 30 or 60 seconds for 30 or 60 minutes for partially and 
severely deficient plasma respectively.  A chromogenic substrate for thrombin (H-D-
Phe-Pip-Arg-pNa.2HCl, S2238, Chromogenix) was then added to determine the amount 
of thrombin generated in each subsample and the colour reaction measured at 405nm.  
The full method is described in Chapter 2. 
4.2.2 Development of the subsampling assay 
Initially tissue factor (at concentrations of 10 pg/mL, 20 pg/mL and 40 pg/mL) was used 
to initiate thrombin generation in plasma with 100%, 50%, 25%, 10% and <1% 
concentrations of FXI (created by diluting normal pooled plasma into FXI deficient 
plasma).  A dose response was demonstrable for the different FXI concentrations at 10 
pg/mL with measurable thrombin generation even at FXI:C of <1 U/mL (Figure 4.1).  
Although the standard assay time of 15 minutes was satisfactory for normal plasma, it 
was too short for FXI deficient plasmas and was subsequently extended to 30 minutes 
for partially deficient plasma and 60 minutes for severely deficient plasma with the 
sampling interval increased from 30 seconds to 60 seconds.   
 
To ensure a reliable source of TF with a specific concentration, Recombiplastin Batch 
number N0828542 was standardised against a lipidated recombinant human tissue 
factor of known concentration (American Diagnostica, product number 4500L, 50 ng 
TF).  The concentration of this batch of Recombiplastin was calculated at 26,453.33 
ng/mL.  This TF source was used in all thrombin generation assays. 
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Figure 4.1:  Dose response of varying concentrations of FXI using TF 10 pg/mL as 
initiator in the subsampling method. 
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4.2.3 Patient selection 
The subsampling method was used to assay thrombin generation in plasma from 12 
patients with severe FXI deficiency and 11 patients with partial FXI deficiency (Table 
4.1).  Random patient lists were seperately obtained for partially deficient and severely 
deficient patients. In the case of partially deficient patients every sixth patient from the 
list was chosen for thrombin generation by the subsampling method. This generated 10 
patients. An additional patients plasma was assayed as part of the FaXID study (see 
Chapter 7) and was included. This gave a total number of patients of 11. For the 
severely deficient patients every fifth patient was chosen. This gave a total of six 
patients. A further five patients were specifically chosen because they were the only 
severely deficient patients with a bleeding score of 4 (probable non-bleeders). One 
patient had thrombin generation assayed as part of the FaXID study. This gave a total 
number of patients of 12.  
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Overall, six of the total of 23 patients had also participated in the FaXID study and 
therefore had plasma samples available pre and post treatment with recombinant Factor 
VIIa which were evaluated for thrombin generation.  
 
Table 4.1:  Patient selection for thrombin generation by subsampling method. 
Patient Selection Severe FXI deficiency Partial FXI deficiency 
Random 6 10 
Bleeding score 4 5 0 
FaXID trial participant 1 1 
Total 12 11 
 
 
4.2.4 Results 
AUC: comparison between severe and partial FXI deficiency 
The AUC for normal plasma using this subsampling assay varied from 2360.9 to 2910.9 
U/mL.  The same batch of commercial normal plasma was used in all assays.  The 
median area under the curve for thrombin generation in severely deficient plasmas was 
1574.2 U/mL with a range from 1260.4 to 3119.4 U/mL.  The median area under the 
curve for partially deficient plasmas was 3119.5 U/mL with a range from 1402.5 to 
5354.1 U/mL. The P value for the comparison between the severely deficient and 
partially deficient plasma is significant at 0.0062 (Wilcoxon two-sample test).   
 
Of note, five of the eleven partially deficient plasmas had AUCs which were more than 
10% above the highest value for normal plasma, raising the possibility of activation of 
the plasmas in the course of the assay.  Only three partially deficient plasmas had AUCs 
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which were more than 10% below the lowest value obtained for normal plasma.  Four 
of the severely deficient plasmas had AUCs which were in the range found for normal 
plasma. 
 
Peak thrombin generation: comparison between severe and partial FXI deficiency 
The peak thrombin level was also analysed and compared between patients with severe 
and partial deficiencies.  The median peak thrombin level generated was found to be 
1.95 U/mL in severely deficient plasma versus 6.5 U/mL in partially deficient plasma.  
The range for peak thrombin generation in normal plasma was 7.1 – 9.0 U/mL while the 
respective ranges for peak thrombin generation were 1.4 – 4.3 U/mL and 3.7 – 12.8 
U/mL in severely and partially deficient plasmas.  The p value for the comparison 
between severely and partially deficient plasmas was significant at <0.0001 (Wilcoxon 
two-sample test).  All of the peak thrombin levels in the severely deficient plasmas were 
below the range found in normal plasma and there was minimal overlap with the peak 
values seen in partially deficient plasmas.  Within the partially deficient group, one had 
a peak thrombin value which was in the range seen in normal plasma while three 
plasmas had peak thrombin values greater than normal plasma. 
 
AUC and peak thrombin generation: comparison between bleeders and non-
bleeders 
Tables 4.2 and 4.3 show the relationship between AUC and peak thrombin levels 
generated, according to the bleeding history in patients with severe and partial 
deficiency respectively.  A trend to lower AUC and peak thrombin levels is seen in 
bleeders in both categories of FXI deficiency but the p values were not significant by 
the Wilcoxon two-sample test (Fig 4.2). 
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Table 4.2:  Relationship between bleeding history and FXI:C, AUC and peak thrombin 
generated in severely deficient patients evaluated for thrombin generation by 
subsampling method. 
 
Severe FXI deficiency 
Bleeding 
history 
N 
FXI:C*
 
 
 
Range 
U/mL 
AUC
†
 
 
 
Median 
U/mL 
AUC 
 
 
Range 
U/mL 
Peak 
thrombin
†
 
 
Median 
U/mL 
Peak 
thrombin 
 
Range 
U/mL 
Bleeder
††
 7 3 - 12 1357.6 
1260.4 – 
2304.7 
1.85 1.4 – 2.9 
Non-
bleeder
¶
 
5 <1 - 8 1790.9 
1312.9 – 
3119.4 
2.5 1.8 – 4.3 
 
*One patient with a FXI:C of <1 U/mL had a high responding FXI inhibitor and    
another with a FXI:C of <1 U/mL had a lupus anticoagulant. 
†
p values for the comparison between bleeders and non-bleeders not significant 
††
Bleeder includes patients with bleeding scores 1 and 2. 
¶
Non-bleeder includes patients with bleeding scores 4 and 5. 
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Table 4.3:  Relationship between bleeding history and FXI:C, AUC and peak thrombin 
generated in partially deficient patients evaluated for thrombin generation by 
subsampling method. 
 
Partial FXI deficiency 
Bleeding 
history 
N 
FXI:C 
 
 
 
Range 
U/mL 
AUC*  
 
 
Median 
U/mL 
AUC 
 
 
Range 
U/mL 
Peak 
thrombin* 
 
Median 
U/mL 
Peak 
thrombin 
 
Range 
U/mL 
Bleeder
†
 6 15 – 83†† 2322.1 
1402.5 – 
5354.1 
5.15 3.7 – 12.8 
Indeterminate 
bleeding 
history 
1 50 n/a n/a n/a n/a 
Non-bleeder
¶
 6 44 - 64 3480.6 
2291.4 – 
3769.9 
6.55 6.2 – 8.2 
 
*p values for the comparison between bleeders and non-bleeders not significant 
†
Bleeder includes patients with bleeding scores 1 and 2. 
††
One patient with partial FXI deficiency had concomitant liver disease, accounting for 
a FXI:C of 15 U/mL. If this patient is excluded, the range of FXI:C levels in partially 
deficient patients was 41 to 83 U/mL.  
¶
Non-bleeder includes patients with bleeding scores 4 and 5. 
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Figure 4.2:  AUC of patients according to bleeding score (excluding one patient with an 
indeterminate score). Median values indicated by red horizontal line. 
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AUC and peak thrombin generation: pre and post treatment with rFVIIa  
In the six patients who had received recombinant Factor VIIa the median AUC 
increased to 3804.5 U/mL after the administration of rFVIIa compared to 2147.55 
U/mL prior to rFVIIa adminstration (normal plasma range 2360.9 – 2910.9 U/mL).  
Typical thrombin generation curves are shown in figure 4.3.  The peak thrombin level 
also increased after adminstration of  rFVIIa from a median of 4.9 U/mL to 11.5 U/mL 
(normal plasma range 7.1-9.0 U/mL).  
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Bleeder Non-bleeder Bleeder      Non-bleeder 
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Figure 4.3:  Typical thrombin generation curves pre and post rFVIIa using sub-
sampling method. 
 
 
 
 
 
 
 
 
 
 
 
4.2.5 Conclusions from Thrombin Generation Subsampling method assays 
From these preliminary studies of the subsampling Thrombin Generation method in FXI 
deficiency, the following conclusions were drawn: 
1. Thrombin generation was measurable in FXI deficient plasma at low tissue 
factor concentrations. 
2. Using a low TF concentration, a dose response was detectable at different 
FXI plasma concentrations, including in severely FXI deficient plasma. 
3. The difference in thrombin generation between severely and partially 
deficient plasmas was significant. 
4. There was a non-significant trend to lower thrombin generation in patients 
classified as bleeders versus non-bleeders. 
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However, the subsampling assay is cumbersome and the possibility of activation of 
some plasmas during the assay cannot be discounted.  Therefore, development of a 
continuous thrombin generation assay was undertaken.  
 
4.3 Continuous Thrombin generation test 
4.3.1 Method 
Defibrinated platelet-poor plasma was incubated briefly with phospholipid 
(concentration 6.5 μM), rTF (concentration 10 pg/mL) and buffer.  Coagulation was 
initiated by adding calcium and a chromogenic substrate for thrombin (MM-MeAla-
Arg-pNa.HCl, CBS 00.68, Diagnostica Stago) was added to enable continuous 
measurement of thrombin generation by reading the colour of the reaction mix every 30 
seconds for 30 minutes.  The full method is described in Chapter 2.    
 
4.3.2 Development of assay 
As a consequence of the limitations of the sub-sampling thrombin generation method, a 
continuous thrombin generation method was developed.  Optimisation of published 
methods was required in particular because a relatively low TF concentration was used 
relative to previously published methods of continuous thrombin generation (10 pg/mL 
as in the sub-sampling assay).   
 
Initially, a titration of rTF from 1/10 to 1/100,000 in normal plasma was performed to 
confirm that the TGT would be sensitive to varying rTF concentrations (Fig. 4.4a).  
Next, a similar rTF titration was performed in FXI deficient plasma (Fig. 4.4b).  It is 
notable that the ETP curves are not very different to normal plasmas at higher rTF 
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concentrations (i.e. 1/100 and 1/1000) dilutions and only become significantly abnormal 
at dilutions of 1/10,000 or more (Fig 4.4 a & b).  Reaction volumes had to be adjusted 
since microtitre plates were being used instead of test-tubes.  A phospholipid 
concentration of 6.5 μM in the final reaction mixture was found to be optimal and was 
superior to frozen PS/PC vesicles.  The raw OD data represents the total amount of 
substrate cleaved by thrombin and the α2 macroglobulin-thrombin complex which is 
formed during the reaction.  A computer program was developed to rapidly calculate the 
contribution related to thrombin alone by subtracting the contributions from the α2 
macroglobulin-thrombin complex, as described by Hemker.(116) 
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Figure 4.4a and b:  Comparison of TF titration in normal plasma and FXI deficient (FXI:C <1U/mL) plasma(Raw OD curves).  With higher 
concentrations of TF (1/100 and 1/1000 dilutions) the steady state OD achieved for both plasmas is between 0.015 and 0.025.  With lower 
concentrations of TF, the lag time for NP increases and the curve becomes flatter for the severely deficient plasma.       
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4.3.3 Reproducibility of the continuous TGT 
The intra-assay co-efficient of variation (CV) for normal plasma varied from 7.1% to 
16.2% (Table 4.4).  The inter-assay CV for a normal pool (20 normal individuals) 
comparing four results (in duplicate) on four separate days was 14.9%.  The reliability 
of the results achieved was found to be sensitive both to the manual methods used (e.g. 
type of pipette) and to the reagents (e.g. necessity to ensure the correct pH of the buffers 
for example).  The ETP was calculated for the normal plasma control (Cryocheck) twice 
on each 96 well plate.  The normal controls were assayed in duplicate in the first two 
wells of the 96 well plate and a second set of duplicates in the last two wells.  The ETP 
of patient samples was expressed as a % of the average from the four normal control 
wells on each plate. 
 
Table 4.4:  Intra-assay imprecision studies for normal plasma in the continuous 
thrombin generation test. 
 
 Cryocheck 
Normal 
pool  
Expt 1* 
Normal 
pool  
Expt 2 
Normal 
pool  
Expt 3 
Normal 
pool  
Expt 4 
Mean 1.654 1.3225 1.5275 1.265 1.245 
SD 0.118 0.214 0.205 0.183 0.101 
CV(%) 7.1 16.2 13.4 14.5 8.1 
*Expt: Experiment 
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4.3.4 Patients 
A total of 100 patients had plasma available for analysis.  Results are available for 66 
patients.  Patients were not selected specifically and the remaining 34 patients were not 
assayed or required repeat assays which could not be performed due to time constraints. 
4.3.5 Results 
Comparison of severe and partial FXI deficiency 
At higher TF concentrations, the ETP was normal even in severely deficient plasmas.  
At a TF concentation of 10 pg/mL and following the optimisation steps above, a clear 
distinction could be made between different concentrations of FXI:C (Figure 4.5).  The 
median ETP for all 66 patients was 57% with a range of 1-141.6% (compared to normal 
plasma, allocated a value of 100%). Table 4.5 shows the results for the ETP for all 
patients and according to the severity of the FXI deficiency.   
One severely deficient patient with a bleeding score of 2 had an unusally high ETP of 
38.5%. Apart from this patient, two other severely deficient patients had ETPs of 
approximately 25%, one with a bleeding score of 1 and the other with a bleeding score 
of 4. The remaining nine severely deficient patients had ETPs of <20%. 
 
Of the partially deficient patients, only 6 of 54 patients had an ETP of <30%.  One 
patient with a bleeding score of 1 and a relatively low FXI:C of 30%, had an ETP of 
8.7%. This is in the range of severely deficient patients. The other five patients had 
ETPs ranging from 21.4 to 29.1% and included one definite non-bleeder while the 
others were classed as probable (n=3) and definite bleeders (n=1). 
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Table 4.5:  ETP results for all patients and according to severity of FXI deficiency. 
 
 
Number 
of patients 
ETP (% Normal Plasma) 
Median Range 
25
th
-75
th
 
percentile 
5
th
-95
th
 
percentile 
All patients 66 57 1-141.6 n/a n/a 
Severe FXI 
deficiency 
12 10.9 1-38.5 6-18.6 3.1-31.6 
Partial FXI 
deficiency 
54 68.8 8.7-141.6 48.4-83.4 24.7-116.8 
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Figure 4.5:  Titration of FXI:C in the continuous ETP method. 
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Correlation of Bleeding score and FXI:C with ETP in Partial FXI deficiency 
A total of 54 patients with partial FXI deficiency were included. Of these, two patients 
had an indeterminate bleeding history (score 3) and were not included in this analysis.  
Therefore 52 partially deficient patients were evaluated.  The results for FXI:C and ETP 
according to bleeding scores 1 or 2 (i.e. bleeder) or 4 or 5 (non-bleeder) are given in 
table 4.6.  The p value for the comparison between bleeders and non-bleeders is 0.02 
(Wilcoxon two-sample test).   
 
Table 4.6:  The relationship between ETP and bleeding score for partially deficient 
patients (ETP expressed as % of normal plasma). 
 
Bleeding score 
Number of 
patients 
FXI:C 
 
Median 
(Range) 
ETP* 
 
Median 
ETP 
 
Range 
Bleeder
†
 26 52 (30-113) 52.4 8.7-135.6 
Non-bleeder
††
 26 57.5 (40-110) 77.3 24.8-141.6 
*p value for the comparison of median ETP between bleeders and non-bleeders =0.02 
†
Bleeder includes patients with bleeding scores 1 and 2. 
††
Non-bleeder includes patients with bleeding scores 4 and 5. 
 
The median and range for FXI:C between the ―bleeder‖ versus the ―non-bleeder‖ groups 
are similar.  This further demonstrates the lack of relationship between the FXI:C and 
bleeding history.  The correlation co-efficient for the relationship between FXI:C and 
ETP in these patients is 0.43, confirming that FXI:C is not the only determinant of ETP. 
 
As only 12 severely deficient patients were evaluated a statistical analysis of the 
relationship between ETP and bleeding history was not possible.  Two severely 
deficient patients had a bleeding score of 4 (probable non-bleeder).  These two patients 
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had ETPs of 16.3% and 25.3% but there were also two of 10 patients in the ―bleeder‖ 
category with ETPs of >20%.   
 
Concomitant bleeding disorders and thrombophilic traits in Partial FXI deficiency 
Patients were assessed for concomitant bleeding disorders.  In the bleeder category, one 
patient had a low FVIII:C while in the non-bleeders, one patient had a low FVIII:C, two 
patients had von Willebrand disease and one patient had dysfibrinogenaemia.  There did 
not appear to be a correlation between bleeding tendency and other bleeding disorders.  
Of the four patients with a low FVIII:C or von Willebrand disease, two had an ETP 
which was less than the 25th percentile for the partially deficient patient group. 
 
Ten of 54 partially deficient patients had an abnormal thrombophilia screen.  Seven of 
these 10 patients had ETPs above the 75th percentile for the partially deficient patient 
group and three of seven had an ETP above the 95th percentile.  However, this trend 
was not clearly linked to bleeding tendency –  of the seven patients with an elevated 
ETP, three were classified as bleeders and four as non-bleeders. 
4.4 Comparison of TGT methods 
Different thrombin generation methods are not easily comparable.  The sub-sampling 
thrombin generation method described here utilises a thrombin standard and the results 
are expressed in units of thrombin. On the other hand, the continuous ETP method 
refers to a normal plasma run in parallel and given a nominal value of 100%. 
 
There were 12 patients whose plasma was assayed by both methods, four severely 
deficient and eight partially deficient patients.   Of the severely deficient patients, two 
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sets of results were broadly concordant with one another while two sets were discordant 
e.g. an ETP higher than the median for the group with a sub-sampling AUC lower than 
the median.  Within the group of eight partially deficient patients, five had concordant 
results and three had discordant results. 
 
4.5 Discussion 
The results of the Thrombin Generation test performed by the subsampling method 
confirm that there is a difference in thrombin generation potential between severely and 
partially FXI deficient plasma.  This is in contrast to a previous report that plasma from 
patients with severe Factor XI deficency had normal thrombin generating 
potential.(119)  However considerably higher concentration of tissue factor was used in 
this study to initiate thrombin generation (15pM ≈ 525 pg/mL)  It has been proven that 
the presence of FXI is critical when thrombin is generated using a low concentration of 
tissue factor as the initiator.(43)  In the pivotal study by von dem Borne et al, plasma 
deficient in FXI and FXII was reconstituted with FXI (12.5nM).  At higher 
concentrations of TF there was no difference in fibrin formation between plasma with 
and without FXI.  However at dilutions of TF >1x10
4 
a gradual increase in fibrin 
formation was seen in the presence of FXI as concentrations of TF decreased.  In the 
study by Keularts et al, there was no difference in thrombin generation between normal 
plasma and FXI deficient plasma (FXI:C <1%) at TF concentrations of 37.5 or 300 
pg/mL but a significant difference was seen at a TF concentration of 10 pg/mL.  It is 
now evident from this and other studies that coagulation may be initiated by sub-
picomolar concentrations of TF (134;136;220;222) and that the TF concentration in 
whole blood cannot exceed 20 fM (=0.02pM).(223) 
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Given this data, a low TF concentration of 10 pg/mL(≈0.27pM) was utilised in the 
current work with the express aim of demonstrating differences in thrombin generation: 
firstly between normal, partially deficient and severely deficient plasmas and secondly 
between patients with different bleeding tendencies but similar FXI:C levels.  Using 
higher concentrations of TF would have obscured the role of FXI which is seen 
particularly at low TF concentrations.  A number of TF concentrations were evaluated 
(10,20 and 40 pg/mL).  Compared with the 10 pg/mL concentration, the 40 pg/mL 
concentration resulted in greater thrombin generation for severely deficient plasmas but 
thrombin generation in partially deficient plasmas was near normal.  Since a particular 
aim of the study was to evaluate differences in bleeding tendency in partially deficient 
patients, the lower concentration was chosen. This had the consequence that longer data 
acquisition times were needed for severely deficient patients. 
 
The AUC and peak thrombin generated in the subsampling TGT were also compared in 
patients who were classified as bleeders versus non-bleeders. There was a non 
significant trend for higher area under the curve and peak thrombin in non bleeders.  
However only small numbers of patients were tested in each category due to the 
laborious nature of the test.  Some patients with partial deficiency had higher AUCs and 
peak thrombin than normal plasma raising the possibility of activation of the plasmas 
either at blood sampling, in storage, in the freeze-thaw process or in the assay itself.   
 
Finally it was notable that treatment with rFVIIa normalised thrombin generation.  
Since rFVIIa is not providing replacement therapy in patients with FXI deficiency, it is 
useful to have proof that the goal of therapy, to restore thrombin generation, is achieved.  
In the absence of a specific laboratory marker for efficacy of rFVIIa, a thrombin 
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generation test may be a useful marker of efficacy and safety.  There have been a 
number of small studies of the effect of rFVIIa on thrombin generation.  In a series of 
five patients with severe FXI deficiency and inhibitors, thrombin generation was 
corrected to 50% of normal with rFVIIa at a concentration of 1 μg/mL, equivalent to a 
clinical dose of 45 μg/kg.(106)  Subsequently, plasma from 14 patients with FXI 
deficiency were evaluated in a thrombin generation assay (five had inhibitors and may 
have been the same patients as in the earlier study).(128)  In these patients, no thrombin 
generation was evident in the presence of phospholipids and calcium alone.  However, 
rFVIIa at a concentration of 1.75 μg/mL (35nM, equivalent to a clinical dose of 80 
μg/kg) restored thrombin generation.  The latter effect was reduced if either FVIII or 
FIX were inhibited.  The effect of rFVIIa could be augmented in FXI deficient plasma if 
a small amount of TF was added (0.27pM ≈10 pg/mL) or if the concentration of 
phospholipid were increased. 
 
The subsampling TGT provided proof of principle that at low TF concentrations, 
differences in thrombin generation could be seen between normal plasma and FXI 
deficient plasma and between severe and partial deficiency.  In addition, there was 
evidence of differences in thrombin generation among patients with similar FXI:C 
levels which might relate to their bleeding tendency. 
 
The main difficulty with the subsampling method is that it is non-automated and 
extremely labour intensive.  This reduces the number of patient samples that can be 
assayed.  The accuracy of results and the reproducibility of the assay are affected by 
manual error.  An automated or semi-automated method would allow increased 
numbers of patient samples to be assayed in a more robust way.  Assay of larger 
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numbers of plasmas is important to determine whether there is a clear demarcation in 
thrombin generation between severely and partially deficient plasma.  In addition, a 
larger patient group might allow identification of a relationship between thrombin 
generation and bleeding tendency.  For these reasons, a continuous TGT was developed.  
The parameters chosen for the continuous TGT in this study were developed to allow 
subtle differences in thrombin generation to be detectable between patients with similar 
FXI:C levels but different bleeding tendencies rather than to give a definitive value for 
thrombin generation. 
 
The continuous TGT confirms that the endogenous thrombin potential is significantly 
lower for severely deficient plasma than partially deficient plasma. Although the range 
of ETP results was markedly lower for severely deficient plasma, there were some 
patients in each category of FXI deficiency with values for ETP which overlapped, 
generally in the range 20-30% of normal plasma ETP. 
 
There was a significant relationship between ETP and bleeding tendency in partially 
deficient patients.  There was no relationship between the FXI:C and ETP and the 
median FXI:C levels were similar in the bleeder and non-bleeder categories. 
 
The continuous thrombin generation method was semi-automated and therefore allowed 
for increased numbers of samples to be assayed. However, the assay process still 
contains significant manual steps which do not lend it easily to routine laboratory assay.  
The manual aspects of the assay lead to intra-assay and inter-assay CVs which are 
variable and in some cases higher than those normally accepted in routine laboratory 
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practice.  The measured CVs for normal plasma are in keeping with published CVs for 
similar assays.(125)   
 
Factors which may influence the thrombin generation in patients with FXI deficiency 
include co-existant VWD or thrombophilic traits.  There were limited numbers of 
patients in the group with such laboratory abnormalities.  The most notable trend was 
that patients with a thrombophilic trait had a increased likelihood of having an ETP 
above the 75th percentile and above the 95th percentile of the range of ETP in partially 
deficient patients.  Increased thrombin generation has been reported in plasma from 
patients with haemophilia and FVII deficiency who have concomitant 
thrombophilia.(214;215)  However, the increased ETP did not correlate with bleeding 
tendency in FXI deficient patients.   
 
In patients with a partial deficiency of FXI, the conformation of the FXI dimer may 
influence protein function.(224)  It is feasible that dimers of WT and mutant FXI may 
co-exist with WT-WT dimers and mutant-mutant dimers and the relative proportions of 
each may vary.  One can speculate that relatively higher proportions of WT-WT dimers 
may correlate with higher thrombin generation potential and a lesser tendency to bleed.  
However, none of four mutations proven to cause such a ―dominant negative‖ effect 
(Ser225Phe, Cys398Tyr, Gly400Val, Trp569Ser) has been identified in the patients in 
this study.(224;225) 
 
Inhibition of FXIIa by corn trypsin inhibitor (CTI) has been used in some studies of a 
reconstituted synthetic model of coagulation to ensure that contact activation did not 
play a role in thrombin generation.(134;135)  However, contact activation did not 
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appear to occur to any significant degree in a dilute thromboplastin assay evaluating the 
contribution of FXI to coagulation using low concentrations of TF as the initiator.(136)  
Other studies of thrombin generation in FXI deficient plasmas, using TF as initiator, 
similarly did not use an inhibitor of FXII.(43;106;119)  In a study of thrombin 
generation in FXI deficient plasma (FXI:C <1%), thrombin generation curves were 
obtained in the presence and absence of a monoclonal antibody to FXII and no 
differences were seen.(43) Consequently, corn trypsin inhibitor was not used in the 
assays described in this study.  Subsequently, the use of CTI in a fluorogenic thrombin 
generation assay has been shown to abolish contact activation at concentrations of TF 
<15pM in PPP and PRP.(133;137)  The effects of CTI on thrombin generation in a 
chromogenic assay were not evaluated.   
 
The aim of this study was to provide initial proof of principle regarding differences in 
thrombin generation between patients with similar FXI levels but different bleeding 
histories.  In effect, patient samples which had been collected, stored and treated in a 
similar manner were compared to each other in an assay designed to optimise the 
chances of detecting differences.  Clearly this chromogenic assay using PPP and 
exogenous phospholipid is not physiological but the evidence that the thrombin 
generation assay can differentiate patients with a bleeding tendency supports the future 
development of more physiological TGTs using PRP which may be applicable in the 
routine setting.(226)   
 
Neither the subsampling nor the continuous chromogenic TGT assay as evaluated in 
this study is amenable to reliable use in a routine laboratory.  However, these studies do 
indicate that the TGT may be able to detect subtle differences in thrombin generation 
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potential in plasmas with similar FXI levels.  Preliminary evidence has been presented 
which suggests that ETP differs in plasmas from patients with different bleeding 
histories but similar FXI levels. 
 
Further optimisation of the TGT in FXI deficient plasma would include evaluation of a 
maximally automated assay, preferably using PRP.  Other issues which need to be more 
fully evaluated are the use of CTI and the optimal TF concentration for use in assays of 
severely deficient plasma.   
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Chapter 5 Thrombin Activatable Fibrinolysis Inhibitor 
(TAFI) 
5.1 Introduction 
Thrombin activatable fibrinolysis inhibitor (TAFI) is a recently described indirect 
inhibitor of fibrinolysis, as outlined in detail in the Introduction (Chapter 1).  TAFI 
activation appears to be dependent on thrombin generated in a FXI-dependant fashion 
and it may be the hypothesised that FXI deficient patients will have less inhibition of 
fibrinolysis than normal plasma, leading to more bleeding.(143;165)  Evidence in the 
literature suggests that variability in TAFI antigen levels, TAFI activation or TAFI 
activity could cause differences in the degree of inhibition of fibrinolysis, potentially 
leading to a variability in bleeding tendency.(160;173;177)  For example, it could be 
postulated that a patient with a partial FXI deficiency and higher TAFI antigen or 
activity levels would have greater inhibition of fibrinolysis and reduced bleeding 
compared to a patient with a similar FXI deficiency and lower TAFI levels.   
 
There are a number of TAFI antigen ELISAs available but individual assays have 
variable sensitivity for known polymorphisms in the TAFI protein.  TAFI activity can 
be measured after activation in a commercial enzymatic assay.  TAFI activity is also 
evaluated by the Clot Lysis assay if the plasma sample is assayed with and without 
Potato Tuber Carboxypeptidase inhibitor (PTCI), a specific inhibitor of TAFI. 
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In this study, the following questions are posed: 
1. Is there evidence for variability in TAFI antigen, activity or clot lysis time 
(CLT) in FXI deficient patients? 
2. Are TAFI antigen, activity or CLT associated with FXI:C levels or bleeding 
tendency? 
3. Is there evidence that FXI deficient plasmas have increased fibrinolysis as 
measured by the CLT? 
4. Does rFVIIa correct any abnormalities in the CLT? 
 
5.2 TAFI antigen 
5.2.1 Method 
Briefly, the TAFI Antigen kit used was the Imulyse® TAFI Antigen kit (Biopool 
International, Sweden), subsequently marketed as VisuLize® TAFI Antigen kit 
(Affinity Biologicals Inc., Ontario, Canada). The kit utilises a polyclonal sheep antibody 
to human TAFI as the capture antibody and the detecting antibody is labelled with 
peroxidase to enable detection using a colorimetric reaction.  A standard curve is 
generated using a standard reference plasma diluted in TAFI deficient plasma.  The 
method is a standard ELISA method (See Methods Chapter 2). 
 
5.2.2 Results 
A reference interval for the TAFI:Ag assay was obtained by analysing TAFI:Ag levels 
in twenty normal individuals.  The mean for the normal plasmas was 9.0 ± 5.0 µg/mL, 
with a range of 3.8-13.4 µg/mL.  The reference interval (2.5
th
-97.5
th
 percentile) was 5-
13.4 µg/mL.  TAFI:Ag levels in 102 patient samples had a median and mean of 9 
µg/mL and 9.1 µg/mL respectively, with a range of 3.9-16.8 µg/mL.  Nine patients had 
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TAFI:Ag levels which were higher and four patients had levels which were lower than 
the reference interval.  The patients with low TAFI:Ag levels had bleeding scores of 
1,2,3 and 4.  Three patients with increased TAFI:Ag levels had bleeding scores of 1, 
four had bleeding scores of 2 and two had bleeding scores of 5. 
 
The direct relationship between TAFI antigen and bleeding score for 102 patients is 
shown in Figure 5.1.  There is no correlation between TAFI antigen level and bleeding 
score and the correlation coefficient is -0.5.  The relationship of TAFI:Ag in the highest, 
intermediate and lowest tertiles to bleeding score was assessed by the Kruskal-Wallis 
test.  The distribution of bleeding scores was not significantly different between the 
tertiles of TAFI:Ag levels (p=0.06). 
 
Figure 5.1:  TAFI antigen levels in μg/mL from 102 patients with FXI deficiency versus 
bleeding score.  Bleeding score of 1: definite bleeder, 2: probable bleeder, 3: 
indeterminate, 4: probable non-bleeder, 5: definite non-bleeder. 
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5.3 TAFI Activity (Enzymatic Method) 
5.3.1 Introduction 
TAFIa is known to be a very labile protein and prone to rapid degradation at room 
temperature (estimated t½ of TAFIa is two hours at 25ºC).  In assaying TAFIa, 
particular care was taken regarding specific incubation temperatures and times 
mandated in the assay kit instructions.  Likewise, plasmas for analysis were rapidly 
thawed in a waterbath, then placed in an ice bath until required for assay.  All assays 
were carried out promptly.  Plasmas were thawed only once. 
 
5.3.2 Method 
TAFI activity was assessed using an American Diagnostica Actichrome TAFI kit as 
described in the Methods Chapter 2 and briefly summarised here.  In essence the kit is 
an assay of ―activatable‖ TAFI, based on an assay described in the literature.(176)  All 
plasmas were assayed twice.  One set of duplicate plasma samples was activated with a 
specific TAFI activator - a thrombin/thrombomodulin complex, (termed the activated 
plasma sample) while the second plasma sample was assayed without activation (termed 
the unactivated plasma sample).  After addition of the activation reagent, an exact 20 
minute incubation at room temperature was undertaken and then an activation stop 
reagent was added to all samples, followed by addition of a TAFI developer which 
results in a colorimetric reaction.  The colour reaction was stopped after a further 30 
minutes and the absorbance was read at 490 nm.  The TAFI carboxypeptidase activity 
was derived from the subtraction of the absorbance of the unactivated plasma sample 
from the activated plasma sample.  The concentration of TAFI was then calculated from 
a standard curve generated from TAFI standards included in the kit. 
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5.3.3 Results 
Despite following the specific kit instructions, the TAFI standard did not perform as 
expected.  The absorbances obtained from the TAFI standard were much lower than the 
kit instructions and published data would suggest.  The absorbances derived from the 
TAFI standard  ranged from 0.224 to 0.441 when patient samples ranged from 0.38 – 
0.93.  A second vial of the standard was re-assayed to confirm this finding and again 
low ODs were obtained of 0.52 and 0.578.  The kit insert implied that the top dilution of 
the standard might have an OD of approximately 1.4.  The manufacturer was contacted.  
The manufacturers suggested that the standard may have been damaged in transit and a 
new kit was provided with the same lot of standard.  This time the top standard gave an 
OD of 0.257 and was similar to the first kit standard.  A normal plasma pool had an OD 
of 0.5785 and patient samples ranged from 0.4175 to 1.122.   
 
The manufacturer was again contacted and another kit was received.  The standard was 
from a different lot from that received previously.  A series of dilutions of a normal 
plasma pool were also included on the plate so that results could be calculated as a % of 
normal even if the TAFI standard was unsatisfactory.  On this occasion the top standard 
had a corrected OD of 0.587.  Nine of 15 test samples had ODs which were outside the 
standard curve.  Eleven of 15 test samples had TAFI levels which were more than 50% 
of normal when calculated against the normal plasma pool.  When calculated against the 
TAFI standard, all 15 test samples had TAFI levels which were more than the quoted 
normal range in the kit insert. 
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A laboratory normal range was constructed by assaying 17 individual normal plasma 
samples and a plasma standard curve was constructed by including four dilutions of a 
normal plasma pool.   
 
In regards to the unsatisfactory performance of the TAFI standard, multiple email 
communications with the manufacturers ensued.  However, a definitive explanation for 
the poor performance of the standard could not be provided.  A possible explanation 
was that the standard was being damaged in transit. 
 
A researcher (J.Antovic, personal communication), based at the Karolinska Institut in 
Stockholm, Sweden, who presented data on TAFI activity using the American 
Diagnostica kit at the 2003 ISTH meeting was contacted.  This researcher did not use 
either of the two batches used in this study but using two other batches, the top standard 
gave an OD of 1.1 with the first batch and 2.5 with the second batch.  These ODs are in 
keeping with the ODs expected.  Other researchers in the Netherlands are believed to 
have reported problems with variation in the standard curve with this particular assay. 
 
The performance of the kit TAFI standard was not satisfactory.  The reason for the poor 
performance was not clear but may have been related to storage conditions in transit.    
The assay involves multiple reagent addition steps and strict incubation steps so there is 
also the possibility that the standard or the plasma test samples were being activated or 
degraded inadvertently.  However, it is noted that the kit instructions regarding storage, 
thawing and assay methodology were followed meticulously.  Ultimately, the kit in 
question was determined not to be sufficiently reliable or robust.  Since the aim was to 
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determine the concentration of functional TAFI present in the sample, it was decided to 
develop a functional clot lysis assay. 
 
5.4 Clot Lysis Assay 
5.4.1 Introduction 
The clot lysis method is a surrogate method for evaluation of TAFIa.(154;160)  
Coagulation is activated in plasma by the addition of thrombin or recombinant tissue 
factor and fibrinolysis is promoted by the addition of tPA.  In this system, the plasma 
components of fibrinolysis are measured in a global assay encompassing all of the 
proteins required for both thrombin generation and fibrinolysis.  Since plasma contains 
a number of proteins with carboxypeptidase activity, potato tuber carboxypeptidase 
inhibitor which is a specific inhibitor of TAFI is added to tandem plasma samples.  The 
contribution of TAFI to the clot lysis time (CLT) is defined by the difference between 
the CLT with and without PTCI. 
 
5.4.2 Method 
The clot lysis assay is a determination of the lysis time of a tissue factor-initiated clot by 
exogenous tPA.  The method used was described by Mosnier in 2001 and used in a 
number of studies of clot lysis by the same group.(172;173;177)  In brief, plasma is 
added to a reaction mix containing a phospholipid source, tPA (56ng/mL) and buffer.  
Coagulation is initiated with rTF (10pg/mL) and CaCl2 (17mM).  The reaction mix is 
incubated at 37
0
C and the plate is read every 2.5 minutes for 120 minutes to detect 
changes in turbidity (See Methods Chapter 2).  All plasmas are analysed in duplicate 
and the CLT is the average of both results.  PTCI (final concentration 25µg/mL) was 
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added to an identical plasma reaction mix, in tandem, to enable the contribution of 
TAFI to fibrinolysis to be calculated. 
 
Recombinant tissue factor was used to initiate coagulation because the purpose of the 
assay is to analyse the influence of FXI-dependent thrombin generation on subsequent 
fibrinolysis and the addition of exogenous thrombin is likely to confound the results.  
Since the influence of FXI is seen at low tissue factor dilutions, a 1x10
5
 dilution of rTF 
was utilised for all clot lysis assays.(43;143)  Concentrations of rTF are similar to those 
used in the thrombin generation assay.  Clot lysis times were evaluated with and without 
the addition of PTCI to assess the contribution of TAFI. 
 
Ex vivo spiking of a selection of patient plasmas with rFVIIa (final concentration 
40nM) was utilised to evaluate the effect of this compound on fibrinolysis in FXI 
deficient plasmas.  
 
For the purpose of evaluating the role of TAFI in fibrinolysis in FXI deficient patients 
in this study, the TAFI:CLT refers to the contribution attributable to TAFI (i.e. the 
difference between the CLTs obtained in the presence and absence of PTCI: CLT+PTCI 
and CLT-PTCI).  Two methods to calculate CLT are used in the literature, which will 
be termed CLT1 and CLT2 here (figure 5.2).  CLT1 is calculated as the time between 
the midpoint of the clear-to-maximum turbid transition and the midpoint of the turbid- 
to-clear transition.(173)  CLT2 is calculated as the time from the occurrence of the 
maximum OD to the midpoint of the turbid-to-clear transition.(165;174)  Both CLT 
measurements are given in units of time (minutes).   
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Figure 5.2:  Clot lysis assay: optical density changes with time and calculation of CLT1 and CLT2. 
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CLT1: Time from the midpoint of the clear-to-turbid transition to the midpoint of the turbid-to-clear transition 
CLT2: Time from the point of maximum turbidity to the midpoint of the turbid-to-clear transition 
 
 
Point of maximum turbidity 
CLT1 Start of clotting 
phase.  
Plasma clear. 
Fibrinolysis phase 
CLT2 
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5.4.3 Results 
Analysis of Patient samples and Normal Pool 
Plasma samples from 102 patients were available for analysis (Table 5.1).  Samples 
from 53 patients were either not assayed (n=19) or results were not available for 
technical reasons (n=34).  In particular, lipaemic samples were unsuitable for analysis 
due to a high baseline optical density.  Samples with FXI:C levels <2 U/dL did not 
generate a satisfactory curve, and were not analysed.  Samples with > 20% difference 
between duplicate samples were deemed unacceptable for analysis. 
 
Samples from 49 patients fulfilled the acceptance criteria for results and are reported. Of 
167 individual Clot lysis curves, 82% of duplicate curves were within 10% of each 
other and 94% were within 15% of each other.  The within-assay variation is 5-16%.  
The inter-assay coefficient of variation for the normal pool was 18%. 
 
Table 5.1:  Summary of analysis of 102 patient samples for CLT. 
 
Summary of CLT assays No. of patient samples Notes 
Total patient samples  102  
Patient sample not assayed 19 No sample available 11 
FXI <2 U/dL  8 
Sample assayed but no 
result 
34 Lipaemic sample 11 
Error in curves 23 
CLT results available 49  
Severe FXI deficiency 9 Range FXI:C 3-11 U/dL 
Partial FXI deficiency 40 Range FXI:C 40-110 U/dL 
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There is a clear relationship between CLT1 and CLT2 with a correlation co-efficient of 
0.84 (Figure 5.3).  Since the shape of the OD curve obtained may influence the time to 
maximum OD from which the CLT2 is calculated and since there is a close relationship 
between both measurements, it was decided to conduct further analysis in relation to 
CLT1 only. 
 
 
 
Figure 5.3:  A comparison of the analysis of the contribution of TAFI to the Clot Lysis 
curve, measured by two methods (n=49) – CLT1 (midpoint of the clear-to- maximum 
turbid transition to the midpoint of the maximum turbid-to-clear transition) and CLT2 
(time to occurrence of the maximum OD to the midpoint of the turbid-to-clear 
transition). 
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r=0.84 
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CLT  
The CLT without the addition of PTCI was analysed in 49 patients and in a normal 
plasma pool (representative curve, Figures 5.4).  The addition of PTCI considerably 
shortened the time to complete lysis since TAFI is specifically inhibited (figure 5.5). 
 
Figure 5.4:  Optical density curve representing the turbidity changes in the normal 
pool, analysed without PTCI (CLT-PTCI). 
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Figure 5.5:  Optical density curve representing the turbidity changes in the normal 
pool, analysed with PTCI (CLT+PTCI).  Note the CLT is considerably shorter that the 
CLT-PTCI. 
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The Normal Pool (20 individual samples) had a mean CLT of 61±22.4 minutes.  The 
median CLT in the 49 FXI deficient patients was 59.2 minutes with a wide range (37.7-
104.2 minutes).  Surprisingly, there was no difference in CLT-PTCI between patients 
with severe or partial FXI deficiency (Table 5.2).   
 
Table 5.2:  Comparison of CLT in patients with severe and partial FXI deficiency.  
CLT-PTCI represents the clot lysis time in the absence of PTCI.  The contribution of 
TAFI to the CLT is termed TAFI:CLT and is derived by the subtraction of the CLT in 
the presence of PTCI from the CLT-PTCI. 
  
 Severe FXI deficiency Partial FXI deficiency 
Number of patients 9 40 
   
CLT-PTCI*  23 
Median 59 59 
Range 43.5-76.8 37.7-104.2 
Interquartile range 57.6-72.5 51.1-65.8 
   
TAFI:CLT
†
   
Median 29.4 23 
Range 16.1-43.9 13.8-50.5 
Interquartile range 26.3-34.2 19.2-28.7 
*p=0.8, ANOVA single factor analysis      
†
p=0.12, ANOVA single factor analysis 
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There was no correlation between the TAFI:Ag and the CLT-PTCI (correlation co-
efficient 0.14).  Non-bleeders tended to have a lower and less variable CLT-PTCI than 
bleeders but this was non-significant (p=0.16, Figure 5.6). 
 
Figure 5.6:  Relationship between CLT-PTCI and patients with Bleeding Score 1 and 2 
(definite and probable bleeders) and Bleeding Score 4 and 5 (probable and definite 
non-bleeders). Note: n=47, two patients with bleeding score 3 excluded. 
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p=0.16, ANOVA single factor analysis 
 
TAFI activity as calculated by the CLT 
The contribution related to TAFI is calculated by analysing the CLT with and without 
PTCI. The TAFI:CLT is the difference between the two measurements.  The TAFI:CLT 
was not correlated to the TAFI:Ag (correlation coefficient 0.1) nor to the FXI level, 
p=0.12 (see table 5.2).  There was no significant difference in TAFI:CLT between 
bleeding and non-bleeding patients (Figure 5.7, p=0.4). 
 
4               5  1              2     
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Figure 5.7:  The contribution of TAFI to the CLT (TAFI:CLT) related to the bleeding 
scores of the patients (n=47, two patients with bleeding score 3 excluded). 
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p=0.4, ANOVA single factor analysis 
 
Influence of rFVIIa on CLT 
The addition of rFVIIa prolonged the CLT in the majority (68% of samples) but not in 
all samples (representative curve shown in figure 5.8).  The mean change was a 5% 
increase in CLT in the presence of 40nM of rFVIIa.  Thirty-two of 47 patients had an 
increase in CLT with the addition of rFVIIa, ranging from 0.5-41%.  The increase in 
CLT was more than 10% in 11 patient samples.  Fifteen patient samples had a decrease 
in the CLT by 2-14%. 
 
 
 
 
   1               2 4                5 
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Figure 5.8:  The Optical Density curve of the normal pool, analysed in the presence of 
rFVIIa (40nM). 
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5.5 Discussion  
The majority of patients in this study had normal TAFI:Ag levels and only 13 patients 
had levels outside of the reference interval (nine patients had higher TAFI:Ag levels and 
four patients had lower TAFI:Ag).  Of those 13 patients, there was no observed 
relationship with bleeding tendency.  When TAFI:Ag was assessed in relation to 
bleeding tendency across all 102 patients there was no correlation identified.  The 
conclusion therefore is that TAFI:Ag is not significantly variable in patients with FXI 
deficiency and levels do not appear to vary according to bleeding tendency.  Of note, 
the TAFI:Ag kit used is associated with the detection of lower TAFI levels in patients  
with the Thr325Ile polymorphism.  This could be postulated to result in an under-
estimation of TAFI levels in those individuals and a weakening of the relationship 
between increased TAFI levels and protection from bleeding.  However, the absolute 
level may not be the only factor involved in protection from bleeding as the Ile isoform 
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of TAFI may result in lower TAFI levels but more inhibition of fibrinolysis due to its 
increased activity and stability.(159) 
 
TAFI activity as measured by a commercial kit was found not to be sufficiently reliable 
in assaying stored samples from FXI deficient patients.  The main problem was the 
performance of the supplied TAFI standard which meant that the patient samples could 
not be assigned a value for the TAFI activity level.  Despite attempts to rectify this 
problem with new standards (from both the same and different ―lots‖), the standard 
continued to perform sub-optimally and a clot lysis assay was developed to evaluate 
TAFI activity instead. 
 
The CLT has been validated as a surrogate assay for TAFIa in plasma.(160)  The 
reported inter-assay and intra-assay CVs are 3.8% and 7.6% and 4% and 3.4% which 
are lower than those seen in the current study.(160;172) 
 
The addition of PTCI enables the contribution of TAFI to be calculated although it is 
recognised that many other proteins involved in thrombin generation and fibrinolysis 
influence this assay.   
 
The CLT results obtained for normal plasma in this study are very similar to those 
reported in the literature.  The mean CLT was 61 minutes (range 38.8-135.2 minutes) in 
469 control subjects analysed as part of the Leiden Thrombophilia study.(172)  In that 
study, CLT increased with age and were slightly higher in men.  Mosnier et al reported 
a mean CLT for normal plasma of 62 ± 11.5 minutes (calculated by the CLT2 method) 
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which is in keeping with the result for the normal pool in this study (61±22.4 
minutes).(160)  However, the reduction in CLT seen with the addition of a neutralising 
antibody to FXI in that study (to 38.7 ± 8.6 minutes) is not replicated in plasma samples 
from patients with FXI deficiency.  Of note, however patients with FXI:C < 2U/dL were 
excluded from the CLT assays since it was found that reproducibility of the assay at low 
FXI:C levels was not acceptable.  In addition, thrombin was used as the activator of 
clotting the Mosnier study and it has been suggested that higher levels of thrombin are 
needed to activate TAFI.(149)  This raises the possibility that using a TF mediated CLT, 
the amounts of thrombin generated are too low to activate TAFI.   
 
In a study of clot lysis in plasma from patients with severe Haemophilia A, the same 
investigators described a Clot Lysis assay, in which coagulation was initiated by 
varying dilutions of Innovin (1x10
3
 to a 1x10
7
) and the CLT was measured using the 
CLT1 method.(177)  Of note, the CLT in normal plasma was approximately 60 minutes 
at all dilutions of TF.  In the presence of an inhibitory antibody to FXI, the CLT was 
normal in the presence of higher concentrations of TF (i.e. <1x10
5
 dilutions but the CLT 
was significantly reduced when the concentration of TF was lower.  The CLT in 
patients with severe Haemophilia was investigated using a TF dilution of 1x10
5
.  In 
these patients CLT were considerably lower than the normal pool and were similar to 
CLT in the presence of PTCI.  The CLT was increased to normal levels by addition of 
TAFI or small amounts of FVIII (1U/mL).  There was no correlation between TAFI 
levels and the severity of bleeding. 
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TAFI:Ag levels were found to correlate with CLT only in the presence of FXI in normal 
patients and in the presence of FVIII in individuals with severe Haemophilia. (160;177)  
The lack of correlation of TAFI:Ag and CLT in patients with severe FXI deficiency is 
therefore not surprising but individuals with partial FXI deficiency have residual 
thrombin generation via the intrinsic pathway and would therefore be expected to have a 
correlation between TAFI:Ag and CLT. 
 
Individuals in the Leiden Thrombophilia study with a CLT > the 90
th
 percentile had a 
two-fold increased risk of thrombosis.(172)  Interestingly the correlation between CLT 
and individual coagulation and fibrinolytic proteins was weak.  There was an 
association between increasing TAFI levels and increasing CLT but the contribution of 
TAFI to the overall CLT was small.  Likewise, increases in FXI levels were very 
weakly associated with increasing CLT.  Surprisingly, there was also no correlation 
between ETP and CLT considering that in earlier studies the amount of thrombin 
generated determined the amount of TAFI activation which occurred.(165)  Therefore, 
it appears that the CLT is governed by the balance of procoagulant and fibrinolytic 
factors, rather than by any one factor. 
 
Regarding the effect of rFVIIa on FXI plasma, a study of CLT initiated with thrombin 
found that there no significant difference between the CLT of normal plasma versus 
FXI deficient plasma (24±2.2 minutes compared to 22.5±0.7 minutes).(179)  The 
addition of rFVIIa at a concentration of 9.6 μg/mL prolonged the CLT by two minutes.  
The contribution of TAFI (as measured by comparing the CLT before and after the 
addition of PTCI) appeared to increase slightly with higher doses of rFVIIa.  These 
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results in conjunction with the results of the current study appear to indicate either that 
the CLT is insensitive to variations in fibrinolytic activity in patients with FXI 
deficiency or that differences do not occur.  CLT assays do not confirm the theory that 
rFVIIa down-regulates fibrinolysis in a TAFI dependent manner. 
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Chapter 6 FXI gene mutations and molecular model 
6.1 Introduction 
The mutations commonly causing FXI deficiency in persons of Jewish heritage have 
been well described.(58;59)  The mutations have been termed type I to IV but all are 
characterised by low FXI coagulant activity and antigen levels.  The type II 
(Glu117stop) and type III alleles (Phe283Leu) are most common while type I and IV 
mutations (splice site mutation and deletion in intron N respectively) are rare.  While 
the allele combinations have been shown to influence mean FXI:C levels in 
homozygotes and compound heterozygotes, a link between genotype and bleeding 
phenotype has not been demonstrated.(56)  In patients with partial FXI deficiency, the 
presence of individual alleles appears not to influence either the mean FXI:C levels or 
the bleeding phenotype.(7;56) 
 
The FXI gene is 23 kb long and contains 15 exons and 14 introns which are translated to 
an 18 amino acid signal peptide and a 607 amino acid mature protein.(9)  The first exon 
encodes the 5‘ untranslated region and the second encodes the signal peptide.  Exons 
III-IV, V-VI, VII-VIII and IX-X encode for four apple (Ap) domains, also known as 
PAN modules (Ap1 to Ap4 respectively: Figure 6.6(a)).  These Ap domains show 
sequence homology with each other and with the Ap domains of PK.(10)  The Ap 
domains of FXI also show sequence similarity and disulphide bridge conservation 
characteristic of other Ap/PAN modules such as EtMIC5, a adhesin from Eimeria 
tenella.(227)  Exons XI-XV contain the coding sequence for the serine protease domain 
(SP: Figure 6.6(a)).(9)  The SP domain is homologous to other members of the trypsin 
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family of serine proteases.  Both FXI and PK have five potential N-glycosylation sites 
(three are shared), but the overall carbohydrate content of FXI is 5% whereas in PK it is 
15%.(10;12) 
 
Uniquely amongst the coagulation factor serine proteases, and in contrast to PK, FXI 
circulates as a dimer.(17)  The two identical FXI monomers are linked by non-covalent 
interactions between the Ap4 domains and by a Cys321-Cys321 disulphide bond, 
although the latter is not critical for dimerisation.(18-20;228)  Dimerisation appears to 
be essential for secretion of FXI and may be essential for cleavage of its physiological 
substrate factor IX (FIX).(27;229)  FXI can be activated by thrombin or by activated 
FXII, or may undergo auto-activation.(230)  Activation results in cleavage of the 
scissile bond at Arg369-Ile370 to form a heavy chain containing the Ap domains and a 
light chain containing the SP domain with the catalytic triad at His413, Asp462 and 
Ser557.  Both monomers are cleaved during activation, and the dimer structure is 
retained after activation.(17) 
 
Recently there has been a rapid increase in reports of FXI mutations 
(www.factorXI.org).  The majority of these are missense mutations. The Ap3 and SP 
domains contain the largest number of these mutations, and mutations have now been 
reported for all the FXI exons except the untranslated exon I.  The functional analysis of 
these mutations ranges from simple measurement of FXI:C with or without FXI antigen 
(FXI:Ag) to detailed expression studies of mutant FXI. Measurement of FXI:C and 
FXI:Ag enables the phenotypic classification of mutations as either Type I/ cross-
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reacting material negative (CRM-) with low FXI:Ag and low FXI:C or Type II/ cross-
reacting material positive (CRM+) with normal FXI:Ag and low FXI:C.   
In this study, 101 patients had DNA available for analysis, of whom 77% were of 
Jewish origin.  Since some patients may have an unsuspected Jewish heritage, the 
mutational analysis strategy was to firstly screen all patients for the four Jewish 
mutations by restriction enzyme analysis.  Patients without an identifiable Jewish 
mutation or with inconclusive results by restriction enzyme analysis, proceeded to have 
the entire FXI gene sequenced to identify possible mutations.  Suspected 
polymorphisms were compared to known SNPs in the NCBI SNPs database.  
 
While experimental study of the mutant protein in a mammalian expression system is 
the gold standard for the interpretation of mutations to distinguish between disease-
causing mutations and neutral polymorphisms, it was not possible to conduct such 
experiments for all reported mutations.  For many other coagulation proteins, three-
dimensional structural models are essential in order to predict the impact of a given 
point mutation on the protein structure and its consequence for disease.  For FXI, this 
was not possible up to 2006 because of the nonavailability of a crystal structure. 
Between 1998 and 2002, publication of the crystal and NMR structure determinations 
for Ap domains in an adhesin protein EtMIC5 from the protozoan Eimeria tenella, a 
leech anti-platelet protein, and human hepatocyte growth factor made homology 
modelling of the FXI Ap domains possible for the first time.(231-233)  Crystal 
structures for almost one hundred SP domains were available in the Protein Data Bank, 
and some of these, such as that of -tryptase, provided close structural templates for 
modelling the SP domain in FXI.  Accordingly, homology models were built for the 
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Ap1 to Ap4 and the SP domains in FXI.  This resulted in the first three-dimensional 
structural analysis of mutations causing FXI deficiency. 
 
6.2 Methods 
6.2.1 DNA extraction 
For genetic analysis, DNA was extracted from the buffy coat of whole blood using a kit 
according to the manufacturer‘s instructions (QIAamp DNA Blood Mini kit, Qiagen 
GmBH, Hilden, Germany).  The DNA samples were stored at –700C until use. 
 
6.2.2 Screening for Jewish Mutations 
To screen for the Jewish mutations, DNA samples were thawed and specific primers 
were used to amplify exons 5 and 9 by PCR to identify type II and III mutations 
respectively. A third set of primers which amplify the junction of exon 14-intron N were 
used to identify patients with type I and IV mutations.  The PCR products were digested 
overnight with BsmI, Sau3A and MaeIII for the type II, III and I/IV mutations 
respectively and the samples were then run on a 2% or 4% (for the type I and IV 
mutations) gel at 120v for two hours.  The gel was examined under UV light and 
photographed.  A blank and normal, heterozygous and homozygous controls (where 
available) were run with each sample.  Full details of primers, PCR amplification 
conditions and restriction enzyme analysis are found in Chapter 2 Methods. 
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6.2.3 Sequencing of F11 gene 
Primers and PCR and sequencing conditions for sequencing of all 15 exons of F11 are 
also given in Chapter 2, section 2.7.6.  Sequencing of the PCR products was carried out 
on an Applied Biosystems 3100 Avant Sequencer. The cycle sequencing reactions using 
Big Dye Terminators v1.1© were carried out using the recommended protocol. 
 
6.2.4 Molecular modelling 
Identification of FXI mutations 
As described in chapter 2, all mutations in the F11 gene causing FXI deficiency 
published at the time, were identified by searching the Human Gene Mutation database, 
Medline and hand searching of meeting abstracts.  A particular emphasis was placed on 
gathering as comprehensive a set of phenotypic data as possible.  This data set included 
FXI:C in most cases, and FXI:Ag and/or bleeding phenotype in some cases.  Mutations 
published in abstract format were grouped according to the presence or absence of 
phenotypic data. 
 
Construction of FXI homology models 
A detailed description of the construction of the homology models of the Ap1 to Ap4 
and SP domains is given in chapter 2, section 2.8.  In brief, INSIGHT II 98.0 modelling 
software with HOMOLOGY, DISCOVER and BIOPOLYMER modules (Accelrys, San 
Diego, CA) and the structural refinement program O (185) on Silicon Graphics 
workstations were used to construct the models.  Structurally conserved regions (SCRs) 
were identified within the five FXI domain sequences and their template structures 
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following alignments of members of the PAN-module superfamily, in particular the E. 
Tenella adhesin protein (PDB code: 1HKY) and the anti-platelet toxin from H. 
officinalis (PDB code: 1I8N_A).  Five close homologues for the serine protease domain 
were similarly identified: human -thrombin (PDB code: 1H8I), human protein C (PDB 
code: 1AUT), human complement C1r (PDB code: 1GPZ), boar sperm -acrosin (PDB 
code: 1FIZ) and human mast cell -tryptase (PDB code: 1AOL). 
The SCRs were built using a rigid body fragment assembly method and the intervening 
loop regions were then either modelled from a database of protein fragments using the 
Brookhaven loop database of INSIGHT II or generated using a constrained 
minimization algorithm implemented by HOMOLOGY.  Energy refinements were done 
using the DISCOVER module and the structures were verified using PROCHECK (186) 
and O, the energy minimisation program of the DISCOVER module and the structure 
idealisation program REFMAC5 of CCP4i (187).  The DSSP program (200) was used 
to assign secondary structures as follows: H and G, -helix and 310 helix; E and B, -
strand; T, turn; C and S, coil and loop. Side chain solvent accessibilities in the structures 
and models were calculated using NACCESS (201), on a scale of 0 to 9 for each 
residue, where 0 corresponds to 0% to 9% accessibility, 1 corresponds to 10% to 19% 
accessibility, and so on. Buried residues have accessibilities of 0 or 1.  
 
 
 
 
 
   185 
6.3 Results of screening for the Jewish mutations in the F11 gene 
6.3.1 Genotypes for the Jewish mutations 
Screening for the four Jewish mutations by restriction enzyme analysis was done in 101 
patients (with a suitable DNA sample), of whom 78 were of Jewish heritage.  One of the 
four mutations found in Jewish populations was confirmed in 77 of 101 patients.  The 
breakdown of genotypes according to the severity of the FXI deficiency is given in 
Table 6.1.   
 
The Jewish mutations were found in 30 of 32 severely deficient patients.  Half of all 
severely affected Jewish patients were compound heterozygotes for the type II and III 
mutations whereas homozygosity for either the type I or II mutations were equally 
common (20% and 27% of severely deficient patients with Jewish mutations 
respectively).  Neither of the two rarer disease causing alleles (types I and IV) was 
found in this group.   
 
Of the remaining two severely deficient patients, one was of English, non-Jewish 
heritage and has an unknown mutation.  The other is Jewish but has a lupus 
anticoagulant.  The latter patient had a positive lupus-type FXI inhibitor screen and a 
normal FXI:Ag 105 U/dL, suggesting that this patient does not have a true FXI 
deficiency.   
 
Amongst the partially deficient patients, the type II and III alleles were equally common 
but there were also two patients from one family who were heterozygous for the type I 
mutation. 
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Table 6.1:  Genotype of 101 patients with FXI deficiency. 
 
Genotype 
Severe deficiency* 
N=32 
Partial deficiency* 
N=69 
II/II 6 0 
II/III 15 1 
III/III 8 0 
I/WT 0 2 
II/WT 0 25 
III/WT 1 19 
Total Jewish mutations 30 47 
Negative for Jewish mutations 2 22 
*Number of patients 
 
6.3.2 Bleeding phenotype related to genotype (Jewish mutations) 
Amongst patients with a confirmed Jewish mutation, there was a significantly higher 
incidence of bleeders in patients with severely deficient genotypes compared to patients 
with partially deficient genotypes (p=0.005) as shown in Table 6.2.  No significant 
difference in bleeding phenotype was seen between genotypes II/II, II/III and III/III in 
severe FXI deficiency or between genotypes II/WT and III/WT in partial deficiency 
(p=0.49 in both cases, Kruskal-Wallis test). 
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Table 6.2:  FXI genotype (Jewish mutations) and relationship to FXI:C and bleeding phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* excluding one patient with chronic liver disease  ** excluding one patient with a compound heterozygote genotype but a partially deficient FXI:C level 
FXI deficiency Genotype 
Number of 
patients 
FXI:C 
Mean (range) 
Bleeder (%) Non-bleeder (%) Indeterminate (%) 
Severe 
II/II 6 1   (<1-1.2) 6   (100) 0   (0) 0   (0) 
II/III 15 4.3   (1.1-10) 11   (73) 3   (20) 1   (2) 
III/III 8 9.4   (7-12) 7   (87.5) 1  (12.5) 0   (0) 
Total* 29  24   (83) 4   (14) 1   (3) 
Partial 
I/WT 2 47, 50 1   (n/a) 1   (n/a) 0   (n/a) 
II/WT 25 62   (37-110) 14   (56) 10   (40) 1   (4) 
III/WT 19 62.4   (41-90) 7   (37) 9   (47) 3   (16) 
Total** 46  22   (48) 20   (43) 4   (9) 
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6.3.3 Discrepant FXI:C and genotype 
Two discrepant results were found between FXI:C levels and genotype.  One of the 
severely affected patients was heterozygous for the type III mutation but this patient 
also had chronic liver disease, unrelated to her FXI deficiency.  It is probable that the 
FXI:C level was lowered to the severely deficient range by an acquired defect in liver 
synthesis in addition to the genetic defect.  A patient with FXI:C levels of 50 U/dL was 
found to have the genotype of a compound heterozygote.  This finding is unexplained 
and sequencing of exons V and IX is required to clarify the genotype. 
 
6.4 Results of sequencing the F11 gene 
6.4.1 Patients with Jewish heritage but lacking the Jewish F11 gene 
mutations 
Three of 24 patients without evidence of the Jewish mutations on restriction enzyme 
analysis, had definite Jewish heritage.  It is likely that these patients do not have a true 
inherited FXI deficiency.  One Jewish patient has a concomitant lupus anticoagulant and 
a normal FXI:Ag as mentioned above, raising the possibility that the FXI:C levels are 
erroneously low.  Another has Gauchers disease and was not on enzyme replacement 
treatment when first diagnosed with FXI deficiency and thrombocytopenia.  Both the 
FXI:C and the platelet count have normalised on enzyme replacement and no further 
bleeding symptoms have been reported.  The last Jewish patient with a negative screen 
for the Jewish mutations has had the FXI:C and FXI:Ag rechecked and both were >100 
U/dL, raising a doubt over the accuracy of the original diagnosis.  In conclusion, the 
three Jewish patients in this group are not believed to have a true FXI deficiency. 
. 
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6.4.2  Screening for mutations in the F11 gene in 21 patients without a 
Jewish mutation or heritage 
A total of 21 patients have a definite FXI deficiency but no identifiable Jewish mutation 
and no known Jewish heritage.  One of the 21 patients has a severe deficiency (FXI:C 
7.4 U/dL) and the remainder are partially deficient.  The strategy to identify mutations 
in the FXI gene in 21 patients without an identifiable Jewish mutation consisted of 
direct sequencing of the 15 exons and exon-intron borders of the FXI gene.  Numbering 
of cDNA is taken from RefSeq # NM_000128.2, where +1 corresponds to the A of the 
ATG translation initiation codon.  Mutation names are given in the traditional format 
with respect to the mature protein.  The recommended numbering where codon 1 is the 
ATG primary translation start is also given and is identified by a ―p.‖ prefix. 
 
Missense mutations: Genotype and Phenotype 
Missense mutations were identified in six patients (table 6.3).  Three had previously 
been reported in the literature. 
 
Table 6.3:  Missense mutations identified in 21 non-Jewish patients with confirmed FXI 
deficiency (references are as published at the time of this study, see discussion for 
subsequent publications).  Ap and SP denote apple and serine protease domains. 
Mutation 
name 
HGVS 
nomenclature 
Nucleotide 
substitution 
Exon Protein 
domain 
FXI:C FXI:Ag Ref 
Pro48Leu p.Pro66Leu c.197C>T 3 Ap 1 52 40 No 
Gly155Glu p.Gly173Glu c.521G>A 6 Ap 2 43 64 (234;235) 
Glu297Lys p.Glu315Lys c.943G>A 9 Ap 4 38 34 No 
Glu380Lys p.Glu398Lys c.1192 G>A 11 SP 30 32 No 
Cys398Tyr p.Cys416Tyr c.1247 G>A 11 SP 57 36 (236) 
Ser576Arg p.Ser594Arg c.1782C>A 15 SP 46 71 (237) 
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Patient characteristics of six missense mutations identified 
Four of six patients gave their ethnic origin as English with one patient of Bangladeshi 
origin and one of Portuguese origin as indicated below. 
 
Pro48Leu 
A missense mutation was identified in exon 3.  A change from C to T at nucleotide 197 
leads to substitution of a leucine residue for a proline at amino acid 48 (Pro48Leu, 
p.Pro66Leu).  This patient had a FXI:C of 52 U/dL and a FXI:Ag of 40 U/dL.  The 
patient was registered as a probable bleeder.  The FVIII:C was borderline at 50 U/dL 
while the VWF:Ag was 57 U/dL and the VWF:Ac was 58 U/dL. The patient‘s blood 
group was group O.  The thrombophilia screen was negative and TAFI antigen was 
normal. Thrombin generation was assayed by the continuous method and was 29% of 
that found in normal plasma. 
Gly155Glu 
Substitution of A for G at nucleotide 521 (figure 6.1 and 6.2) results in a change from 
Glycine to Glutamate at amino acid 155 in exon 6 (Gly155Glu; p.Gly173Glu).  The 
patient had a FXI:C of 43 U/dL and a FXI:Ag of 64 U/dL.  The patient was a definite 
non-bleeder.  The von Willebrand screen and thrombophilia screens were negative.  
TAFI antigen levels were normal and thrombin generation tests were not performed. 
 
Figure 6.1: Gly155Glu forward sequence (heterozygosity for G and A at position 521 is  
shown at the red arrow). 
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Figure 6.2: Gly155Glu in reverse sequence showing heterozygosity for C and T at the 
arrow. 
 
Glu297Lys 
In exon 9, a change in amino acid at position 297 from Glutamate to Lysine results from 
a G to A transition at nucleotide 943 (figure 6.3).  The patient is a definite bleeder with 
a FXI:C of 38 U/dL and a FXI:Ag of 34 U/dL.  The von Willebrand and thrombophilia 
screens were negative and TAFI antigen levels were normal.  Thrombin generation was 
assayed by the continuous method and was 28% of that found in normal plasma. 
Figure 6.3: Heterozygosity for Glu297Lys showing the dual G and A signals in forward 
sequence. 
 
Glu380Lys 
A Bangladeshi patient with a FXI:C of 30 U/dL and a FXI:Ag of 32 U/dL had a 
missense mutation identified in exon 11.  Glu380Lys results from substitution of A for 
G at position 1192 and causes the replacement of a glutamic acid residue with a lysine 
in the serine protease domain.  The patient had a negative von Willebrand screen and a 
borderline Protein C level of 66 U/dL (reference interval 70-140 U/dL) but the 
thrombophilia screen was otherwise negative.  The TAFI level in this patient was the 
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lowest of any of the patients in the study and the ETP as measured by the continuous 
thrombin generation assay was similarly very low at 8.7% of normal.  The bleeding 
score for this patient was 2 (probable bleeder). 
Cys398Tyr 
A substitution of A for G at position 1247 of exon 11, causing replacement of a 
Cysteine at position 398 with Tyrosine, was found in a patient of Portuguese origin with 
a FXI:C of 57 U/dL and a FXI:Ag of 36 U/dL.  The patient had a negative von 
Willebrand screen and a normal thrombophilia screen. TAFI levels were normal and the 
ETP as measured by the continuous method was 74.2% of normal. In keeping with the 
ETP, the bleeding score registered for this patient was 5 (definite non-bleeder). 
Ser576Arg 
A missense mutation was identified in exon 15 in another patient.  Substitution of A for 
C at nucleotide 1782 (figure 6.4) results in a change from Serine to Arginine at position 
576 (Ser576Arg, p.Ser594Arg).  The patient had a FXI:C of 46 U/dL and a FXI:Ag of 
71 U/dL.  The patient was a probable bleeder.  The von Willebrand screen revealed a 
borderline FVIII:C and VWF:Ac at 50 U/dL with a VWF:Ag of 64 U/dL.  Of note, the 
patient was blood group O.  The thrombophilia screen was negative and TAFI antigen 
was normal.  Thrombin generation tests were not performed. 
Figure 6.4: Heterozygosity for the Ser576Arg mutation – dual signals for A and C at 
position 1782(forward signal). 
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Synonymous Polymorphisms 
Six synonymous polymorphisms were identified in six patients (Table 6.4).  Three 
patients had two distinct polymorphisms present.  Four of these polymorphisms were 
reported on the NCBI SNP database at the time of the study and two were not. 
 
Table 6.4:  Synonymous polymorphisms detected in 21 patients during screening of the 
F11 gene. 
Amino acid (+ 
signal peptide) 
Nucleotide Triplet Reported 
Asp 125 (143) 602 GAC>GAT NCBI 
Ala 181 (199) 771 GCT>GCG No 
Ala 202 (220) 833 GCC>GCT No 
Asp 551 (569) 1704 GAC>GAT NCBI 
Arg 586 (604) 1985 CGG>GAA NCBI 
Glu 595 (613) 2012 GAG>GAA NCBI 
 
6.5 Molecular modelling of 42 mutations in the F11 gene 
6.5.1 F11 gene mutations 
A total of 42 mutations in the FXI gene were identified from databases, literature and 
abstracts, 25 of which were located in the Ap domains and 17 in the SP domain.  
Phenotypic information was available for 28 of the 42 mutations (Table 6.5).  The 
remaining 14 mutations were mostly obtained from abstracts, from which detailed 
phenotypic characterisations were not possible (Table 6.6).  
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Table 6.5  FXI mutations with phenotypic and expression data(continued on next page). 
Domain Mutation site  Heterozygotes Homozygotes 
Expression in mammalian cells  
(% WT) 
Reference 
  
No. of 
patients 
FXI:C 
(U/dL or %) 
FXI:Ag 
(U/dL or 
%) 
No. of 
patients 
FXI:C 
(U/dL or 
%) 
FXI:Ag 
(U/dL or 
%) 
FXI:C  
Medium 
FXI:Ag 
Medium 
FXI:Ag 
Lysate 
 
Apple 1 Cys38Arg 8 18-45 .
¶
 1 <1 . <1 <1 74 (51) 
Apple 2 Gly155Glu
‡
 3 41; 43; 44.3 64 0 . . . . . (234;235)
,**
 
Apple 3 Phe221Ser* 1 1 1 0 . . 9 <5 100 (238) 
 Gln226Arg
†
 1 42-55 70 0 . . . 100 . (239) 
 Cys237Tyr
§
 2 <1 . 0 . . <1 3 92 (51) 
 Ser248Asn
†
 2 42-55; 67-72 70; 80 0 . . . 100 . (239) 
 Lys252Ile
±
 1 4-4.5 . . . . . 34 104 (240) 
Apple 4 Phe283Leu Multiple 67 . Multiple 9.7 . 
. 8 20-34 
(mRNA) 
(56) 
 Leu302Pro . . . . . . 
. decreased 
secretion 
. (241) 
 Thr304Ile . . . . . . 
. decreased 
secretion 
 (241) 
 Arg308Cys 1 41-45 32.7 0 . . . . . (237) 
 Glu323Lys . . . . . . . 
decreased 
secretion 
. (241) 
 Gly336Arg
¶¶
 1  <1 2.5 . . . . . . (242) 
 Gly350Ala
§§
 1 1 44 . . . . . . (242) 
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Domain Mutation site  Heterozygotes Homozygotes  
Expression in mammalian cells  
(% WT) 
Reference 
Serine 
Protease 
Thr386Asn 1 108 . 2 2 Decreased . . . (243) 
 Cys398Tyr 2 40-50 . 1 <1 . 
. No 
secretion 
. (236) 
 Gly400Val Several 20-40 . 0 . . . 2 40-60 (244) 
 Ala412Val 1 48 38.6 0 . . . . . (237) 
 Phe442Val 1 47 50 0 . . . . . (183) 
 Gly460Arg 2 42; 51 . 0 . . 
. No 
secretion 
. (234;245) 
 Tyr493His
††
 2 2; 1 . 0 . . 12 12 31 (51) 
 Trp501Cys 2 36; 40 36; 32 1 1.6 <1 . . . (246) 
 Lys518Asn
‡‡
 2 1 12 0 . . . . . (247) 
 Pro520Leu 1 34-48 . 0 . . . 100 . (236) 
 Gly555Glu 0 . . 1 <1 100 <1  82 . (51;248) 
 Trp569Ser Several 20-40 . 0 . . . 2 40-60 (244) 
 Thr575Met
±±
 1 1 42 . . . . . . (242) 
 Ser576Arg 2 27; 46 22.9; 71 0 . . . . . (237)
**
 
¶No data available 
‡ Two reports may relate to a single patient. 
*Compound heterozygote with Lys535Ter. The expression data was presented in the poster resulting from (238).   
**N. M. O‘Connell, unpublished data 
†Index patient compound heterozygous for Glu226Arg and Ser248Asn. 
§Compound heterozygote with Glu117Ter  
±Compound heterozygote with Cys128Stop   
¶¶Compound heterozygote with Arg210Stop 
§§Compound heterozygote with Cys581Stop     ††Compound heterozygote with Cys38Arg    
‡‡Compound heterozygote with G324G splicing mutation   ±±Compound heterozygote with Gln88Stop
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Table 6.6:  FXI mutations published with insufficient phenotypic data. 
Domain Mutation site Reference 
Apple 1 Asp16His (241) 
 Gln29His (245) 
Apple 2 Gly104Asp (234) 
 Tyr133Ser (245) 
 Ala134Pro (245) 
Apple 3 Cys182Tyr (245) 
 Cys212Arg (238;245) 
 Trp228Cys (182) 
 Arg234Ile (245) 
 Arg250Cys (245) 
Apple 4 Gly350Glu (229) 
SP Thr389Pro (245) 
 Thr475Ile (183;245) 
 Ile600Ser (245) 
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6.5.2 Construction of Ap domain models 
The four Ap domains in FXI show 24% to 38% sequence identity with one another.  In 
order to model these four Ap domains, three crystal and NMR structures that were 
homologous to the four Ap domains in FXI (Figure 6.5(a)) were identified from 
database searches. These were the ninth PAN module of an adhesin protein, EtMIC5, 
from the protozoa E. tenella (PDB code: 1HKY) (227;231), the N-domain of human 
hepatocyte growth factor (PDB code: 2HGF) (233), and an anti-platelet toxin from H. 
officinalis (PDB code: 1I8N).(232)  A total of 23 other Ap sequences were obtained as 
described in Chapter 2 Methods, section 2.8.2.  Even though these three structures 
shared low sequence identity of 8% to 13% with one another, and 11% to 22% sequence 
identity with the four Ap domains in FXI,  they exhibit two or three conserved 
disulphide bridges and a conserved secondary structure consisting of a five-stranded -
sheet (-strands C, E, D, G and A) flanked by a single -helix on one surface and a 
distorted two-stranded -sheet (-strands B and F) on the other surface (Figure 6.6(b)).  
Although the Cys residues C1 and C6 at the amino and carboxy termini of the FXI Ap 
domains are not conserved in all the Ap domain sequences, they are present in two of 
the structural templates, those of EtMIC5 and the anti-platelet toxin.  Superimposition 
of these three structures permitted reliable sequence and structure alignments and 
models to be made for the Ap1 to Ap4 domains (Figure 6.5(a)).  The 1HKY template 
had the highest sequence identity (15-22%), and modelling based on this template 
required only three insertions and no deletions, which is fewer compared with the other 
two structural templates.  All four resulting Ap models shared a short two-residue 
insertion at F12-E13 (Ap1), M102-K103 (Ap2), F192-A193 (Ap3) and F283-L284 
(Ap4).  The Ap1 model also has two insertions of ten residues (A45-W55) and three 
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residues (E66-L68), whereas the Ap2, Ap3 and Ap4 models have an insertion of nine 
residues at T133-H143 (Ap2), S225-Q233 (Ap3) and P316-G324 (Ap4) and another 
insertion of four residues at G155-T158 (Ap2), G245-S248 (Ap3) and G336-T339 
(Ap4). 
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Figure 6.5:  Multiple sequence alignment of the Ap and PAN module superfamily. 
 
(a) The Ap and PAN sequences are shown. Conserved cysteine residues are highlighted in black and labelled C1 to C6. The secondary structures are highlighted by shaded  boxes. The three insertions are underlined. The FXI 
mutations in Ap1 to Ap4 are highlighted within black ellipses. Sequences are numbered with respect to FXI_AP1. (b) The secondary structure assignments using DSSP are shown for the 1HKY, 2HGF and 1I8N structures. The 
shading follows that in (a). H, -helix; E, -sheet. The strands are lettered A to G to correspond to those seen in Figures 6.6(b). (c) The consensus secondary structure prediction for Ap1 calculated from 30 aligned sequences is 
compared with the DSSP analysis of the final Ap1 homology model. (d) The NACCESS sidechain accessibilities are given for each side chain of the 1HKY, 2HGF and 1I8N structures and for each of the four Ap homology 
models. Mutations in Ap1 to Ap4 are highlighted within black ellipses. The shading corresponds to the secondary structures of (a).
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All three insertions were confined to loop regions in the 1HKY structure as desired for 
optimal modelling (figure 6.5(a)).  The unpaired Cys321 sidechain is on the surface of 
the Ap4 domain as required in order that it can form the FXI dimer. The Cys11 residue 
of Ap1 is also surface exposed and can form a disulphide bridge.(11)  The sidechain 
accessibilities between the three known structures and the four models showed good 
concordance in Figure 6.5(d).  The putative N-glycosylation sites at Asn72 (Ap1), 
Asn108 (Ap2) and Asn335 (Ap4) all show varying degrees of solvent exposure in the 
models, suggesting that oligosaccharide chains can be attached to all these. 
Glycosylation at Asn72 and Asn108 has been confirmed (249) while the lack of 
observed glycosylation at Asn335 in Ap4 may be attributable to the dimerisation of the 
Ap4 domains as this occurs on the same face of the structure as Cys321 in the Ap4 
model.  The four models all satisfied validation using PROCHECK. 
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Figure 6.6:  Domain structure of FXI. 
 
 (a) Cartoon of the FXI domains to show the four tandem apple domains (Ap1-Ap4) and the serine protease domain 
(SP). The residue numbers at the beginning and end of each domain are indicated, and the five putative glycosylation 
sites are highlighted by Y symbols, of which four have been confirmed (see text). 
(b) Secondary structure cartoons of the FXI domains to show their -helix (red) and -sheet (green) structures. The 
-strands of the Ap domains are indicated by letters C, E, D, G and A.  The -helices of the SP domain are indicated 
by A2 and A3, and its 310 helix is denoted by G. The catalytic triad in the SP domain is highlighted in black at the 
interface between the two subdomains shown above and below the triad. Disulphide bridges are shown in yellow. 
Mutations with phenotypic data are shown in blue, and those without phenotypic data are shown in orange.  
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6.5.3 Construction of SP domain model 
In order to model SP domains in the coagulation proteases, classic SP domains such as 
those in chymotrypsin and trypsin have been used.(250)  To improve the choice of an 
appropriate template, 84 unique SP structures were identified in the Protein Data Bank 
and five close templates were identified using CLUSTALW analysis.  These five 
templates were used for the structural alignment with the SP domain of FXI (Figure 
6.7). 
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Figure 6.7:  Structural alignment of the sequences for the five closest matches to the SP domain of factor XI. 
 
The sequences are labelled as follows: Throm, human thrombin; Prot_C, human Protein C; C1R, human complement C1r; B-Acro, human -acrosin; B-Tryp, human -tryptase; fXI_SP, human Factor XI. Regions identified as 
structurally conserved by the INSIGHT Cα distance matrix are highlighted by dashed boxes. The seven most conserved cysteine residues and three catalytic residues (His413, Asp462, Ser557) are highlighted in black. The 
secondary structure was assigned using DSSP and indicated by the arrowed ranges above the grey shaded boxes in the alignment. The 14 conserved β-strands are labelled from A to O and the three α-helices from A1 to A3. The 
four insertions and deletions between FXI-SP and its closest template β-tryptase are underlined. Sequences are numbered relative to FXI_SP. Mutations are highlighted with black ellipses. The NACCESS sidechain 
accessibilities (fXI_SP_Ac) are given for each side chain of the final SP model. 
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The 14-stranded -sheet secondary structure is well conserved as a double Greek key 
supersecondary motif.  The closest template to the FXI SP domain in terms of insertions 
and deletions was 1A0L, this being the crystal structure of human β-tryptase (251) with 
a high sequence identity of 40%.  Interestingly, three of the remaining four templates 
corresponded to two other coagulation proteases (human -thrombin and protein C) and 
one complement protease (human complement C1r).  The model of the FXI SP domain 
built from the 1A0L template possessed a conserved core of 224 residues, with 
insertions and deletions only affecting 14 residues.  These 14 residues corresponded to 
two small insertions at surface loop regions (V418—E419 and G548-G549) and two-
residue and eight-residue deletions at the surface loop regions between N512-T513 and 
between H534-K535 respectively.  These changes corresponded to surface loops of the 
SP structure as desired.  The putative N-glycosylation sites at Asn432 and Asn473 are 
both located at the back of the FXI SP domain on the opposite face to that of the 
catalytic triad, and either can be solvent exposed, suggesting that oligosaccharide chains 
can be attached.  Glycosylation at both of these sites has been confirmed.(249)  The SP 
model was validated using PROCHECK. 
6.5.4 Structural interpretation of 28 missense mutations in the F11 gene 
 
The structural effects of the 28 mutations in the FXI gene that are associated with 
known phenotypes (Table 6.5) are listed in Table 6.7.  
 
In the Ap domains, protein misfolding is predicted to be the underlying mechanism of 
FXI deficiency in six of 14 mutations.  Of the remaining eight mutations, two are 
predicted to affect the functional role of the Ap domains in that they are located at 
known binding sites, four mutations appear to affect the dimerisation site in FXI, one 
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mutation appears to affect the solubility of FXI and one mutation appears to be a non-
disease causing polymorphism.  
In the SP domain, protein misfolding is predicted to be the underlying mechanism of 
FXI deficiency in eight of 14 mutations.  Of the remaining six mutations, four mutations 
are predicted to affect the ability of FXI to proteolytically cleave its substrate and two 
mutations appear to cluster in one structural region with functional significance but their 
phenotypic characterisation is impaired by compound heterozygosity. 
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Table 6.7:  Structural features of the FXI mutations with known phenotypes.  (CH: Compound heterozygosity). 
 Domain Mutation DSSP Accessibility Type Predicted Effect 
Apple 1 Cys38Arg C 0 I Structural; Disrupts disulphide bridge 
Apple 2 Gly155Glu C 4 II Functional; Disturbs proposed FXIa binding loop 
Apple 3 Phe221Ser E 1 I Structural; Buried residue 
 Gln226Arg C 6 CH Polymorphism 
 Cys237Tyr E 0 I Structural; Disrupts disulphide bridge 
 Ser248Asn C 1 II Functional; Replaces platelet binding site 
 Lys252Ile E 7 CH Structural: May affect solubility 
Apple 4 Phe283Leu C 0 I Functional/Structural;  May prevent dimerisation  
 Leu302Pro H 4 I Structural; Disrupts helix formation and disulphide bridge 
 Thr304Ile H 7 I Structural; Disrupts disulphide bridge 
 Arg308Cys C 9 I Structural; Disrupts disulphide bridge 
 Glu323Lys B 4 I Functional/Structural ;  May prevent dimerisation 
 Gly336Arg S 9 CH Structural; May prevent dimerisation 
 Gly350Ala C 1 CH Structural; Buried residue; may affect dimerisation  
SP Thr386Asn E 0 I Structural; Buried residue 
 Cys398Tyr E 0 I Structural; Disrupts disulphide bridge 
 Gly400Val E 0 I Structural; Buried residue 
 Ala412Val G 0 I Structural; Disrupts secondary structure 
 Phe442Val S 2 I Structural; Disrupts correct folding pathway 
 Gly460Arg S 0 I Structural; Buried residue 
 Tyr493His C 9 CH Functional; At surface near N-terminal Ile370 
 Trp501Cys S 0 I Structural; Buried residue; Extra Cys residue 
 Lys518Asn E 5 CH Functional;  At surface near N-terminal Ile370 
 Pro520Leu C 2 II Functional;  At surface near N-terminal Ile370 
 Gly555Glu T 2 II Functional; Perturbs active site 
 Trp569Ser E 2 I Structural; Disrupts correct folding pathway 
 Thr575Met E 0 CH/II Functional; Perturbs active site 
 Ser576Arg E 0 II Functional; Perturbs active site 
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Ap mutations with known Type I (CRM-) phenotypes 
There are three disulphide bridges in the Ap domains (C1-C6, C2-C5 and C3-C4). In 
four mutations with known Type I phenotypes, the integrity of the C3-C4 bridge is 
disrupted (Cys38Arg, Leu302Pro, Thr304Ile and Arg308Cys: Table 6.7 & Figure 
6.8(a)).  Energy minimisation of the Cys38Arg mutation in the Ap1 domain suggested 
that, with the disulphide bridge broken and the introduction of the larger bulkier side 
chain of Arg38, the α-helix was broken and the small loop at the C-terminal of the helix 
changed its conformation to accommodate Arg38.  This interpretation is supported by 
the phenotypic data, which demonstrated that there was significant intracellular 
accumulation of the FXI protein but negligible secretion.  The Leu302Pro mutant after 
energy minimisation also showed a similar effect, where the substitution of proline in 
the middle of the -helix next to the C3-C4 bridge caused the -helix to break.  The 
Thr304Ile substitution replaced a hydrophilic side chain with a bulky hydrophobic one 
next to the C3-C4 bridge.  This appeared to alter the hydrophobic nature of the helix 
which may be sufficient to cause it to twist to form contacts with the hydrophobic -
strand C of the central -sheet, altering the C3-C4 loop conformation.  The Arg308Cys 
substitution introduced a new Cys residue adjacent to the C3-C4 bridge of the Ap4 
domain, suggesting that the correct disulphide pairing may not be formed. 
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Figure 6.8:  Molecular views of selected mutated residues in two Ap domains. 
 
(a) The wild type Ap1 domain model is depicted with its three cysteine disulphide bridges highlighted in yellow 
(left). These are labelled C1-C6, C2-C5 and C3-C4. One of these Cys residues is replaced by Arg (blue) in the Type I 
Cys38Arg FXI mutant (right). Note that the secondary structure is altered after energy minimisation.  
(b) The wild type Ap2 domain model is depicted to show a face-on view of its substrate binding loop (left). The 
replacement of Gly155 by Glu in the Type II mutant (right) altered the -sheet and loop structure after energy 
minimisation.  
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In two other Ap mutations, the C2-C5 disulphide bridge was disrupted.  The Cys237Tyr 
mutation results in loss of the C5 sidechain and failure to form the C2-C5 disulphide 
bond.  Phe221Ser is likely to perturb protein folding since it involves a fully buried 
residue on -strand D, close to the C2-C5 bridge that is conserved in many other Ap 
sequences and exemplified for the Ap1 domain in Figure 6.8(a).  A third mutation 
Lys252Ile (compound heterozygous) in Ap3 is distant from any disulphide bridge in 
this domain, but is associated with reduced secretion of FXI implying that this is a Type 
I disorder.  It is possible that the introduction of a surface hydrophobic Ile252 sidechain 
at the protein surface adjacent to the exposed Ile251 sidechain may affect its solubility.  
 
Impaired FXI dimerisation has been confirmed in one type I Ap4 mutation (Phe283Leu) 
and may be implicated in four other type I mutations in Ap4 (Glu323Lys; Gly336Arg; 
Gly350Ala; Gly350Glu).  Phe283 is on a surface exposed loop between residues Thr281 
and Leu288.  This protein loop forms the second side of a cleft with Cys321 on the first 
side.  Cys321 stabilises the dimer by forming a disulphide bridge with Cys321 of the 
opposite FXI monomer, although this Cys321 interchain bond is not required for dimer 
formation.(18;19)  Glu323Lys is adjacent to Cys321.  The surface charge reversal 
caused by the Glu323Lys substitution within this cleft may perturb the association of 
two FXI molecules.  The Gly336Arg mutation (compound heterozygous) in Ap4 
appears to result in impaired secretion.(242)  Gly336Arg occurs adjacent to the 
nonglycosylated glycosylation site at Asn335 (Figure 6.6(a)).  As this region of Ap4 
may be implicated with FXI dimerisation, this may offer an explanation of the effect of 
this mutation.  The  effect of the Gly350Ala mutation (compound heterozygous) in Ap4 
on secretion is unclear (242), but the Gly350Glu mutation at the same position 
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corresponds to a severe defect in dimer formation.(18;224)  Since Gly350 occurs within 
the five-stranded -sheet in a buried position on -strand G, the introduction of either an 
Ala or a Glu sidechain may disrupt the folding of Ap4, and in turn the ability of Ap4 to 
mediate FXI dimerisation.  
 
Ap mutations with known Type II (CRM+) phenotypes 
Only two Type II mutations were identified in the Ap domains (Gly155Glu, 
Ser248Asn), for which the phenotypic data (Table 6.5) gives some evidence of a 
functionally defective protein. The Gly155Glu mutation in the Ap2 domain occurs at an 
exposed position in the Ap2 substrate binding loop between -strands E and F, which 
was identified from functional studies.(252)  Energy minimisation suggested that the 
localised loop conformation changed and altered the sidechain orientation of residues 
such as Arg159 (Figure 6.8(b)).  Given the absence of a sidechain in Gly155, further 
modelling showed that this localised change in loop conformation is invariant of the 
position of the new Glu155 sidechain.  The Ser248Asn mutation in the Ap3 domain 
occurred on the corresponding substrate binding loop by analogy with the Ap2 domain 
(Figure 6.5).  Ser248 is functionally important for platelet binding (14;35) and 
substitution is presumed to affect the conformation of the substrate binding loop.  
Expression studies confirm a decreased affinity of FXI-N248 for platelet binding and 
impaired activation by thrombin in the presence of activated platelets.(253) 
 
The phenotypic and modelling data suggest that Gln226Arg is a non-disease causing 
polymorphism in the Ap3 domain. Gln226 is located on a large surface loop insertion 
that is present in all FXI Ap domains, but not in the template structures.  It is fully 
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solvent exposed on the modelled structure and the loop is remote from the substrate 
binding region.  Substitution with Arg is not predicted to result in structural or 
functional disruption.  Compound heterozygosity for Gln226Arg and Ser248Asn was 
confirmed in the index patient, but FXI:C was consistent with only a partial deficiency 
of FXI.(239)  Expression of recombinant FXI-R226 was similar to recombinant wild-
type FXI while the catalytic efficiency of FXIa-R266 was also similar to wild-type FXI, 
suggesting a non-disease-causing polymorphism.(253)  The patient‘s mother also had a 
partial deficiency of FXI and was heterozygous for Ser248Asn only.  
 
SP mutations with known Type I (CRM-) and Type II (CRM+) phenotypes 
Eight of the 14 SP mutations with known phenotypes are classified as Type I and all 
these occur in residues with reduced sidechain solvent accessibilities.  The Ala412Val 
mutation provides one example of this. As Ala412 is adjacent to the catalytic triad 
(Figure 6.9(a)), it was first thought that this mutation has altered the conformation of the 
active site, so corresponding to a Type II phenotype.  However the FXI SP model 
indicated that the fully buried Ala412 sidechain pointed away from the triad into a 
tightly packed protein core.  Figure 6.9(a) showed the FXI SP model after the 
substitution with the bulkier Val412 sidechain and energy minimisation.  The 
minimisation removed the 310 helix to which the catalytic His413 was attached. This 
indicated that the mutation reduced the stability of the SP fold, while not affecting the 
formation of the active site at the catalytic triad. This interpretation is consistent with 
the Type I phenotype, in which both the activity and antigen levels are low. 
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Most of the other Type I mutations in the SP domain (Thr386Asn, Gly400Val, 
Phe442Val, Gly460Arg, Trp501Cys, Trp569Ser; all show low solvent accessibility and 
are buried) can be interpreted in a similar fashion to that for Ala412Val and appear to 
relate to protein packing or the folding pathway.  For example, Gly460 is close to the 
catalytic triad His413-Asp462-Ser557, however phenotypic data shows that it is a Type 
I mutation (Table 6.5).  Energy minimisation for the Gly400Val mutation supported this 
analysis, demonstrating that the protein core structure was clearly disrupted.  One 
mutation (Cys398Tyr) breaks a disulphide bridge between Cys398 and Cys414, hence 
disrupting the folding of the SP domain.  The Trp501Cys mutation introduces an 
additional Cys residue that may perturb the correct disulphide bridge formation during 
the folding of the SP domain.  
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Figure 6.9:  Molecular views of selected mutated residues in the SP domain. 
 
(a) The catalytic triad of the SP domain model is depicted in black at the centre, with the Type I 
Ala412Val mutant in yellow. Note that the secondary structure is altered after energy minimisation.  (b) 
The close-up view of the catalytic triad of the SP domain model is depicted in black at the centre, with the 
Type II Ser576Arg mutant shown in yellow. Note that the secondary structure is NOT altered after energy 
minimisation.  
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Two Type II mutations in the SP domain (Gly555Glu and Ser576Arg) correspond to 
instances where partially buried small side chains are replaced by large bulkier side 
chains.  Both these are structurally located near to the catalytic triad, and are seen to 
affect the active site.  For Gly555Glu, Schmidt et al showed that the Glu sidechain in 
the mutant may impair the accessibility of the substrate for the active site cleft.(250)  
For Ser576Arg, Figure 6.9(b) showed that Ser576 partially projects into the substrate 
binding cleft formed between the two subdomains of the SP domain.  The replacement 
by Arg576 is expected to block the binding of substrate to the cleft.  This interpretation 
was supported by energy minimisation which showed that no conformational changes 
had occurred in the SP domain (Figure 6.9(b)).  The Thr575Met mutation is also 
compound heterozygous with Gln88stop.(242)  Thr575Met is considered to be a Type II 
mutation because its antigen level is halved (consistent with Gln88stop being a Type I 
mutation) and it is adjacent to the Ser576Arg mutation which has a Type II phenotype, 
both being close to the catalytic active site cleft.   In the case of Pro520Leu, which 
appears to be a type II mutation on the basis of expression data, direct interference with 
the substrate binding cleft is not implicated since Pro520 is distant from the catalytic 
triad.  However, because the model suggests that Pro520 is near Ile370 at the N-
terminus, which is inserted into the SP domain during activation, and Pro520 defines the 
rim of the pocket into which Ile370 is inserted during activation, it was considered 
possible that this mutation may block the development of catalytic activity in FXI.  
Pro520 is conserved in Factor X and Factor VII, and the mutation of Pro520 in both 
these other proteins also caused Type II phenotypes.(254-256)  The equivalent of 
Pro520 is also conserved in chymotrypsinogen and occupies similar positions in the 
crystal structures of chymotrypsinogen and chymotrypsin, indicating that its location is 
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invariant with the activation state of the protease.  Two mutations (Tyr493His, 
Lys518Asn) are compound heterozygous, hence the phenotype of both these are 
unclear.  It was interesting that both these residues form a surface cluster with 
Pro520Leu near the N-terminus of the SP domain, as this suggested that these may have 
a similar effect as the Pro520 mutation.  Reduced secretion and intracellular level of the 
Tyr493His construct in expression studies implies that there is also a significant 
structural element to this mutation.  
 
Mutations with no phenotypic data 
A total of 14 FXI mutations are associated with insufficient phenotypic data at the time 
of this study (Table 6.6), accordingly the interpretation of these must be less certain. 
These are included in order to display the distribution bias of all mutations throughout 
the AP and SP domains, which is seen to be nonspecific (yellow spheres in Figure 
6.6(b)).  
 
Of the 11 mutations in the Ap domains, five involve directly or indirectly the conserved 
disulphide bridges (Gln29His, Cys182Tyr, Cys212Arg, Trp228Cys, Arg250Cys), hence 
these will probably involve protein misfolding and Type I phenotypes.  The Gln29His 
substitution occurs at the centre of the -helix next to Cys28-Cys58, and energy 
minimisation suggested that the charged His sidechain appeared to be close to the N-
terminal charged Glu1 sidechain.  This mutant is apparently not secreted but data are 
limited.  The Asp16His and Gly104Asp mutations are aligned in the same region with 
the Phe283Leu mutation in Ap4 (Figure 6.5(a)), both are fully exposed on a surface 
loop (Figure 6.5(d)), and it was not possible to interpret these mutations further.  The 
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Tyr133Ser and Ala134Pro mutations are both buried together on -strand D at the start 
of the substrate binding loop in the Ap2 domain (Figure 6.5), and may affect FXI 
activity.  Limited data for Tyr133Ser suggests that the FXI:C level in one patient was 
38% and that secretion of the FXI mutant protein was reduced.  The Arg234Ile mutation 
replaces a hydrophilic exposed charged residue with a hydrophobic one.  
Of the three mutations in the SP domain, Thr389Pro is a buried residue on -strand B, 
so misfolding may be implicated as the causative effect of this residue change.  The 
Thr475Ile mutation removes one of the five N-glycosylation sites (Figure 6.6(a)), 
although the loss of the glycosylation site does not appear to be responsible for the 
deficient phenotype.(257)  The Ile600Ser mutation is located on the C-terminal -helix 
A3 at a buried position (Figure 6.7), hence this may affect the packing of this helix 
against the SP domain core.  
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6.6 Discussion 
Factor XI deficiency in the Jewish population is caused by four well described distinct 
mutations (termed Types I-IV).  The Jewish mutations are characterized by low FXI 
coagulant activity and antigen (i.e. cross-reacting material negative, CRM-).(56;59) The 
two most common mutations are a nonsense mutation in Apple 2 (Glu117Stop) and a 
missense mutation in Apple 4 (Phe283Leu).  These two mutated alleles occur with 
equal frequency in severely deficient patients (49% and 47% of mutant alleles 
respectively) and result in a heterozygote frequency of 9% and a homozygote frequency 
of 0.22% in persons of Ashkenazi descent. (49;56)  The Type I and Type IV mutations 
affect splicing in the catalytic domain (a G to A transition at the donor splice site in 
intron N and a 14 bp deletion at the exon 14 / intron N splice site, respectively) and 
allele frequencies are 1.2% and 0.4%.  A founder effect has been confirmed for patients 
with the Type II and Type III mutations by comparison of FXI intragenic 
polymorphisms in FXI deficient Iraqi, Sephardic and Ashkenazi Jews with unaffected 
Jewish individuals.(60) 
 
Factor XI deficiency is a rare bleeding disorder in other populations and the incidence in 
general populations is generally given as one per one million population.  However, a 
number of other mutations have been reported at higher frequencies in distinct 
populations e.g. 1% in the French Basque population for Cys38Arg.(51)  A founder 
effect was confirmed for the latter mutation and subsequently for a number of other 
mutations in specific populations (Cys128Stop in British patients, Gln88Stop in French 
patients).(242;258) 
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The unique conformation of the FXI protein as a dimer also causes a further specific 
―dominant negative‖ effect in certain mutations in the heterozygous state.(224;225)  In 
these mutations, the FXI:C in heterozygotes is less than expected (usually <25 U/dL).  
This has been postulated to be caused by dimerisation of the mutated FXI with wild-
type FXI intracellularly and prevention of secretion of wild-type FXI dimers in 
quantities normally expected in heterozygotes.  Mutations for which this effect has been 
confirmed in expression studies are Ser225Phe, Cys398Tyr, Gly400Val and Trp569Ser.  
One of these mutations is located in Apple 3 and three in the serine protease domain. 
 
Where conventional screening fails to identify a causative mutation, deletion of the 
whole gene may be considered which is masked in the heterozygous state by the normal 
allele.  Two of 39 patients were found to have a whole gene deletion as the causative 
mutation of factor XI deficiency as the result of unequal homologous recombination 
between flanking Alu repeat sequences.(259) 
 
A number of sequence alterations were identified in the study population. The Pro48Leu 
change had been unreported at the time of the study.  Both Proline and Leucine are 
hydrophobic residues and the location of the residue is on a surface exposed loop region 
between two β sheets.  This amino acid change has subsequently been identified as a 
non-synonymous polymorphism and hence is not likely to be the causative mutation in 
the case of the reported patient.(260) 
 
The Gly155Glu mutation in exon 6 was previously reported in abstract form in 
2000.(235)  The patient was non Jewish and had a FXI:C of 44.3 U/dL.  This patient did 
not have a bleeding history.  This mutation was also reported by the same group in a 
non Jewish patient with a FXI:C of 41 U/dL.(234)  Glycine 155 is found in the second 
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apple domain of FXI at an exposed position in a substrate binding loop. Although there 
was a discrepancy between the FXI:C and FXI:Ag in the patient under study here, 
subsequent analysis of this residue in a consensus apple structure showed that mutations 
in the aligned Glycine residues in Apples 3 and 4 causes a concordant decrease in 
FXI:C and FXI:Ag.(260)  Expression studies would be useful to determine the precise 
effect of this mutation on protein secretion and function. 
 
Glu 297 is located in the apple 4 domain in a random coil area of the structure and 
replacement of the acidic Glutamate residue with a larger basic Lysine residue would be 
expected to disrupt the structure of the coil region. Subsequent to this study, the 
Glu297Lys mutation has been reported in a number of French patients with FXI 
deficiency.(261;262)  Patients in the latter studies who were heterozygous for this 
mutation had FXI:C levels of 38 to 58 U/dL and concordant FXI:Ag.  This is in keeping 
with the FXI:C and FXI:Ag described in the UK patient in this study (38 and 34 U/dL 
respectively).  Secretion was confirmed to be reduced to 4.5% of normal when the 
mutated protein was expressed in BHK cells but dimerisation was reported to be 
normal.(263) 
 
The Glu380Lys mutation in the serine protease domain has not been reported to date.  
The replacement of Glu by Lys replaces a medium sized acidic residue with a large 
basic residue.  The residue is exposed.  The residues surrounding Glu380 have had 
disease causing mutations reported e.g. Arg378Cys (264), Trp381Leu (265) and 
Pro382Leu (261;266) although one non-synonymous polymorphism has been reported 
in the region (Trp381Arg ,www.factorxi.org). 
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The Cys398Tyr mutation had been reported in FXI deficient patients in abstract form at 
the time of this study (see table 6.3) and heterozygous patients were reported to have 
FXI:C levels of 40-50 U/dL similar to the patient reported here (57 U/dL).  
Subsequently, a heterozygous patient was reported with concordant FXI:C and FXI:Ag 
(225) and the mutation was reported the homozygous, heterozygous and compound 
heterozygous states.(263;266)  This mutation has been reported to cause a dominant 
negative effect.(225)  However, the patient in this study had a well preserved FXI:C of 
57 U/dL although the FXI:Ag was somewhat lower (36 U/dL).  The FXI:Ag would be 
in keeping with the dominant negative type effect but the FXI:C in this patient and in 
other heterozygotes reported by Gailani (FXI:C40-50 U/dL) and Mitchell (FXI:C 58 
U/dL) would not. (236;237)  Structurally, the Cys398Tyr mutation breaks a disulphide 
bridge between Cys398 and Cys 414.(260) 
 
The Ser576Arg mutation was described in a patient with FXI:C of 27 U/dL and a 
FXI:Ag of 22.9 U/dL.(237)  No clinical details were given for this patient.  The patient 
reported in table 6.3 had a FXI:C of 46 U/dL but a normal FXI:Ag of 71 U/dL 
suggesting normal secretion of the protein. Serine 576 is found in the catalytic domain 
of the FXI protein and partially projects into the substrate binding cleft.  The 
replacement of Ser576 with Arg is expected to block binding of the substrate but is not 
expected to result in conformational change. 
 
This study resulted in the first detailed homology models for the structure of the FXI 
domains based on appropriate template crystal and NMR structures.  The accuracy of 
the Ap domain models was demonstrated by the following: (i) DSSP analyses showed 
that the major secondary structure elements seen in the NMR structure of 1HKY were 
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present in the four Ap models after extensive energy refinement, (ii) there was general 
agreement between the DSSP secondary structure assignments and the consensus 
secondary structure predictions (Figure 6.5(c)), (iii) there was high agreement between 
the sidechain solvent accessibilities of the experimental and modelled structures (Figure 
6.5(d)), (iv) the models were stereochemically satisfactory according to PROCHECK.  
The low sequence identities were as expected for small homologous -sheet proteins, as 
illustrated by the 8% to 12% sequence identities seen between the three Ap 
structures.(267)  The accuracy of the SP domain model was demonstrated using similar 
techniques. For all five domain models, the cores of these protein models were expected 
to be well predicted, while their accuracy was expected to diminish in the regions of 
insertions and deletions in loops at the protein surfaces.  This was sufficient to locate 
the positions of individual amino acids, while the positions of their sidechains may not 
be as well determined. It was additionally not possible to predict with certainty the 
effect of mutations on the interactions between domains. 
 
Previously, models for the four Ap domains had been presented using an ab initio 
molecular dynamics and energy minimisation techniques.(14;35;252;268-270)  As the 
models presented here were based on experimentally solved homologous structures, the 
predictions were felt to be significantly more accurate.  The major difference from the 
ab initio predictions is that these earlier models had predicted that three anti-parallel β-
strands formed a continuous binding surface, with many important residues being 
mapped to this area.  In distinction, the homology models predicted that this same 
region also contains three β-strands E, F and G (Figure 6.5(b)), but only two of these (E 
and G) participate in the five-stranded -sheet (Figure 6.6(b)). Part of this -sheet is 
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buried, while the remainder contributes to two large surface exposed loops with two 
distorted -strands B and F beneath the five-stranded -sheet. 
The structural analysis of the mutations in the four Ap domains of FXI gave insight into 
the effects governing both Type I (CRM-) and Type II (CRM+) mutations, where either 
its folding, substrate binding or dimerisation is altered.  The Ap domain comprises a 
small Cys-rich structure whose fold is primarily stabilised by its disulphide 
bridges.(271)  This makes it susceptible to protein misfolding if these disulphide bridges 
are disrupted.  
 
The majority of the 42 modelled mutations mapped to the Ap domains were classified 
as Type I (CRM-), where phenotypic data (Table 6.5) showed a low concordant FXI:C 
and FXI:Ag implying a problem with expression or secretion of the protein or its rapid 
degradation.  The relatively frequent occurrence of mutations that affect the C3-C4 
bridge indicates the importance of this disulphide bridge for the overall fold of the Ap 
domain.   
 
Of the type II (CRM+) mutations affecting the Ap domains, only Ser248Asn had been 
previously well defined.(239;253;272)  In the case of Gly155Glu, there is a discrepancy 
in reported FXI:Ag levels.  Two patients appear to have a Type I disorder with 
concordant FXI:C/FXI:Ag levels (234;235) while a third has a higher FXI:Ag than 
FXI:C (table 6.3).  The homology model was used to investigate this mutant and 
supported a Type II functional defect in the Glu155 mutant. 
 
Dimerisation in FXI occurs due to covalent and non-covalent interactions between the 
Ap4 domains.(11;18-20;228)  The structural modelling has implicated two mutations to 
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be on the surface of Ap4 in the region where more extensive interactions between the 
homodimers may occur and close to Cys321 which forms the covalent link.  Of these 
two mutations, Phe283Leu is one of the most frequent ones causing FXI deficiency in 
the Jewish community.(49;56)  This interpretation is supported by expression studies 
that indicated a reduction in secretion of the mutant Leu283 (approximately 8% of WT 
FXI) and an intracellular accumulation of mutant FXI monomers.(18;229) 
 
Detailed analyses of the structural effect of mutations on the SP domain had not been 
possible prior to the existence of the homology model.  The eight mutations associated 
with Type I (CRM-) phenotypes affect sidechains that are either fully buried or have 
low solvent accessibility (Table 6.7).  The FXI homology model predicts protein 
misfolding in these cases, leading to rapid degradation and/or impaired secretion.  Four 
other mutations have Type II (CRM+) phenotypes, and also correspond to low sidechain 
accessibility, with three of them being close to the catalytic binding site.  Confirmation 
that the substrate binding cleft is obstructed by the mutant residue was observed in the 
homology model.  In addition, the model suggests a mechanism for the functional defect 
produced by Pro520 (and by extension, the type II/CRM+ mutations seen in FX and 
FVII).  While a definitive structural explanation for the defect in two further mutants 
(Tyr493His, Lys518Asn) reported in compound heterozygosity was not possible, the 
model shows that both mutations form a surface cluster with Pro520, and these may 
indicate a region of functional significance. 
 
As with all molecular homology models, the FXI Ap and SP models are an essential 
adjunct to clinical and experimental data, but need to be interpreted with caution.  
Nonetheless, in the absence of a crystal structure for the FXI dimer, these domain 
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models were of use to investigators seeking to characterise new FXI mutations.  The 
development of a curated database of known FXI mutations, together with the FXI 
homology models, meant that all investigators had access to the models and could 
determine the structural effects of novel mutations (www.factorXI.org).(273)  Crystal 
structures for the catalytic domain of FXI in complex became available after this study 
was completed and on publication of the crystal structures for the complexed FXI 
catalytic domain, dimeric FXI in 2006 and the A4 domain in 2007, the database was 
updated to allow modelling of mutations on the crystal structure.(21;45-47) 
 
Comparison of the homology models and the crystal structures was undertaken once the 
latter were available.(260)  The structural alignment between the FXI crystal structures 
and the template structures (EtMIC5 and human β-tryptase) correlated well with the 
sequence alignment used to generate the homology models.  Additionally, the root mean 
square deviations in the α-carbon positions between the five homology models and the 
FXI crystal structure were within accepted norms.  There were small differences in the 
insertion loops and N and C termini of the Ap domains and of course, the homology 
models could not give information regarding Ap packing with the secreted FXI protein.  
The serine protease domain was shown to have reproducible secondary structures 
between the available crystal structures and the homology model.  Within the Ap 
domains, the B-F β-sheet was shown to have the most variability when the homology 
model and crystal structures were compared, in contrast to the central five-stranded β-
sheet and α-helix which were more conserved.  
 
Of the 28 mutations with known phenotype which had been modelled on the homology 
models, interpretations were correct in 26 and only two mutations had been incorrectly 
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assigned to predicted loops (Phe283Leu and Gly350Ala).  This occurred because the 
predicted β-strands in the crystal structure were longer than those in the homology 
models.  In addition, 25 of 28 solvent accessibility assignments were correct in the 
homology models.  Therefore, it may be concluded overall that the homology models 
were accurate and reliable in the interpretation of mutations causing FXI deficiency.  
However, given the limitations of all homology models (which were discussed on 
publication), the current crystal structures are the gold standard for interpretation of the 
structural effects of mutations in the F11 gene. 
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Chapter 7 Prevention of peri-operative haemorrhage in FXI 
deficiency: FXI concentrate and rFVIIa 
7.1 Introduction 
The variable bleeding tendency in patients with FXI deficiency creates considerable 
difficulty in managing surgical bleeding in particular.  At present, the decision to give 
FXI replacement, an antifibrinolytic agent or no treatment is an empiric one and is 
dependent on the prior bleeding phenotype.  The level of FXI coagulant activity also 
plays a role in the decision to treat, since patients with FXI:C < 20 U/dL have a 
increased likelihood of bleeding although this is not universal even at low FXI levels.  
Bleeding in FXI deficiency is related to invasive procedures, especially those involving 
tissues with high fibrinolytic activity.(6;7;62)   
 
Bleeding complications can be avoided by the use of FXI replacement (55) but at the 
risk of certain adverse events.  In the case of FXI replacement with plasma, there is 
concern regarding fluid overload, allergic reactions and FXI levels may not be 
normalised.(86)  With FXI concentrate, concerns exist around thrombo-embolic 
complications.(72;92;94) As has been discussed in the Introduction (Chapter 1), FXI 
concentrates have been associated in the literature with thrombo-embolic complications.  
In particular, risk factors for thrombosis include age >60 years, pre-existing 
cardiovascular disease and administration of doses of FXI concentrate > 30U/kg.  The 
FXI concentrate produced by BioProducts Laboratory (BPL) in the United Kingdom 
always contained antithrombin (at a mean level of 102 U/mL).  After 1993 and 
following case reports of thrombotic complications with other FXI concentrates, the 
BPL FXI concentrate was modified to include heparin (10 U/mL) and in-vitro batch 
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testing for thrombogenicity was undertaken.(72)  A review of experience with FXI 
concentrate was reported in the 1998 paper and 12 probable or definite thrombotic 
episodes were reported for 229 treatment episodes in 161 patients.  No further 
evaluation of the modified product has been published. 
 
Since FXI concentrate is manufactured in the United Kingdom and France and is 
available on a named patient basis only, this therapy is not widely available world-
wide.(88;89)  Transfusion transmitted infection, including emerging pathogens, remains 
a consideration for all patients receiving blood products even where viral inactivation 
steps are undertaken.(274) 
 
An alternative treatment option is required for FXI deficient patients.  Ideally, treatment 
should be recombinant and capable of replacing the role of FXI in augmenting thrombin 
generation in the consolidation phase of coagulation.(143;165;173)  Recombinant factor 
VIIa (rFVIIa; NOVOSEVEN
®
, Novo Nordisk, Bagsvaerd, Denmark) fulfils these 
requirements, in particular because it generates a burst of thrombin on the surface of the 
activated platelet. (275-277)   
 
The use of rFVIIa in FXI deficiency was first reported in a patient with an inhibitor to 
FXI in 1990 when rFVIIa was used to prevent surgical bleeding after 
orchidectomy.(102)  Subsequently, a small number of case reports in patients with and 
without inhibitors have confirmed that rFVIIa is effective in preventing surgical 
haemorrhage (See Table 7.1).(107-109)  In all of the above case reports, haemostatic 
efficacy of rFVIIa was reported and no adverse events were documented. 
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Table 7.1:  Dose and dose schedule of rFVIIa in FXI deficiency with and without inhibitors prior to 2001. 
 
Case 
report 
Patient FXI:C 
(U/dL) 
FXI:Inh 
(BU) 
Surgery Bolus dose 
rFVIIa 
(μg/kg) 
Continuous 
infusion and 
dose 
Tranexamic 
acid 
Hedner 
(102) 
Male 
(no 
other 
details) 
N/A* Present. 
Titre 
N/A 
Orchidectomy 60 q 3h x 3 
days 
No No 
Lawler 
(107) 
62 year 
old 
female 
<1 48 Cataract 
extraction 
90 x 1 dose Yes  
20 μg/kg/hr 
x 24 hours 
No 
Musso 
(109) 
38 year 
old 
female
¶
 
<1 N/A Laparotomy  60 x 8 
doses over 
48 hours 
No Yes (5g/d) 
Musso 
(109) 
38 year 
old 
female
¶
 
<1 N/A Resection of 
breast mass 
60 x 5 
doses over 
36 hours 
No Yes (5g/d) 
Billon 
(108) 
75 year 
old 
female† 
5 38 Pleural 
aspiration 
30 x 2 
doses over 
4 hours 
No No 
*N/A: Not available 
¶ 
One patient treated twice due to history of excessive bleeding following surgery covered with FFP. 
†Acquired FXI inhibitor secondary to chronic myelomonocytic leukaemia 
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The aim of this chapter is to audit the use of FXI concentrate in practice as a 
haemostatic agent to prevent surgical bleeding and to evaluate rFVIIa as an alternative 
treatment to prevent peri-operative haemorrhage in patients with FXI deficiency. 
 
7.2 Audit of the use of FXI concentrate in FXI deficiency 
7.2.1 Methods 
The use of the modified BPL FXI concentrate between 1996 and 2001 was evaluated in 
a retrospective audit of the medical records of 296 patients registered with FXI 
deficiency.  The need for FXI replacement had been determined by the treating 
physician.  In line with the policy of the Katharine Dormandy Haemophilia Centre, FXI 
concentrate was dosed according to UKHCDO guidelines: i.e. the dose of FXI 
concentrate was not more than 30 U/kg and the peak FXI:C was maintained < 100 
U/dL. 
 
All patients who had received FXI concentrate in the period September 1996 to 
September 2001 were identified from the Haemophilia centre database.  A structured 
data collection instrument was used to extract data on the use of FXI concentrate to 
cover invasive dental or surgical procedures. 
 
7.2.2 Results 
Seventy surgical episodes were identified in 43 patients (Table 7.2).  The median age 
was 41 years (range 1-91 years).  Baseline FXI:C levels ranged from <1 to 58 U/dL and 
20 patients (47%) had FXI:C in the severely deficient range.  The seventy surgical 
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procedures comprised 19 major, 38 minor and 13 dental surgeries.  Five patients 
undergoing dental procedures received concomitant tranexamic acid mouthwash. 
 
Table 7.2:  Patient characteristics of 43 FXI deficient patients who received FXI 
concentrate over a five year period 1996-2001. 
Patient Demographics  
Total number of patients 43 
Males 19 
Females 24 
Age (years)                      Median 41  
                                         Range 1-91 
Baseline factor XI levels (U/dL)  
Severe deficiency (factor XI < 20 U/dL) 20 
Partial deficiency (factor XI 20-70 U/dL) 23 
Type of surgical procedure  
Major 19 
Minor 38 
Dental 13 
Total 70 
 
 
Patients received a median of one dose of FXI concentrate with a range of 1-5 doses 
(Table 7.3).  The median dose administered was 1065 units (range 200-2640).  The 
median post-infusion FXI:C was 65 U/dL and only one level > 100 U/dL was recorded.  
Haemostatic efficacy was documented in 66 of 70 surgical procedures (94%). 
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Table 7.3:  Factor XI concentrate - Dose and post infusion levels. 
Number of doses                          
              Median 1 
              Range 1-5 
Total dose per episode (IU)
     
      
              Median 1065 
              Interquartile Range 750-1950 
Post infusion factor XI level (U/dL)  
              Median 65 
              Interquartile Range 58.3-78 
 
A total of seven adverse events were documented but none were thrombotic events 
(table 7.4).  No thromboembolic events were seen despite the fact that five patients aged 
> 70 years were treated and that seven angiography procedures were performed in 
individuals with ischaemic heart disease. 
 
Four episodes of bleeding were recorded (6% of procedures); two resolved with further 
treatment with FXI concentrate and two resolved with surgical or local measures.  
Arterial punctures seem especially associated with bleeding but it should be noted that 
one patient had sub-optimal FXI:C levels and another had a surgical perforation.  Three 
non-haemorrhagic adverse events were documented and none was serious or persistent.  
The development of FXI inhibitors was observed in two patients with severe FXI 
deficiency.   
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Table 7.4:  Adverse events associated with factor XI concentrate. 
 
Bleeding complications Surgical procedure Baseline factor 
XI level 
(IU/dL) 
Post infusion factor 
XI level (IU/dL) 
Outcome 
Bilateral inguinal haematomata Angioplasty 12 44 Resolved with 3 further doses FXI 
concentrate 
Scrotal bruise/ 
subconjunctival haemorrhage 
Insertion of 
endovascular stent 
37 60 Resolved with a further dose FXI 
concentrate 
Pericardial tamponade due to 
arterial perforation 
Angioplasty 36 67 Resolved with serial pericardiocentesis 
and coronary artery stenting 
Dental socket ooze Extraction of 4 
wisdom teeth 
32 56 Resolved on packing with gauze 
Adverse events     
Hypotension Arthroscopy 
(cancelled due to 
reaction) 
3.5 N/A Resolved with IV hydrocortisone and 
chlorpheniramine 
Bilateral parotid swelling Hysterectomy/ 
nephrectomy 
1 N/A Resolved spontaneously 
Paraesthesiae Myringotomy 38 62 Resolved spontaneously 
Inhibitor development     
BU =  7.6 Arthroscopy 1.5 38 Inhibitor screen negative 11/2001 
BU =  1.9 Cataract extraction  <1 38 N/A 
N/A = not available 
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7.2.3 Discussion 
This five year evaluation of the use of a modified FXI concentrate confirms its efficacy 
and safety.  A 94% haemostatic efficacy rate was recorded and no thrombotic 
complications were documented.  FXI concentrate was successfully administered to five 
elderly patients (>70 years) and to patients with a history of cardiovascular disease 
although caution must be exercised in these categories of patients and a careful risk-
benefit analysis done.  This audit confirms that bleeding is effectively prevented by FXI 
concentrate.  Thrombotic complications appear to be rare when guidelines regarding 
infusion of FXI are implemented.   
 
7.3 The use of recombinant factor VIIa to prevent peri-operative 
haemorrhage in FXI deficiency 
7.3.1 Methods 
Between November 2001 and December 2002, consecutive patients with FXI deficiency 
with a planned major, minor or dental procedure were recruited to the study.  Treatment 
with rFVIIa was offered to patients who, in the opinion of their treating clinician, would 
require haemostatic cover with FXI concentrate (i.e. the presence of a previous history 
of bleeding, procedure likely to result in bleeding, procedure with potential to result in 
bleeding in a critical area).  Patient inclusion criteria were age > 18 years and severe 
(FXI:C <20 U/dL) or partial ( FXI:C 20-70 U/dL) FXI deficiency or FXI deficiency 
with persistent high responding inhibitors.  Exclusion criteria were known 
hypersensitivity to rFVIIa, uncontrolled disseminated intravascular coagulation, a recent 
thromboembolic event (within six weeks) or treatment with any haemostatic agent 
within 48 hours of the first dose of rFVIIa.   
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As a consequence of a thrombo-embolic adverse event after six months of patient 
recruitment, subsequent patients with a history of cardiovascular disease or with current 
angina or intermittent claudication were excluded.  Informed consent was obtained in all 
cases and the protocol was approved by the Local Research Ethics Committee. 
 
The first dose of rFVIIa was given immediately pre-operatively.   A total of two doses 
(90 μg/kg) four hours apart was given to patients undergoing minor or dental 
procedures.  For major procedures, rFVIIa at a dose of 90 μg/kg was given two hourly 
for the first twenty-four hours and four hourly for the second twenty-four hours.  Oral 
tranexamic acid was given post-operatively for seven days, once rFVIIa treatment had 
finished for minor and dental procedures and once the patient was taking oral intake for 
major procedures. 
 
The primary endpoints were the clinical assessment of haemostasis and the recording of 
adverse events.  Clinical haemostasis ratings were graded as effective, partially effective 
or ineffective.(278)  Secondary end-points were the use of additional haemostatic agents 
and the requirement for more than a two unit red cell transfusion.  All endpoints were 
evaluated immediately post-operatively in all cases.  Further evaluations were 
performed four hours post-operatively in patients undergoing minor or dental 
procedures and eight, 24 and 48 hours post-operatively in patients undergoing major 
procedures.   
 
Pre-operatively, blood was collected into citrate tubes (0.106mol/L trisodium citrate, 
SARSTEDT Monovette, Nümbrecht, Germany) for analysis of the prothrombin (PT) 
time, d-dimers and factor VII coagulant activity (FVII:C).  The coagulation tests were 
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repeated 15 minutes after the first dose of rFVIIa and pre and post the two or four hour 
dose in the case of major or minor/dental surgery respectively.  Patients undergoing 
major surgery also had these coagulation tests repeated pre and post the 24 and 48 hour 
doses.   
 
Thromboelastography (TEG) and a thrombin generation assay were also performed in a 
subgroup of samples where plasma was available(see Chapter 2 Methods).(116;279) 
The thrombin generation assay was performed on plasma which had been double spun 
and stored at -80
0
C until assayed.  Briefly, plasma was thawed and defibrinated with 
Reptilase, coagulation was initiated with recombinant tissue factor at a concentration of 
10pg/mL and calcium.  Subsampling from the test sample was performed at 30 second 
intervals into a stop solution containing EDTA and thrombin generation was determined 
by adding the chromogenic substrate S2238 and reading the absorbance at 405nm.   
Calculations of peak thrombin and area under the curve (AUC) were performed with 
reference to a standard curve generated using dilutions of bovine thrombin (starting 
concentration 1000 U/mL). 
7.3.2 Results 
 
Fourteen patients were recruited to the study and fifteen surgical or dental procedures 
were performed.  Patient characteristics including severity of FXI deficiency, prior 
bleeding history and procedure type are given in Table 7.5.  One patient (patient 14) had 
a high responding inhibitor to FXI.  Inhibitors to FXI were not detected in the remaining 
patients. 
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Table 7.5:  Patient demographics and procedures. 
Patient Age Gender Baseline FXI:C Bleeding history Procedure 
Classification of 
procedure 
1 24 Male 9 Yes Molar tooth extraction Dental 
2* 43 Female 44 Yes 
Removal of titanium 
implant 
Dental 
3 42 Female 56 Yes 
Repair of common 
extensor origin (elbow) 
Major 
4 77 Male 48 Yes Bilateral herniorraphy Major 
5 31 Female 44 Yes 
Endometrial 
ablation/bilateral 
salpingectomy/diathermy 
Major 
6* 43 Female 44 Yes 
2 dental titanium 
implants 
Dental 
7 77 Male 3 Yes Hydrocoele repair Major 
8 38 Male 39 
No (dental 
extractions) 
Colonoscopy and biopsy Minor 
9 20 Female 45 Yes Bone biopsy Minor 
10 25 Female 56 
No (dental 
extractions) 
Breast Symmetrisation Minor 
11 37 Male 58 Yes Vasectomy Minor 
12 43 Female 42 Yes 
Extraction 3 impacted 
wisdom teeth 
Dental 
13 62 Male 10 Yes 
Extraction 1 impacted 
molar tooth 
Dental 
14
†
 65 Female 1 Yes Total hip replacement Major 
 
15 
59 Male 11 
No 
(tonsillectomy, 
circumcision) 
Extraction 1 wisdom 
tooth & 1 molar tooth 
Dental 
*Two procedures undertaken in the same patient.    
†
 This patient had a FXI inhibitor.  
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Haemostasis was classified as effective at all time points in all patients.  No patient 
required an additional haemostatic agent or surgical intervention for unexpected 
haemorrhage and no red cell transfusions were given.  One female patient, who 
underwent breast symmetrisation, had a decrease in haemoglobin from 11.4 g/dL pre-
operatively to 9.5g/dL post-operatively and was given post-operative iron 
supplementation. 
 
The prothrombin time shortened from a mean of 13.6 to 8.2 seconds (reference interval 
12.9-13.9 seconds) after the first dose of rFVIIa and remained below the lower limit of 
the reference interval at all time points in all patients.  FVII:C increased after 
administration of rFVIIa but there was considerable inter-individual variation (Figure 
7.1).  The median FVII:C level post the first dose of rFVIIa was 44 U/mL with a range 
of 28-65 U/mL.  The trough level prior to the next dose was >6 U/mL in all cases with a 
range of 11-26 U/mL in major cases and 7-13 U/mL in minor cases.   
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Figure 7.1:  FVII:C levels pre and post first dose of rFVIIa for all 15 procedures.  All 
pre FVII:C levels were within the normal range (0.5-1.5 U/mL).  Note that some 
patients had identical post rFVIIa FVII:C levels (three patients: 50 U/mL, two patients: 
46 U/mL, two patients: 44 U/mL, two patients: 40 U/mL).  
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The thromboelastogram was evaluated pre and post rFVIIa in nine patients (four 
severely deficient, five partially deficient).  All patients had a prolonged k time and a 
reduced angle pre rFVIIa while six of nine patients had an abnormally prolonged r time 
(Table 7.6).  The TEG parameters corrected in all cases following therapy with rFVIIa. 
 
Table 7.6:  Thromboelastography (TEG) and thrombin generation test (TGT) results 
pre and post the first dose of rFVIIa. 
Test TEG TGT 
Parameter 
(Normal) 
r time 
(14-23s) 
k time 
(3-7s) 
Angle 
(31-49) 
AUC 
(2910.9 U/mL) 
Peak 
Thrombin 
(9.0 U/mL) 
Patient Pre Post Pre Post Pre Post Pre Post Pre Post 
1 32 14.9 10.7 4.8 18.5 37.5 . . . . 
2 22.5 7.6 9.2 3 20.5 53.5 3365.2 3829.9 11.3 11.4 
3 28.6 9.9 24.8 3.8 9 44.5 1990.4 3313.8 5.1 10.5 
4 23.9 9.2 8.7 2.4 25 49.5 1402.5 4303.4 4.7 11.6 
5 16.9 11.4 11.6 5.8 18.5 44 . . . . 
9 . . . . . . 3884.4 4614.1 12.1 13.8 
12 20.8 11.8 7.3 3.6 30 46 . . . . 
13 28 11.3 10.1 3.1 21 59 . . . . 
14 55.1 10.7 12.7 2.4 20.5 62 2304.7 3779.2 2.9 16.6 
15 36.4 16.8 12.6 5.9 19 39.5 1333.9 2832.5 1.8 10.1 
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Six patients (two severely deficient, four partially deficient) had thrombin generation in 
plasma measured before and after the first dose of rFVIIa (Table 7.5).  The median 
AUC pre-rFVIIa was 2147.55 U/mL (AUC of pooled normal plasma 2910.9 U/mL) 
which increased to 3804.55 U/mL after rFVIIa.  Peak thrombin increased from a median 
of 4.9 U/mL to a median of 11.5 U/mL after rFVIIa (pooled normal plasma 9.02 U). 
 
Three adverse events were documented during the study.  A 77-year-old male patient 
(patient 7, Table 7.4), with a history of a myocardial infarction eight years previously, 
developed clinical and radiological evidence of a cerebrovascular infarct after the 17
th
 
of 19 planned doses of rFVIIa and died three days later.  The FVII:C levels obtained pre 
and post the first, second and 24 hour rFVIIa doses were similar to other patients in the 
study on the same dosing regimen.  The maximum FVII:C level obtained was 73 U/mL 
post the second dose of rFVIIa.  D-dimers became elevated in this patient at 24 hours 
post-operatively, as occurred in all patients undergoing major procedures.  A 31-year-
old female patient (patient 5, Table 7.4) with a strong history of atopy developed 
periorbital rash and itching associated with mildly elevated liver function tests.  These 
symptoms resolved after discontinuation of treatment.  Further investigations suggested 
an allergy to polysorbate 80, an excipient of rFVIIa.  A 42-year-old female patient 
(patient 3, Table 7.4) developed a mild local phlebitis, which resolved with conservative 
therapy. 
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7.3.3 Discussion 
There is no recombinant FXI replacement product under development at the present 
time.  The efficacy and safety of rFVIIa is well established in the management of acute 
bleeds and invasive procedures in patients with severe FVIII or FIX deficiency and 
inhibitors.  Inhibitors to FXI have been well described and are associated with severe 
FXI deficiency and exposure to plasma-derived FXI.(106)  There was an early report of 
the use of rFVIIa (60 μg/kg three hourly for three days) in a patient with FXI deficiency 
and a FXI inhibitor undergoing an orchidectomy for testicular haemorrhage.(102)  A 
number of case reports subsequently documented the use of rFVIIa in FXI deficiency 
and inhibitors.(107-109)  Doses used ranged from 30-90 μg/kg.  At the time that this 
study was designed and conducted, there were no other available data on the use of 
rFVIIa in patients with FXI deficiency.  The dose of 90 μg/kg used in this study was 
chosen since there was extensive experience in prevention of bleeding in haemophilic 
patients undergoing surgical procedures at this dose.(280)  There is also laboratory 
evidence that the haemostatic dose of rFVIIa is >70 μg/kg.(178) 
 
Tranexamic acid has been used safely with rFVIIa in severe haemophilia with 
inhibitors.  In this study, the additional use of tranexamic acid was deemed necessary 
since the period of cover with rFVIIa was limited to the immediate post-operative 
period and tranexamic acid was used to prevent late bleeding. 
 
Thromboembolic adverse events are an uncommon but recognised adverse event 
associated with therapeutic use of activated clotting factors.(281)  In common with 
other reports, the patient affected by a cerebrovascular accident in this study had pre-
existing risk factors.  Following this experience the protocol was modified and 
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subsequent patients were excluded if risk factors for thromboembolic disease were 
present.  Patients with FXI deficiency do not appear to be inherently protected from 
arterial thrombosis by their coagulation factor deficiency.(169)  Therefore, rFVIIa 
should be used with caution in such patients.  More recently, reports have suggested that 
much lower doses of rVIIa, analogous to those used in FVII deficiency, may be 
effective in achieving haemostasis in FXI deficiency.(110;111)  In the first of these case 
reports, a single dose of 12 µg/kg was sufficient to arrest a postpartum haemorrhage 
while in the second report, the use of bolus doses of 29 µg/kg and 18 µg/kg and 
continuous infusion rates of 1.1-3.6 µg/kg/hr was reported to prevent surgical bleeding 
during two separate spinal procedures in a single patient.  These alternative dosing 
schedules merit further study in larger groups of patients. 
 
Since the mechanism of action of rFVIIa is not replacement of a deficient coagulation 
factor, the optimal monitoring method is unclear.(282-284)  Levels of FVII:C reach 
supra-physiological levels after therapeutic doses of rFVIIa and in vitro data suggest 
that haemostasis occurs if FVII:C levels are maintained at > 6 U/mL for several 
hours.(178)  Clinical studies have revealed considerable inter-individual variation in 
FVII:C levels and the peak level of FVII:C is now felt to be the critical factor in 
promoting normal clot structure and maintaining haemostasis in patients with 
haemophilia.(285;286)  In this study, all patients studied achieved peak FVII:C levels of 
>25 U/mL after one dose of rFVIIa.  Trough levels were >6 U/mL, both with two 
hourly and four hourly bolus dosing (data not shown), which correlated with 
satisfactory haemostatic efficacy in all cases.  Lower target FVII:C levels may be 
effective in patients with FXI deficiency as documented in a recent case report.(111) 
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Defective thrombin generation in FXI deficient patients causes inadequate activation of 
thrombin activatable fibrinolysis inhibitor (TAFI) and a consequent increase in 
fibrinolysis.(287)  This correlates with the clinical observation of increased bleeding in 
areas of high fibrinolytic activity in patients with FXI deficiency.(62)  In patients with 
severe haemophilia A, in-vitro studies have demonstrated that rFVIIa inhibits 
fibrinolysis via TAFI and the concentration of rFVIIa required shows considerable 
individual variation, mirroring the variability seen in FVII:C in-vivo.(173)  Generation 
of thrombin at normal or supra-normal levels post therapy with rFVIIa is suggested by 
the normalisation of the TEG parameters in patients in this study and by the marked 
increase in the AUC and peak thrombin levels in the thrombin generation assay.  
Increased thrombin is postulated to lead to enhanced activation of TAFI with 
consequent downregulation of fibrinolysis.  More recently, in a fluorogenic thrombin 
generation assay using PPP from five patients with inhibitors to FXI, rFVIIa corrected 
the ETP to 50% of normal at a concentration of 1 μg/mL (equivalent to a clinical dose 
of 45 μg/kg).(106) 
 
7.4 Conclusion 
Haemostatic therapy is indicated in some patients with FXI deficiency having invasive 
procedures, especially those with FXI:C in the severely deficient range, those 
undergoing surgery in areas with high fibrinolytic activity and patients with a history of 
surgical bleeding.  The decision regarding haemostatic cover is also influenced by 
evaluation of the side-effect profile of individual treatment modalities. 
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The results of the audit of FXI concentrate confirm that this is an effective treatment 
and that thrombotic side effects are less common than previously reported, probably due 
to changes to the manufacturing process and implementation of treatment guidelines.  
However, it cannot be excluded that certain patients at higher risk of thrombo-embolic 
complications were not given FXI concentrate due to the presence of pre-existing risk 
factors.   
 
In the pilot study of rFVIIa in combination with post-operative tranexamic acid, 
haemostatic efficacy was excellent in all patients.  The use of a recombinant product to 
prevent surgical bleeding in FXI deficiency is especially desirable in younger patients, 
children and pregnant women, in view of emerging risks of transfusion including new 
variant Creuzfeldt Jakob disease.(288;289)  However, one fatal thrombo-embolic event 
occurred in a patient whose only risk factor was a remote history of coronary artery 
disease.  This patient received cover with rFVIIa at a dose of 90 μg/kg two to four 
hourly for 48 hours and was receiving concomitant tranexamic acid orally.  Lower doses 
of rFVIIa have been effective in clinical case reports and a concentration of rFVIIa 
equivalent to a dose of 45 μg/kg normalised thrombin generation in-vitro.(106;110;111)  
In addition to a reduction in dose, a reduction in the duration of cover with rFVIIa 
should also be evaluated.  Tranexamic acid could be used to provide haemostatic cover 
after rFVIIa cover has been discontinued but probably should not be used with rFVIIa 
in FXI deficient patients.  Caution is required when considering either FXI concentrate 
or rFVIIa in patients with pre-existing risk factors for thrombosis including 
atherosclerosis.  This group of FXI deficient patients continues to present a therapeutic 
dilemma to clinicians when undergoing invasive procedures. 
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Chapter 8 Discussion 
8.1 Introduction 
Factor XI deficiency is classified as a rare bleeding disorder.(80)  However, when 
registry data is evaluated FXI deficiency is one of the more common of the rare 
bleeding disorders recorded, accounting for approximately 37% of rare bleeding 
disorders registered with the World Federation of Haemophilia global survey and the 
International Rare Bleeding Disorders database.(290)  Many affected patients are 
concentrated in geographic areas associated with ethnic groups with a high allele 
frequency for F11 gene mutations causing FXI deficiency.  While important 
information may be gleaned from individual cases or small case series, only a few 
research centres worldwide are located in geographic areas with the potential to recruit 
larger numbers of FXI deficient patients.  The Katharine Dormandy Haemophilia centre 
and Haemostasis unit is located in such a geographic area and researchers based here 
have made significant contributions to the published literature in FXI 
deficiency.(5;7;55;64;241)  The purpose of the research work conducted for this thesis 
was to further develop and advance the clinical research programme in FXI deficiency 
at the Royal Free & University College Medical School. 
 
The aim of the work presented in this thesis was  
 to comprehensively document the bleeding tendency in a cohort of patients with 
FXI deficiency 
 to accurately diagnose the FXI deficiency in those patients by evaluating the 
FXI:C, FXI:Ag and the causative genetic mutation where possible 
 to investigate factors which may influence the bleeding tendency in FXI 
deficiency (including those previously published i.e. VWF, those which had 
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recently been identified i.e thrombophilic traits and TAFI and those which had 
not been comprehensively evaluated in FXI deficiency i.e. Thrombin generation) 
 to develop a molecular homology model for the FXI protein (in the absence of a 
crystal structure) and to model known and novel FXI mutations 
 to evaluate a novel treatment (rFVIIa) for the prevention of surgical bleeding in 
FXI deficiency 
 
8.2 Summary of thesis findings 
8.2.1 Bleeding tendency, diagnosis of FXI deficiency and other coagulation 
tests 
The 102 participating patients in this study represent a large cohort of patients with FXI 
deficiency.  In particular, two thirds of the patients included in this study are partially 
deficient in FXI which is an under-represented group in the literature.   
 
The bleeding tendency was recorded using a standardised data collection form 
(appendix 10.1).  The bleeding score was assigned independently by three clinicians 
experienced in Haemostasis and a consensus score was obtained (81% agreement 
overall).  The source data, on which the bleeding score was determined, was recorded in 
an Access (Microsoft ® 2001) database to allow additional evaluation of bleeding 
related to haemostatic challenges.  At the time of this study, the bleeding score 
described had previously been used in patients with FXI deficiency.(5)  Subsequently, 
the importance of a standardised bleeding score has been recognised and disease 
specific bleeding questionnaires and scores have been developed.(291-294)  The 
bleeding score used in this study has not been compared to the more recently developed 
scores, nor have the recently developed scores been validated in FXI deficiency. 
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The evaluation of the patients participating in this study included the reassessment of 
the FXI:C levels in these patients and comparison to their registered levels.  FXI:C 
levels in the normal range were found in 17 patients who had previously been registered 
as FXI deficient.  Of these 17 patients, 10 patients were confirmed to have a causative 
Jewish mutation for FXI deficiency (eight had known Jewish heritage, the others were 
English and Turkish respectively) emphasising that in a minority of patients, carrier 
status for this condition will be present even in the presence of normal FXI:C and 
FXI:Ag levels.  This has implications for genetic counselling in individuals with normal 
FXI:C levels.  The possibility of changing levels with age or with changes in assay 
techniques should be considered in previously diagnosed patients whose current FXI 
levels are normal and consideration should be given to genetic confirmation in these 
cases.   
 
In this study, FXI:Ag was documented for all patients, which had not been done 
previously.  Indeed, there had been a view that there were no CRM+ mutations causing 
FXI deficiency and that all FXI deficiency was caused by a failure of secretion of the 
mutated protein.(295)  This has been demonstrated not to be true, both by the 
identification of patients with a CRM+ phenotype within this study (Gly155Glu, 
Ser576Arg) and by the identification of 11 CRM+ mutations in the F11 gene, mainly 
within the SP domain.(260)  In this study, there was good concordance between FXI:C 
and FXI:Ag (r=0.95).  However, one severely deficient patient was documented to have 
a normal FXI:Ag and a lupus type inhibitor causing a severe reduction in FXI activity 
and this patient does not have a true inherited FXI deficiency.  Nine partially deficient 
patients had discordant results, in five of these cases FXI:C was normal, FXI:Ag was 
low and a Jewish mutation was confirmed.  Therefore, accurate and comprehensive 
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diagnosis requires the analysis of FXI:Ag as well as FXI:C in patients with suspected 
FXI deficiency.   
 
Genetic mutations causing FXI deficiency were identified in 83 patients in this study, of 
a total of 98 patients with definite FXI deficiency who were screened.  Of 21 patients 
with a definite FXI deficiency and without the presence of a Jewish mutation, six were 
found to have a mutation in the F11 gene and novel mutations were found in two 
patients (Glu297Lys and Glu380Lys).  One patient had a mutation identified which was 
subsequently shown to be a non-disease causing polymorphism (Pro48Leu, NCBI 
dbSNP ID rs5968).  Therefore, there are 16 patients, in this cohort, in whom a mutation 
has not been identified.  Of these, 11 are of English descent and the C128X mutation 
has been outruled in all of them.(258)  Further sequencing work is being undertaken to 
clarify whether a mutation is present in these 16 patients.  
 
In regards to factors influencing the bleeding tendency, the firmest association was 
confirmed to be the presence of a severe deficiency of FXI in this study, with 82.3% of 
severely deficient patients being classified as bleeders.  A number of other factors were 
evaluated to determine whether an effect on bleeding tendency was evident (including 
VWF, FVIII, blood group, thrombophilic traits).  No relationship is proven between the 
levels of VWF:Ag or VWF:CBA  and bleeding tendency and the use of VWF and FVIII 
cut off levels of 70 IU/dL was not predictive of bleeding in contrast to earlier 
studies.(7;61;65)  There was no significant difference in proportions of bleeders 
between the common blood groups.  A slightly higher proportion of patients with 
thrombophilic traits were identified as bleeders (63.5%) thus making it unlikely that 
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thrombophilic traits were attenuating the bleeding tendency, as had been reported for 
severe Haemophilia.(67;211-214)   
 
Evaluation of one potential genetic modifier of glycosylation did not reveal an 
association with an increased tendency to bleed but considering the evidence for 
alterations in clinical phenotype in VWD and the association between congenital 
disorders of glyscosylation and FXI deficiency, this is a research area which would 
benefit from further study.(216-218) 
 
It should be noted that no studies of platelet function were done as part of this work and 
therefore, it is possible that some patients with a significant bleeding tendency have an 
underlying, undiagnosed inherited or acquired platelet function defect (diagnosed in 
23.2% of patients under investigation for mucocutaneous bleeding in one study).(296)  
However, it is difficult to accept that such conditions would account for the bleeding 
tendency in the 50% of partially deficient patients in this study who are classified as 
bleeders. 
 
8.2.2 Thrombin generation assays  
Thrombin generation has been recently re-evaluated in disorders of bleeding and 
thrombosis as researchers have identified the need for a more ―global‖ test of 
haemostatic function.  Since the FXI:C level in partially deficient patients is not 
correlated with bleeding tendency, the determination of global thrombin generation as 
measured by the ETP offers an alternative means of identifying those 50% of partially 
deficient patients who are likely to bleed with invasive procedures.  The TGT test, like 
the CLT described above, is a dynamic test and results vary depending on 
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concentrations of reagents used, in particular the type and concentration of the initiator 
of coagulation.  Consequently, the earliest reports of thrombin generation in FXI 
deficient plasma stated that thrombin generation was normal.(119)  However, this study 
and subsequent studies have shown this is not the case if lower concentrations of TF are 
used to initiate coagulation.(43)  In this study, a significant difference in ETP was 
demonstrated between partially deficient patients with a history of bleeding (median 
ETP 52.4%) versus partially deficient patients without a bleeding history (median ETP 
77.3%).  Concomitant low levels of FVIII, VWF or fibrinogen or conversely the 
presence of a thrombophilic trait were not clearly linked to the variations in ETP 
between bleeders and non-bleeders.   
 
There are limitations to the TGT used in this study.  A chromogenic, semi-automated 
method was used but more recently, a calibrated automated fluorogenic thrombin 
generation assay (Thrombinoscope BV, the Netherlands) has been developed and allows 
more standardisation of the method.  Timed pipettes, the use of a calibration standard 
and a specific software program enabling calculation of thrombin activity results in 
lower CVs.(297)   
 
The use of PPP was required for this study as patients attended a dedicated clinic for 
clinical review and blood draw some months in advance of the laboratory analysis of 
the plasma samples.  However, analysis of PRP may be expected to give a more 
comprehensive evaluation of global thrombin generation and would include the 
contribution of platelets, which are known to bind FXI via specific residues in apple 
3.(34) 
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The specific inhibitor of the contact pathway, CTI, was not used in the TGT described 
in this study.  Available data at the time showed that contact activation did not occur to 
a significant degree in a dilute thromboplastin assay and that no differences were seen in 
the thrombin generation curves obtained in the presence and absence of a monoclonal 
antibody to FXII in severe FXI plasma.(43;136)  The use of CTI has been recommended 
in a fluorogenic TGT but has not been evaluated in a chromogenic assay.(137)  More 
recently, studies have suggested that the requirement for CTI may be dependent on the 
concentration of TF used to initiate thrombin generation with CTI not needed at TF 
concentrations greater than 0.5pM.(298;299) 
 
In a recent study, thrombin generation has been evaluated in 24 patients with FXI 
deficiency (9 severely deficient, 15 partially deficient) in a fluorogenic assay using PRP 
in the presence of CTI.(300)  Results show that lag-time, thrombin peak and thrombin 
velocity but not ETP are correlated with FXI:C levels and with bleeding tendency 
independent of FXI activity.  Of note, in this study only 9 patients had a documented 
bleeding tendency and only three of these had a partial deficiency of FXI.  In the latter 
study, all patients were documented to have a normal prothrombin level.  In the cohort 
of 102 patients under study here, prothrombin levels were not specifically assayed and 
could be a determinant of ETP, therefore in future studies of thrombin generation, 
prothrombin levels should be assayed and consideration given to assaying other relevant 
coagulation factors (both pro- and anticoagulant) in addition to FXI. 
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8.2.3 TAFI 
The discovery of the TAFI molecule generated significant interest in the late 1990s as 
TAFI represents a clear link between the coagulation and fibrinolysis systems.(152)  
The role of TAFI is of particular interest in patients with FXI deficiency since it has 
been long recognised that bleeding is especially likely to occur after invasive procedures 
to areas with high intrinsic fibrinolytic activity.(63)  TAFI activation has been 
demonstrated to be dependent on thrombin generated in a FXI dependent fashion.(165)  
The hypothesis generated was that alterations in TAFI antigen or activity could account 
for some of the variation in bleeding tendency seen in FXI deficient patients.  In this 
study, there was no link identified between TAFI antigen and bleeding tendency 
although a possible limitation is the use of an elisa TAFI:Ag kit which gives a lower 
TAFI:Ag level in patients with one or two Isoleucine alleles at position 325, as a 
consequence of the TAFI polymorphism Thr325Ile.  The TAFI-Ile325 isoform has a 
longer half-life and greater antifibrinolytic activity than the Threonine isoform.(301)  So 
while the lower TAFI:Ag levels might be expected to lead to an increased bleeding 
tendency,  the greater antifibrinolytic effect of the Ile isoform might be expected to be 
associated with a decreased bleeding tendency.  Notably, the lower TAFI levels in 
patients homozygous for Isoleucine at position 325 have been recently shown to confer 
a lower risk of arterial thrombosis compared to patients homozygous for 
Threonine.(302)   
 
A commercially produced TAFI activation kit was assessed and found not to be fit for 
purpose and therefore TAFI activity was assessed indirectly using a well-described clot 
lysis assay, which has been shown to correlate with both TAFI:Ag and TAFI activity in 
normal individuals.(160)  While the relationship between CLT and TAFI:Ag levels is 
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lost when a specific inhibitor to FXI is added, this experimental situation may be 
expected to mirror severe FXI deficiency rather than partial FXI deficiency.  In partial 
FXI deficiency, thrombin generation is not completely abolished even at low thrombin 
concentrations and therefore the CLT should correlate to TAFI:Ag.  However, in this 
study, no variation in CLT was identified between bleeders and non-bleeders with FXI 
deficiency (9 severely deficient and 38 partially deficient patients).  In addition, the 
CLT was not correlated with TAFI:Ag. 
 
Of note, the CLT was initiated with low concentrations of TF.  It is possible that not all 
of the patient‘s TAFI was activated in this particular CLT since activation is thrombin 
dependent and that the use of thrombin or higher concentrations of TF as the initiator 
would allow more complete activation of TAFI which could then be correlated with 
bleeding tendency.  The concentration of TF used to initiate clot lysis has been shown to 
be a critical factor in determining whether normal or reduced CLT are obtained in 
severe Haemophilia A plasma.(177) 
 
Alternative genotype independent elisa assays have been developed to measure the 
intact TAFI molecule (TAFI), the activation peptide (TAFI-AP) and the inactivated 
TAFI protein (TAFIa(i)).(303)  Using these elisas, TAFIa(i) levels were shown to be 
higher in patients with cardiovascular disease (both coronary artery disease and 
ischaemic stroke) and there were different patterns of association between the various 
measures of TAFI depending on the underlying disease (for example, intact TAFI levels 
were higher than controls and the Ile isoform was protective in coronary artery disease 
only).(302)  Specifically in ischaemic stroke, the activation peptide (TAFI-AP) showed 
the strongest association with all subtypes of ischaemic stroke.(304)  It should be noted 
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that FXI deficiency appears to protect against ischaemic stroke but not against 
myocardial infarction and analysis of  the different TAFI elisas has the potential to shed 
some light on the two disease processes.(169;305)  Overall, a definite link between 
TAFI and bleeding tendency in FXI deficiency has not been proven but clearly there are 
many contentious issues in the appropriate tests required to evaluate the true impact of 
TAFI on bleeding and thrombosis.  This is a research area which requires further 
evaluation. 
 
8.2.4 Molecular modelling of protein structural effects caused by F11 
mutations 
The development of molecular models for the four apple domains and the serine 
protease domain of FXI was a significant advance in this study.(306)  Prior to the 
development of these models, rudimentary ab initio models had been used which were 
not accurate enough to give reliable information about the structural effects of mutations 
on the FXI protein.(14;34;252;268-270)  The other significant advance was the 
universal access to these models and to the comprehensive database of FXI mutations 
which had been generated as part of the project.(273)  The web-based curated database 
(www.factorXI.org) continues to be a widely used and quoted resource for researchers 
in the field of FXI deficiency. 
 
The homology models were limited by the lack of availability of a crystal structure so 
that all interpretations were necessarily guarded in certain respects.  The most obvious 
limitation was the lack of information on how the four apple domains and the serine 
protease packed together, both as monomer and dimer.  In addition, while the core of 
the protein models was well-predicted, prediction of the insertions and deletions in loop 
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regions and the positions of the sidechains of amino acids was expected to be less 
accurate.  The publication of the crystal structure provided both the means to accurately 
model the protein effects of mutations in the F11 gene but also allowed an evaluation of 
the three-dimensional arrangement of the FXI protein domains in their dimeric 
conformation.(47)  The pre-existing molecular homology models were compared to the 
crystal structure and analysis confirmed that the homology models were very accurate 
with small differences found in the surface insertion loops and N- and C- termini of the 
apple domains, as was predicted.(260)  The web-based FXI database now uses the 
crystal structure to predict structural changes in the FXI protein caused by missense 
mutations.  The residual limitation is that modelling is relevant only to missense 
mutations and evaluation of the effects of other sequence changes on protein expression 
and function requires alternative approaches.  Although, genetic mutations in the F11 
gene have not been shown to cause variation in bleeding tendency, knowledge of the 
effect of the mutation on the protein structure does allow understanding and explanation 
of CRM- and CRM+ phenotypes. 
 
8.2.5 Prevention and treatment of bleeding in FXI deficiency 
The variable bleeding tendency in FXI deficient patients is well-recognised and is seen 
in severely and partially FXI deficient patients in the United Kingdom.  In fact, the 
maximum variation in bleeding tendency in this study was seen in partially deficient 
patients, with half of these patients exhibiting a bleeding tendency.  The severely 
deficient patients were almost all designated as bleeders.  As such, the prevailing 
practice in the UK would be to replace FXI in severely deficient patients when 
undergoing major surgery and to consider replacement in partially deficient patients, 
depending on personal bleeding history and the nature of the proposed invasive 
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procedure.(80)  This contrasts with the published approach by the Israeli group.(62;71)  
In Israel, partially deficient patients do not have replacement of FXI and alternative 
bleeding disorders are sought in patients with a bleeding history.  It is felt that such 
patients do not have a significant bleeding tendency (U.Seligsohn, personal 
communication).  It seems unlikely that there are true differences in bleeding between 
Israeli patients heterozygous for the type II or III mutations versus UK residents with 
Ashkenazi Jewish heritage and the same genetic mutations.  An alternative explanation 
may be that there is a cultural difference in the acceptance of bleeding associated with 
invasive procedures. 
 
Severely deficient patients in Israel do not routinely receive FXI replacement as cover 
for major surgery, as stated in a recent publication.(62)  There is agreement that the 
highest risk of bleeding occurs with invasive procedures on tissues with high 
fibrinolytic activity.  The haemostatic level of FXI is felt to be 30-45 U/dL in Israel (U. 
Seligsohn, personal communication) and was said to be 30 U/dL in a small case series 
of 5 severely deficient patients undergoing urological surgery whereas restoring FXI:C 
to 70 U/dL would be normal practice in the United Kingdom if replacement is 
advocated.(54;80)  Finally plasma is used as FXI replacement in Israel whereas virally 
inactivated FXI concentrate obtained by plasma fractionation is generally recommended 
for replacement in the United Kingdom, unless there is a thrombotic contra-
indication.(81) 
 
With-holding of FXI replacement is advocated by Israelis but it is not likely to prove 
acceptable in many countries to expose patients to the morbidity of bleeding, surgical 
wound complications and infection/poor healing and possible requirement for plasma or 
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other cellular blood components which represent a higher risk for transfusion 
transmitted infection than a virally inactivated factor concentrate.  In addition, it is 
questionable whether patients will accept a bleeding risk of up to 40% for surgery on 
sites without high fibrinolytic activity and in some jurisdictions, such bleeding rates 
may be medico-legally unacceptable.(62)  Management of labour and delivery is 
particularly challenging in this regard.  Performing a Caesarean section in the United 
Kingdom in a woman with severe FXI deficiency without FXI replacement is not likely 
to be deemed standard practice although the Israeli group have published data on 
Caesarean sections without FXI replacement in 12 of 18 severely deficient 
women.(71;80)  Two of the twelve women (16.7%) not covered with plasma were 
reported to have had post-partum bleeding in the latter study, compared to 24% of 
vaginal deliveries not covered with plasma. 
 
Bearing in mind these differences in clinical practice globally, the final part of this 
study evaluated haemostatic cover for invasive procedures in FXI deficient patients.  
Initially an audit was performed of 70 surgical episodes in 43 patients treated with FXI 
concentrate over a five year period.  Of these treatment episodes, 19 were classified as 
major procedures and of the patients treated, 20 (46.5%) had a severe FXI deficiency.  
No thrombo-embolic events were recorded although five patients were aged >70 years 
and seven angiography procedures were conducted in patients with suspected ischaemic 
heart disease.  Overall, the results of this five year audit of FXI concentrate usage 
provide reassurance in regards to the lack of thrombotic complications even in patients 
with possible cardiovascular disease. 
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However, the fact that FXI concentrate is a plasma derived coagulation product 
continues to pose a small but real risk for transmission of viral or novel infections.  In 
certain patient groups (e.g. children, expectant women) it may be desirable to avoid 
plasma products where possible.  Consequently, the use of rFVIIa to prevent bleeding 
after invasive procedures was evaluated since there was evidence of efficacy in FXI 
deficiency in case reports in the literature.(102;107-109)  While rFVIIa proved very 
effective and haemostasis was effective in all patients, a possible confounding factor 
was the universal use of tranexamic acid with rFVIIa.  Since rFVIIa has a short half-life 
and since it was being used for a very limited time (two doses for minor procedures and 
three days for major procedures) there was a concern regarding late bleeding.  The 
rationale for the use of tranexamic acid therefore was to provide cover for the short half-
life of rFVIIa and to prevent delayed bleeding.  It may have been preferable to start the 
tranexamic acid after the rFVIIa administration was complete or to exclude it altogether.  
There were three adverse events of which two were minor but one ( a stroke in an 
elderly man with a remote history of cardiovascular disease) resulted in the death of the 
patient.  Subsequently, there has been some interest the use of a reduced dose of rFVIIa 
and it has been suggested that lower doses may be sufficient in FXI deficient 
patients.(110;111)  Lower doses have been successfully used recently in FXI deficient 
patients with inhibitors.(307;308)  Further work is required in-vitro and in-vivo to 
confirm the optimal dose of rFVIIa in FXI deficiency. 
 
8.3 Future work 
Arising from the work presented in this thesis, a number of areas warrant further 
investigation in the elucidation of the variable bleeding tendency in FXI deficiency.  
Firstly, no real-time platelet studies were possible in the patient cohort under study due 
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to the design of the study.  Given that there is still some debate regarding the underlying 
cause of bleeding in the 50% of partially FXI deficient patients with a bleeding history, 
a comprehensive evaluation of platelet function in the patients already characterised in 
this study could be undertaken.  Since the patients in this study have already had a full 
bleeding history and have had other possible confounding factors evaluated (e.g. VWF, 
FVIII, thrombophilic traits, TAFI), measurement of platelet function parameters such as 
platelet aggregometry, platelet flow cytometry, platelet nucleotides or other research 
tests could be correlated relatively easily with bleeding tendency.  The theory that 
patients with partial FXI deficiency bleed due to underlying platelet disorders could 
then be proven or refuted. 
 
While TAFI antigen and activity levels were not shown to be correlated with bleeding 
tendency in the assays undertaken as part of this study, there is no consensus at this time 
regarding the optimal TAFI assay.  Alternative TAFI assays, for example evaluation of 
the activation peptide or the inactive form of TAFI, may prove more relevant measures 
of TAFI activation in-vivo in the future. 
 
Thrombin generation assays are perhaps the most promising area of future study in FXI 
deficiency.  In this regard, evaluation of thrombin generation in PRP is recommended 
and the use of a well-standardised and optimally controlled method is advocated.  In 
particular, such assays may yet hold the key to identifying those partially deficient 
patients with a bleeding tendency who may need haemostatic cover for invasive 
procedures.  This is especially important since many newly diagnosed FXI deficient 
patients have not had unsupported invasive procedures in areas of high fibrinolytic 
activity such as dental extraction or tonsillectomy, as a consequence of improved dental 
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health and changing medical practice.  In these patients, the bleeding history is 
―indeterminate‖ and an informative laboratory assessment of bleeding tendency would 
significantly improve clinical decision making regarding the need for haemostatic 
cover. 
Recombinant factor VIIa remains a promising haemostatic agent for patients with FXI 
deficiency who wish to avoid the use of plasma products.  Further ex vivo evidence for 
haemostatic levels of rFVIIa is required and evaluation of changes in thrombin 
generation are an appropriate assay for ex-vivo investigation.  Subsequently, further in-
vivo studies should be done, using lower doses of rFVIIa, with or without concomitant 
tranexamic acid. 
 
Finally, the link between congenital disorders of glycosylation and FXI deficiency is an 
intriguing one and further assessment of the glycosylation of the FXI protein in these 
patients may yield insight into the function of abnormally glycosylated FXI.  Potential 
modifiers of FXI glycosylation could then be evaluated in FXI deficient patients  
 
8.4 Conclusion 
In conclusion, the aims of this thesis to comprehensively evaluate the bleeding tendency 
in a cohort of FXI deficient patients was achieved.  A number of potential modifiers of 
the bleeding tendency were outruled and thrombin generation was identified as a 
laboratory test with the potential to discriminate between bleeders and non-bleeders 
with FXI deficiency.  Two novel mutations in the F11 gene were identified in patients 
participating in this study.  The first accurate homology models were published along 
with a comprehensive structural interpretation of all known missense mutations.  A 
novel treatment (rFVIIa) was evaluated in clinical study setting in a case series of 
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patients with FXI deficiency.  A number of areas have been identified for future study, 
including evaluation of platelet function, newer assays for TAFI, thrombin generation in 
PRP, glycosylation of the FXI protein and optimal dosing of rFVIIa. 
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10 Appendices 
10.1 Research documentation 
10.1.1 Patient information leaflet and patient consent form for Factor XI 
genetic study 
INFORMATION FOR PATIENTS 
 
A STUDY OF THE GENETIC FACTORS WHICH INFLUENCE BLEEDING IN PEOPLE 
WITH FACTOR XI DEFICIENCY 
 
Version 1: 28/09/01 
 
 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends, relatives 
and your GP if you wish. Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish to take part. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical 
Research and You’. This leaflet gives more information about medical research and 
looks at some questions you may want to ask. A copy may be obtained from CERES, 
PO Box1365, London N16 0BW. 
 
Thank you for reading this.  
 
What is factor XI deficiency? 
 
Factor XI (eleven) is an important clotting protein which is present in blood. It 
helps to create a clot if you cut yourself or if you are having an operation. 
 
Factor XI deficiency is an inherited condition whereby the levels of factor XI are low in 
the blood. This can lead to bleeding after surgical operations, dental extractions, 
childbirth or after accidental injury.  However, some people have no or very little 
bleeding even though their factor XI level is low.  We would like to be able to predict 
which patients have a bleeding tendency and need treatment for surgery and which 
patients do not bleed so that we do not treat them unnecessarily. 
 
We believe that if we had more information about the types of genetic mutation which 
cause factor XI deficiency we would be able to predict the bleeding tendency even in 
someone who has never had an operation before. 
 
 
   288 
What is the purpose of the study? 
 
The purpose of the study is to collect information from patients with factor XI deficiency 
about whether they have had any bleeding problems and to take a blood sample for 
laboratory analysis. 
 
Why have I been chosen? 
 
We are inviting patients registered with Factor XI deficiency in the Katharine Dormandy 
Haemophilia Centre and Haemostasis Unit to attend one clinic visit at the centre. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. This will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
 
You will be seen at the outpatient clinic on a Monday afternoon.  There will be a brief 
interview to document any bleeding problems you may have had.  Then, the blood 
sample will be taken.  It should not take more than one hour.  
 
 
 What are the side effects of taking part? 
 
Taking a blood sample usually does not cause any problems.  Rarely, people may feel 
faint or develop a bruise over the vein. Nurses who are specialists in bleeding disorders 
will take the blood samples.  
 
What are the possible benefits of taking part? 
 
At the end of the study, we hope to be able to predict whether people will bleed or not 
regardless of their level of factor XI.  However, we won’t know until the end of the study 
if we will be successful.  In the meantime you will continue to receive treatment 
according to the national guidelines for treating factor XI deficiency.  Knowing the 
mutation which causes factor XI deficiency may benefit you in the future but we cannot 
guarantee this. 
 
What if something goes wrong? 
 
Any adverse event that occurs during this study will be reported to Professor Lee and 
to the Local Research Ethics Committee.  
If you wish to complain about any aspect of the way you have been approached or 
treated during the course of this study, the normal National Health Service complaints 
mechanisms will be available to you. 
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Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will be 
kept strictly confidential. Your records may also be looked at by people regulatory 
authorities to check that the study is being carried out correctly. Any information about 
you which leaves the hospital will have your name and address removed so that you 
cannot be recognised from it. 
 
What will happen to the results of the research study? 
The results will be published in an internationally renowned journal of bleeding 
disorders. Copies of the article will be available in the Katharine Dormandy 
Haemophilia Centre.  Participants will not be identified in any report/publication. 
 
Who is organising and funding the research?  
 
The research is organised by the doctors at the Katharine Dormandy Haemophilia 
Centre and Haemostasis Unit. The research is funded by a Clinical Research 
Fellowship grant from the Royal Free hospital NHS Trust and charitable grants to the 
Katharine Dormandy Haemophilia Centre and Haemostasis Unit.  
 
Who has reviewed the study? 
 
The study has been reviewed by the Royal Free Hospital and Medical School Local 
Research Ethics Committee. 
 
Contact for Further Information 
 
Dr. Niamh O’Connell, Clinical Research fellow or Professor Lee, Haemophilia Centre 
Director will be happy to answer any questions you may have about factor XI deficiency 
or rFVIIa treatment.   
 
Phone:  0207 830 2068 
Fax:  0208 830 2178 
Email:  n.o’connell@rfc.ucl.ac.uk 
  
We would like to thank you for taking time to read this information leaflet and for 
considering participation in this study. 
 
You may keep a copy of this Patient Information Sheet and your signed consent form. 
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CONSENT FORM 
 
 
 
Title of Project:  
 
A study of genetic factors which influence the bleeding tendency in patients  
with factor XI deficiency. 
 
Name of Researchers: 
Professor Christine A. Lee / Dr. Niamh O’Connell 
Please initial 
box 
 
1. I confirm that I have read and understand the information sheet 
dated............................  (version............) for the above study and have 
had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to 
my taking part in research.   
 I give permission for these individuals to have access to my records. 
 
4. I agree to take part in the above study.    
          
 
 
 
 
 
  
________________________          _______________ ____________________ 
Name of Patient Date Signature 
 
 
 
 
 
________________________ ________________ ____________________ 
Researcher    Date    Signature 
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10.1.2  Patient data collection form 
FACTOR XI GENETIC STUDY 
       
 
DATE:      HISTORY TAKEN BY: 
 
 
 
PATIENT DEMOGRAPHICS: 
 
 
NAME  
MRN  
DOB  
ETHNIC ORIGIN  
RELIGION  
BASELINE FXI LEVEL  
BLOOD GROUP if 
recorded 
 
 
 
 
DIAGNOSIS OF FACTOR XI DEFICIENCY: 
 
Indicate circumstance of diagnosis: 
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BLEEDING HISTORY: 
 
 
 Yes/No Bled?  
Yes/No 
Tfn? Factor Repl? Description 
Dental Extraction      
Bruising      
Epistaxis      
Trauma      
Major Surgery      
      
      
      
Circumcision if male      
Minor surgery      
      
 
 
MEDICATIONS: 
 
NB: record any use of ASA/ NSAIDs/ Anticoagulants 
 
 
 
 
 
FAMILY HISTORY: 
 
 
Other first degree relative affected? Yes              No 
Number of relatives affected  
Type of bleeding problem:  
Dental       Major surgery       Minor surgery        Epistaxis      Trauma       Menorrhagia      PPH 
 
 
 
Attach pedigree:  Yes    No 
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FEMALE PATIENTS: 
 
Menorrhagia?  
Age of menarche  
Ever used?                                                   COCP  
                                                                     POP  
                                                                      IUD  
Periods (subjective) Light            Normal                Heavy 
Clots                                            Yes  /No 
Double protection Yes  /No 
Housebound during menses Yes  /No 
Were menses always heavy? Yes  /No 
Ever anaemic due to menorrhagia? Yes  /No 
If yes, given treatment? Iron                                Blood transfusion 
Seen by a doctor for menorrhagia? Yes  /No 
Given treatment? COCP  Progestagen  T.Acid   Analgesia  Other 
Abortion/Miscarriage Yes  /No 
Gestation  
Bleeding Yes  /No 
Treatment given? ERPC/D&C   Factor Conc….FFP….TA…other 
Post partum haemorrhage? Yes  /No 
Mode of delivery (VD/VD+forceps/vac/epis/ CS)  
Epidural Yes  /No 
Transfusion? Yes  /No 
Number of units transfused  
Treatment given?  
Factor XI concentrate      FFP       Tranexamic Acid                Other 
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TREATMENT EPISODES: 
 
Number of treatment episodes  
Treatment used:  
Factor XI concentrate  
rFVIIa  
FFP  
Tranexamic acid  
Fibrin glue  
Other  
 
Vaccination?  Hep A   Hep B 
 
Date:   
 
 
 
Retested today? 
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10.1.3  Ethics approval number and Trust clearance for Factor XI genetic  
and clinical phenotype study 
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10.1.4  Recombinant factor VIIa (FaXID) information leaflet and consent 
form 
INFORMATION FOR PATIENTS 
 
TRIAL TO ASSESS THE USE OF RECOMBINANT FACTOR VIIA TO TREAT 
AND PREVENT BLEEDING IN PEOPLE WITH FACTOR XI DEFICIENCY 
 
Version 2.3: 23/10/01 
 
 
You are being invited to take part in a research study. Before you decide it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends, relatives 
and your GP if you wish. Ask us if there is anything that is not clear or if you would like 
more information. Take time to decide whether or not you wish to take part. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical 
Research and You’. This leaflet gives more information about medical research and 
looks at some questions you may want to ask. A copy may be obtained from CERES, 
PO Box 1365, London N16 0BW. 
 
Thank you for reading this.  
 
What is factor XI deficiency? 
 
Factor XI (eleven) is an important clotting protein which is present in blood. It helps to 
create a clot if you cut yourself or if you are having an operation. 
 
Factor XI deficiency is an inherited condition whereby the levels of factor XI are low in 
the blood. This can lead to bleeding after surgical operations, dental extractions, 
childbirth or after accidental injury.   
 
The treatment of such bleeding is to give an injection of factor XI concentrate to stop 
the bleeding. The factor concentrate is derived from blood donations and is tested and 
treated to prevent transmission of any infections. However, there is still a tiny risk of 
transmission of an infection with this product. In addition, factor XI concentrate leads to 
clotting in some people. 
 
What is the drug that is being tested? 
 
A new product to stop bleeding, recombinant factor VIIa (rFVIIa) was developed initially 
for the treatment of patients with haemophilia A and B who have inhibitors. It is highly 
effective in treating bleeding in those patients without any significant side effects. It has 
been used successfully all over the world for 12 years in patients with haemophilia. 
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Recently, rFVIIa has been used successfully in 2 patients with factor XI deficiency 
undergoing surgery.  
rFVIIa is a recombinant product which means that it is not made from blood donations. 
No human proteins are involved in the manufacturing process. It should therefore be 
safer than the factor XI concentrate. In addition, it is not associated with clotting 
problems in most people. 
 
What is the purpose of the study? 
 
We feel that rFVIIa is a better treatment for patients with factor XI deficiency than factor 
XI concentrate and therefore we are offering it as first line treatment. In order to learn 
more about how this treatment works in patients with factor XI deficiency, we need to 
gather information about this treatment and the patients receiving it, e.g. baseline 
levels of factor XI, types of surgery, results of monitoring tests, any side effects. This 
study is designed to gather that information by offering this treatment to patients with 
factor XI deficiency who are having an operation, dental extraction or are having a baby 
over the next two years. 
 
Why have I been chosen? 
 
Patients registered with Factor XI deficiency in the Katharine Dormandy Haemophilia 
Centre and Haemostasis Unit who are having a planned surgical procedure or dental 
extraction or who are having a baby or who have bleeding after an accident are being 
invited to participate in this study.  We hope that approximately 30 patients will 
participate in this study over two years. 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. This will not affect the standard of care you receive. 
 
What will happen to me if I take part? 
 
You will be seen at the outpatient clinic to plan your surgery, dental extraction or the 
birth of your baby, as usual. You will be given this information sheet and if you agree to 
participate, we will arrange to give you rFVIIa treatment at the time of the operation or 
birth instead of Factor XI concentrate. The rFVIIa treatment is given by injection into a 
vein like other clotting factor concentrates. The number of injections of rFVIIa needed 
depends on the type of operation you are having and your doctor will discuss this with 
you in advance. We will be monitoring the amount of blood loss during and after your 
procedure as usual. If there is more bleeding than anticipated, some extra injections of 
rFVIIa may be needed or we may need to give you another form of treatment such as 
factor XI concentrate. We will inform you if we think these extra treatments are 
necessary. The study ends once you are discharged from the hospital after your 
procedure. 
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What tests are involved in this study? 
 
Routine blood tests are taken before the operation to check the blood count, kidney 
and liver function, baseline clotting tests and virology tests including tests for hepatitis 
and HIV. These would be taken whether you participate in the study or not. In addition, 
specific tests to monitor the rFVIIa treatment will be taken before the procedure and at 
2, 24 and 48 hours after the procedure. These are to make sure that you are receiving 
the correct dose of rFVIIa for you. If we change the dose, we will check the blood tests 
again. 
 
What do I have to do? 
 
You will be given a medication to take orally for 7 days after the procedure called 
Tranexamic acid. This is a common medicine used in people with factor XI deficiency 
and other bleeding disorders to stop bleeding. It can be used alone or in combination 
with clotting factor concentrates 
 
What are the alternatives for diagnosis or treatment? 
 
There are two alternative treatments used to prevent or treat bleeding in patients with 
factor XI deficiency, factor XI concentrate and fresh frozen plasma.  Both of these 
products are made from human blood donations. They are both tested and treated to 
prevent transmission of infectious diseases but there is still a tiny risk that a donation 
might be infected. 
  
What are the side effects of taking part? 
 
rFVIIa treatment has been used in  many  people with haemophilia and is very safe. 
Rarely, patients can develop clotting test abnormalities and clotting (e.g. heart attacks 
or strokes) but this is less common than with factor XI concentrate.  Other rare side-
effects include abnormalities in liver blood tests, allergy to the drug, high blood 
pressure, skin rash, fever, headache and nosebleeds.  
 
What are the possible benefits of taking part? 
The primary aim is to enable you to have your operation or baby as safely as possible. 
We hope to prove conclusively that rFVIIa is effective and safe in patients with factor XI 
deficiency who are having operations or who have an accident causing bleeding. The 
information we get from this study may help us to treat future patients with factor XI 
deficiency better. 
We hope that the treatment will help you. However, this cannot be guaranteed.  
 
What if new information becomes available? 
 
Sometimes during the course of a research project, new information becomes available 
about the treatment/drug that is being studied. If this happens, your research doctor will 
tell you about it and discuss with you whether you want to continue in the study. If you 
decide to withdraw your research doctor will make arrangements for your care to 
continue. If you decide to continue in the study you will be asked to sign an updated 
consent form. 
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Also, on receiving new information your research doctor might consider it to be in your 
best interests to withdraw you from the study. He/she will explain the reasons and 
arrange for your care to continue. 
 
What happens when the research study stops? 
You will continue to be treated with the clotting factor treatment that is considered to be 
most effective and safe according to national and international best practice.  
 
What if something goes wrong? 
 
Any adverse event that occurs during this study will be reported to Professor Lee and 
to the Local Research Ethics Committee. A decision will be made after considering the 
facts whether the adverse event was likely to have been caused by the drug and 
whether it is likely to happen in other patients. Any procedures or tests that are needed 
to prevent this problem recurring will be taken, including stopping the study if 
necessary. 
 
If you wish to complain about any aspect of the way you have been approached or 
treated during the course of this study, the normal National Health Service complaints 
mechanisms will be available to you. 
 
Compensation for any injury caused by taking the study medication will be in 
accordance with the guidelines of the Association of the British Pharmaceutical 
Industry (ABPI). Copies of these guidelines are available on request. 
 
Your right at law to claim compensation for injury where you can prove negligence is 
not affected.  
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research will be 
kept strictly confidential. Your records may also be looked at by people from the 
company who manufacture rFVIIa or regulatory authorities to check that the study is 
being carried out correctly. Any information about you which leaves the hospital will 
have your name and address removed so that you cannot be recognised from it. 
 
What will happen to the results of the research study? 
The results will be published in an internationally renowned journal of bleeding 
disorders. Copies of the article will be available in the Katharine Dormandy 
Haemophilia Centre.  Participants will not be identified in any report/publication. 
 
Who is organising and funding the research?  
 
The research is organised by the doctors at the Katharine Dormandy Haemophilia 
Centre and Haemostasis Unit. The company who manufacture rFVIIa are donating the 
study drug and providing assistance in monitoring the study.  
The research is funded by a Clinical Research Fellowship grant from the Royal Free 
hospital NHS Trust and charitable grants to the Katharine Dormandy Haemophilia 
Centre and Haemostasis Unit.  
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Who has reviewed the study? 
 
The study has been reviewed by the Royal Free Hospital and Medical School Local 
Research Ethics Committee. 
 
 
Contact for Further Information 
 
Dr. Niamh O’Connell, Clinical Research fellow or Professor Lee, Haemophilia Centre 
Director will be happy to answer any questions you may have about factor XI deficiency 
or rFVIIa treatment.   
 
Phone: 0207 830 2068 Ext. 5237 
Fax: 0207 830 2178 
Email: n.o’connell@rfc.ucl.ac.uk 
 
  
We would like to thank you for taking time to read this information leaflet and for 
considering participation in this study. 
 
You may keep a copy of this Patient Information Sheet and your signed consent 
form. 
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Patient Identification Number for this trial: 
 
CONSENT FORM 
 
 
 
Title of Project:  
Trial to assess the use of recombinant factor VIIa to treat and prevent bleeding  
in people with factor XI deficiency 
 
Name of Researchers: 
Professor Christine A. Lee / Dr. Niamh O’Connell 
Phone: 0207 830 2068 Ext. 5237 
Please initial 
box 
 
1. I confirm that I have read and understand the information sheet 
dated............................  (version............) for the above study and have 
had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care 
or legal rights being affected. 
 
5. I understand that sections of any of my medical notes may be looked at by 
responsible individuals from regulatory authorities where it is relevant to 
my taking part in research.   
 I give permission for these individuals to have access to my records. 
 
6. I agree to take part in the above study.     
         
 
 
 
 
  
________________________          _______________ ____________________ 
Name of Patient Date  Signature 
 
 
 
________________________ ________________ ____________________ 
Name of Person taking consent Date  Signature 
(if different from researcher) 
 
 
 
_________________________ ________________ ____________________ 
Researcher    Date    Signature 
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10.1.5  Ethics approval number and Trust clearance for rFVIIa (FaXID) 
study 
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